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The overall prevalence of overweight and obesity in South African (SA) women is 
high, with black women being more affected than white women (58.5% vs. 52.9%). 
Furthermore, black SA women, similar to African Americans have been shown to 
have a less atherogenic lipid profile than white women. Obesity is a condition 
characterised by chronic low-grade inflammation, which also mediates all stages of 
atherosclerosis. DNA sequence variants in the tumour necrosis factor (TNFA) and 
interleukin-6 (IL-6) genes have been shown to impact molecular processes of the 
inflammatory pathways, serum lipids and the obese phenotype, and to interact with 
dietary fatty acids, modulating these relationships.  
 
The primary aim of the thesis was to investigate associations between TNFA (TNFA 
-308 G>A and -238 G>A) and IL-6 (-174 G>C, IVS3+281 G>T, IVS4+869 A>G) 
sequence variants and obesity and serum lipid concentrations in black and white SA 
women. This included identifying sequence variants in the IL-6 gene with a reported 
high heterozygosity in both the white and black SA populations (rs1554606 and 
rs2069845). Dietary intake data of adequate reporters was then included in the 
analysis to investigate whether dietary fatty acid intake modulated the interactions 
between the TNFA and IL-6 SNPs (TNFA -308 G>A and -238 G>A & IL-6 -174 G>C, 
IVS3+281 G>T, IVS4+869 A>G) and obesity, measures of adiposity and serum lipid 





Normal-weight (body mass index (BMI) ≤ 25 kg/m2, N=107) and obese (BMI ≥ 30 
kg/m2, N=120) black and normal-weight (N=89) and obese (N=62) white urban SA 
women underwent measurements of body composition, fasting lipids and dietary 
intake and were genotyped for the TNFA -308 G>A and -238 G>A polymorphisms, 
and IL-6 -174 G>C, IVS3+281 G>T, IVS4+869 A>G polymorphisms. Dietary intake 
was estimated using a food frequency questionnaire. Under-reporting and over-
reporting were detected by applying the Goldberg cut-offs for energy intake:basal 
metabolic rate. Of the total sample, 42 under-reporters, 268 adequate reporters, and 
73 over-reporters were identified. Only adequate reporters were included in the diet 
analyses, including 73 normal-weight and 74 obese black, and 73 normal-weight and 
48 obese white adequate reporters. 
 
The objectives of the first study of the thesis were to characterise the body 
composition, serum lipid concentrations and dietary intake of the black and white SA 
women. Associations between the TNFA -308 G>A polymorphism and obesity and 
serum lipid concentrations, as well as interactions with dietary fatty acid intake, were 
then explored. White women were taller and heavier than the black women, but 
because of their shorter stature the black women had a higher BMI than the white 
women (P=0.002). The white women had greater waist, waist hip ratio (WHR), and 
visceral adipose tissue (VAT) than the black women, whereas the black women had 
higher body fat % (P=0.004), and subcutaneous adipose tissue (SAT) (P=0.028) 
than the white women. As expected, triglycerides (TAG), total cholesterol (T-C), 
high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol 
(LDL-C) were higher in the white women compared to the black women (P<0.001). 
In terms of dietary intake, the black women consumed more energy (kJ), 
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carbohydrate (CHO) percentage total energy intake (%E)(P< 0.001) and total fat 
(%E)(P=0.002) than the white women. When individual dietary fatty acid intake was 
analysed, the black women consumed more total polyunsaturated fatty acids 
(PUFAs) (%E) and omega-6 (n-6) PUFAs (%E), including greater amounts of linoleic 
acid (LA) and arachidonic acid (AA) (%E)(P=0.001) than the white women. Notable 
was the higher omega-6:omega-3 polyunsaturated fatty acid (n-6:n-3 PUFA) ratio in 
the black women compared to the white women (P<0.001).  
When exploring genotype-phenotype associations in the black and white women, 
there were no differences in the genotype or allele frequency of the TNFA -308 G>A 
polymorphism between the BMI groups. Nor were any genotype associations 
observed for body composition or serum lipid concentrations. However, a diet-gene 
interaction was observed in the black women. When dietary fat intake was 30% of 
total energy intake (%E), the odds of being obese with the TNFA GA+AA genotype 
was only 12% of that with GG, but increasing intake of dietary fat intake (%E) was 
associated with a significantly greater rate of increase in obesity risk in women with 
the TNFA GA+AA genotype compared to those with the GG genotype (P=0.036). In 
the black women, diet-gene interactions were also identified between α-linolenic acid 
(ALA) (%E) intake and total cholesterol : HDL-cholesterol (T-C:HDL-C) ratio 
(P=0.036), and PUFA (%E) intake and LDL-C levels (P=0.026), with subjects with 
the A allele being more responsive to changes in relative fat intake. In the white 
women, an interaction effect between dietary saturated fat (SFA) intake (%E) and 
TNFA -308 genotypes on serum total cholesterol (T-C) concentrations (P=0.047) 
was identified. With increasing SFA intake (%E), T-C levels decreased for the GG 
genotype and increased for the GA + AA genotypes. It was concluded that although 
the TNFA -308 G>A polymorphism was not independently associated with obesity or 
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serum lipid concentrations in this study, dietary fat intake modified the relationship 
between the TNFA -308 G>A polymorphism, obesity risk and serum lipid 
concentrations.  
 
While a number of studies have investigated the TNFA -308 G>A polymorphism, 
only a few have reported on the TNFA –238 G>A polymorphism and obesity and 
serum lipids. Therefore, the aim of the second study was to explore whether the 
TNFA -238 G>A polymorphism is independently associated with adiposity and serum 
lipid concentrations, and whether these associations are impacted by dietary fat 
intake. The black women had a higher TNFA -238 GA genotype frequency than the 
white women (P<0.001), but there were no differences between BMI groups. Black 
women with the TNFA -238 A allele had a greater body fat % than those with the GG 
genotype (P<0.001). Further, when dietary intake data was included in the analyses, 
it was observed that with increasing polyunsaturated : saturated fat ratio (P:S ratio) 
and n-6:n-3 PUFA ratio, HDL-C concentrations decreased and T-C:HDL-C ratio 
increased in black women with the GA genotype but not the GG genotype. In 
addition, with increasing omega-3 polyunsaturated fatty acid intake (n-3 PUFA) 
(%E), T-C:HDL-C ratio decreased in black women with the GA genotype, but not in 
those with the GG genotype. In the white women, with increasing eicosapentaenoic 
acid (EPA) (%E) intake, LDL-C concentrations decreased in those with the GG 
genotype but not the GA genotype. It was concluded that the TNFA -238 G>A 
polymorphism was associated with body fat %, and that the -238 A allele was 
responsive to increasing dietary fat intake on measures of adiposity in black SA 
women. This study also showed that the relationship between the TNFA -238 G>A 
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polymorphism and serum lipid concentrations differed depending on PUFA intake, in 
both black and white SA women, but that these interactions were ethnic-specific.  
 
The cytokine IL-6 is known to regulate inflammation, and within the IL-6 gene, the 
functional and well studied polymorphism IL-6 -174 G>C (rs1800795) has been 
associated with obesity and dyslipidaemia. However, the -174 G>C polymorphism 
has been shown to be rare in persons of African descent. Therefore, the third study 
of this thesis identified two additional informative (more common) polymorphisms in 
both black and white SA populations, and investigated associations between these 
IL-6 polymorphisms (IL-6 -174 G>C, IVS3+281 G>T and IVS4+869 A>G) and 
obesity and dyslipidaemia in black and white women. The IL-6 IVS4+869 G allele 
was associated with greater waist (P=0.014) and fat mass (P=0.034) in black 
women. In the white women, those with the IL-6 IVS3+281 T allele had lower TAG 
concentrations than the IVS3+281 GG genotype (P=0.008). It was concluded that IL-
6 polymorphisms in this study were associated with obesity in the black women and 
serum lipid concentrations in the white women. These findings are novel in that no 
other studies have reported on the association between the IVS4+869 A>G 
polymorphism and adiposity. 
 
It is not known whether these genotype-phenotype associations are impacted by 
dietary fat intake, as was observed for the TNFA -308 G> and -238 G>A 
polymorphisms in the first two studies of this thesis. The aim of this fourth and final 
study of this thesis was therefore to investigate the relationship between the IL-6  
-174 G>C, IVS3+281 G>T and IVS4+869 A>G polymorphisms and dietary fat intake 
on obesity and serum lipids in black and white women. A number of diet-gene 
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interactions were observed for both the white and black women. In the white women; 
with increasing n-3 PUFA intake and decreasing n-6:n-3 PUFA ratio, BMI decreased 
in those with the IL-6 -174 C allele, IL-6 IVS3+281 T allele and IL-6 IVS4+869 AG 
genotype. In the black women, with increasing dietary fat intake, adiposity decreased 
in those with the IL-6 IVS3+281 TT and IL-6 IVS4+869 GG genotypes and increased 
in the IL-6 IVS3+281 GT+GG and IL-6 IVS4+869 AA or AG genotypes. In white 
women, with increasing n-3 PUFA intake; TAG and T-C:HDL-C ratio decreased and 
HDL-C increased in those with the  IL-6 -174 C allele, and  T-C:HDL-C ratio 
decreased in the IL-6 IVS3+281 TT compared to the GG and GT genotype, with 
HDL-C increasing with each T allele. In contrast, HDL-C decreased with each IL-6 
IVS4+869 G allele. In black women, with increasing total fat intake, TAG and T-
C:HDL-C ratio increased in those with the IL-6 IVS4+869 G allele and decreased in 
the AA genotype. It was concluded that dietary fat intake, and the quality of the 
dietary fatty acids, modulated the relationship between the IL-6 -174 G>C, IVS3+281 
G>T and IVS4+869 A>G polymorphisms, on measures of obesity and serum lipids, 
with different effects in black and white women 
 
In summary, this thesis is the first to show that dietary fat intake modulates the 
relationship between TNFA and IL-6 polymorphisms on obesity and serum lipids, 
and that these relationships differ between black and white SA women. These 
findings suggest that diet-gene interactions and ethnicity contribute to the complexity 
and heterogeneity observed within the obese phenotype and serum lipid profiles in 
different populations. The thesis results also highlight the importance of 
understanding the inflammatory impact of different dietary fatty acids and how they 
may differentially interact with genes. The future study of nutrigenomics offers the 
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opportunity to clarify the underlying molecular mechanisms governing the 
interactions between dietary fatty acids and the inflammatory and obese phenotype, 
potentially elucidating the observed differences between ethnic groups and enabling 
the development of population-based targeted interventions to reduce risk 
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CHAPTER ONE 
1.1. Introduction to obesity  
 
1.1.1. Overview of global obesity 
 
An estimated 1.3 billion people are overweight or obese world-wide, of these 
approximately 300 million are obese [1]. Traditionally, obesity has been viewed 
as a disease of developed countries, however, there is an alarming increase in 
obesity in developing countries such as South Africa (SA), Mexico and South 
American countries, likely due to epidemiological and nutrition transition. 
Epidemiological transition is defined as changing patterns of population age 
distributions, mortality, fertility, life expectancy, and causes of death [2-4]. 
 
Obesity is a chronic disorder with a multi-factorial aetiology, which includes a strong 
genetic component [5]. When more energy is consumed compared to energy 
expended, excess energy is stored in adipocytes that enlarge. It is thought by some 
to be adipocyte hypertrophy that generates the metabolic aberrations that result in  
obesity-associated comorbidities [6]. These include cardiovascular disease (CVD), 
coronary heart disease (CHD), hypertension, insulin resistance, type 2 diabetes, and 
certain cancers [6, 7]. The SA prevalence and presentation of these conditions have 
been discussed extensively in the technical report; Chronic Diseases of Lifestyle in 
SA: 1995 – 2005 [8]. Since this thesis investigates associations and interactions 
between dietary fatty acids and tumour necrosis factor alpha (TNFA) and  
interleukin-6 (IL-6) polymorphisms on obesity and serum lipid concentrations in 
urbanized black and white SA women, this literature review focused on obesity and 




1.1.2. Obesity in South Africa 
 
SA presents with a ‘quadruple burden’ of disease, characterised by: i) under-nutrition 
and under-development, found predominantly in children, ii) emerging chronic 
diseases associated with ever-increasing overweight and obesity, iii) HIV/AIDs and 
iv) injuries [3, 8-10]. Despite the need to address under-nutrition, poverty and 
infectious diseases such as HIV/AIDS and tuberculosis, obesity and its  
co-morbidities contribute significantly to the burden on the SA health care system 
[11].  
 
The first SA Demographic Health Survey (SADHS), including 8,162 SA women, and 
5,665 men, aged 15 to 95 years old, reported differences in obesity prevalence 
between SA ethnic groups and between men and women. The overall prevalence of 
overweight (body mass index (BMI) >25 kg/m2) and obesity (BMI >30 kg/m2) in SA is 
high with 29% of men and 56% of women being classified as overweight or obese 
[3]. This is higher than that reported in other African countries [7]. Black women had 
the highest prevalence of overweight and obesity (58.5%), followed by white women 
(52.9%) and coloured women (52.0%) [3]. The ethnic group within the Western Cape 
region of SA self-identified as coloured is ancestrally derived from admixtures of one 
or more of the indigenous African populations (Khoe- and San-speaking or Bantu-
speaking), immigrants from Western Europe, or slave labourers from West Africa, 




Black urban women had higher BMI’s than their rural counterparts. A different 
pattern was seen in men, the prevalence for overweight and obesity was highest in 
white men (54.5%), followed by Indian men (32.7%) and coloured men (31%), with 





1.2. Coronary artery disease and serum lipids profiles in SA 
 
Coronary artery disease (CAD) is a major health problem in all SA population groups. 
In 2000, CAD contributed 23% for black, 41% for white, 31% for coloured, and 52% 
for Indian population groups of the total age-standardised death rates in SA [8, 13]. 
Despite CAD prevalence being the lowest in blacks, several studies have shown that 
increasing urbanization and the nutrition transition has been accompanied by an 
increase in CAD risk factors in this population group [14, 15]. Significant risk factors 
for CAD are obesity and weight gain, with the latter increasing CAD risk irrespective 
of the initial BMI [16].  In the Nurses’ Health Study, CAD risk was 3.3-fold higher 
when BMI was greater than 29 kg/m2 compared with women with a BMI less than 21 
kg/m2 [17].  
 
Dyslipidaemia is associated with an increased risk for atherosclerosis and CVD [18], 
and is characterized by reduced high-density lipoprotein cholesterol  (HDL-C) levels, 
raised triglycerides (TAG), and increased small low-density lipoprotein (LDL) 
particles [19]. Raised serum lipid levels are an important CAD risk factor in all 
population groups in SA. In SA adult men and women (30+ years), approximately 
59% of ischaemic heart disease (IHD) and 29% of ischaemic stroke burden were 
attributable to a high total-cholesterol (T-C) (≥ 3.8 mmol/l). However, the burden 
varied by population group, with cholesterol-attributable mortality estimates being 
significantly lower in black than white SA women (47 vs. 152 deaths per 100 000) 
[20]. Black SA women and African Americans have been shown to have a less 
atherogenic lipid profile than white women, characterized by low TAG, T-C and  
LDL-C [21-23]. Studies in SA women have generally reported no ethnic difference in 
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HDL-C levels [22], whereas African Americans have been shown to have higher 
HDL-C levels than their white counterparts [23]. In contrast, Goedecke et al. found 
HDL-C to be lower in a cohort of black Xhosa women compared to white women, 
although HDL-C levels were still within the reference range [19, 24].  
 
The more favourable serum lipid profiles observed in black versus white women may 
be attributed to relatively low levels of visceral adipose tissue (VAT) [21]. For the 
same level of body fatness, black women have less VAT than white women [22, 25]. 
Nieves et al. showed that increased VAT was a more significant determinant of an 
atherogenic lipid profile than insulin resistance in apparently healthy individuals [26]. 
Despite less VAT and less atherogenic lipids, black women are more insulin resistant 
than their white counterparts [27-29]. In SA women, Goedecke et al. reported that 
lipid levels and LDL particle size correlated with insulin sensitivity and body fatness 
in white women, but not in black women, in whom lipid levels were more closely 
associated with modifiable lifestyle factors [19]. Similarly, Sumner et al. 
demonstrated that triglyceride levels, triglyceride to HDL ratio, and LDL particle size 
were not associated with insulin sensitivity in African Americans and for a given 
triglyceride level, African Americans were more insulin resistant than their white 
counterparts [29]. Although the reasons for the ethnic differences in these 
associations are not known, inflammation has been known to regulate both and to 





1.3. The relationship between inflammation, obesity and lipid 
metabolism 
 
White adipose tissue constitutes the majority of adipose tissue (AT) [30] and can be 
divided into two fractions; the adipocyte fraction composed of mature adipocytes, 
and the stroma vascular fraction (SVF) composed of many other cell types, including 
preadipocytes, macrophages, endothelial cells and fibroblasts [31]. Although AT is 
considered a metabolically active endocrine organ, the macrophages present in the 
SVF are the primary source of obesity-induced inflammation [32-34]. The number of 
macrophages present in the SVF is directly correlated with the level of adiposity and 
adipocyte size [33, 35]. Adipocyte hypertrophy, results in increased chemokine 
secretion e.g. transforming growth factor beta 1, soluble ICAM, and monocyte 
chemotactic protein-1 (MCP-1)[33]. There is a subsequent increase in the infiltration 
of macrophages, which in turn secrete cytokines such as IL-6 and TNFα. Since AT 
expansion is characterized by increased macrophage infiltration, these cells are 
responsible for almost all cytokines, for example TNFα, and significant amounts of 
IL-6 secreted by AT [33].  
 
Low-grade chronic inflammation mediates all stages of atherosclerosis from initiation 
through to the complications of thrombosis. So much so, that elevated inflammatory 
markers are often used to define risk of atherosclerotic complications, independent 
of myocardial damage [36]. One of the proposed mechanisms linking inflammatory 
processes to the development of atheroma, is the LDL oxidation hypothesis [37]. 
LDL in the intima, the innermost layer of an artery or vein, undergoes oxidative 
modification, inducing expression of pro-inflammatory cytokines, chemokines and 
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other mediators of inflammation. Very-low density lipoprotein (VLDL) and 
intermediate-density molecules are also believed to undergo oxidative modification 
and may themselves activate the inflammatory processes of the vascular endothelial 
cells [38], through activation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB)[39]. 
 
1.4. A nutrigenetic approach to inflammation, obesity and serum lipids 
 
Genetic variation, as well as lifestyle factors such as diet and exercise, plays an 
important role in the development and progression of obesity and dyslipidaemia. 
Dietary components such as fatty acids interact with genetic variants to regulate the 
development and progression of obesity and its co-morbidities. These complex 
nutrigenetic interactions may explain differences observed in the obese phenotype 
and its comorbidities that vary both within and across populations [40]. The aim of 
this review is to illustrate the current state of knowledge with regards: 
• The impact of diet and genetic variation on inflammation  
• The associations between genetic variation in cytokine genes and obesity and 
serum lipids 
• The interactions between dietary fatty acids and polymorphisms in cytokine 
genes and their impact on obesity and serum lipids, and 
• The role of ethnicity as a confounder in these interactions. 
  
Specifically, dietary fatty acids modulate the regulation and production of cytokines 
such as TNFα and IL-6, thereby influencing inflammatory status. Furthermore, 
emerging research suggests that diet–gene interactions play an important role in the 
regulation of these inflammatory cytokines, impacting the obese phenotype and 
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serum lipids, and these interactions may differ by ethnic group. This review focuses 
on interactions between polymorphisms in the inflammatory genes TNFA and IL-6, 
and dietary fatty acids, and their relationship with obesity and serum lipid levels as 
proof-of-principle examples. Figure 1.1. illustrates the development of  
obesity-associated low-grade inflammation and the impact of diet-gene interactions 
on obesity and dyslipidaemia. 
 
 
Figure 1.1. A proposed schematic diagram for obesity-associated low-grade inflammation, and the 
relationship of diet-gene interactions on obesity and dyslipidaemia. Adipocytes become hypertrophic 
through over-nutrition. Expansion of adipose tissue in obesity leads to a subsequent increase in the 
production of chemokines by the adipocytes, resulting in increasing macrophage infiltration and 
enhanced production of pro-inflammatory cytokines such as TNFα and IL-6. Together, these 
adipocyte- and macrophage-derived cytokines act in a paracrine and autocrine manner contributing to 
adipose tissue inflammation. Obesity-associated low-grade inflammation results in an increase in 
serum triglycerides, and LDL-C concentrations and is associated with dyslipidaemia. Environmental 
factors, especially diet, and deoxyribonucleic acid (DNA) sequence variations in inflammatory genes, 
interact to impact molecular processes of the inflammatory pathway, serum lipids and the obese 
phenotype. Abbreviations: APOA, Apolipoprotein A; APOB, Apolipoprotein B; APOE, Apolipoprotein 
E; CRP, C-reactive protein; IL-6, interleukin-6; LDL-C, low-density lipoprotein cholesterol; MCP-1, 
monocyte chemotactic protein-1; PAI, plasminogen activated inhibitor; PPARγ, peroxisome 
proliferator-activated receptor gamma; TAG, triglycerides; TNFα, tumour necrosis factor 
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1.5. The impact of diet on inflammation  
 
1.5.1. Dietary intake, physical activity and inflammation 
 
For the purpose of this thesis it is important to understand dietary intake and lifestyle 
choices with regards their impact on low-grade inflammation. The effects of different 
diets, dietary components and exercise on low-grade inflammation have been 
extensively investigated through cross-sectional, prospective and intervention 
studies. A thorough review by Calder et al. provides detail on this topic [41]. However, 
the impact of diet, dietary components and exercise on low-grade chronic 
inflammation may be summarized as follows: 
• Following the consumption of a meal, there is a transient postprandial 
inflammatory response that plays a role in the development of both insulin 
resistance and atherosclerosis [42, 43]. In particular, hyperglycaemia or a high-fat 
meal promotes postprandial inflammation [44, 45]. 
• During hypo-energetic diets or energy restriction, metabolic efficiency is improved 
and inflammatory processes are reduced by decreasing the activation of NFkB 
[46, 47]. A reduction in energy intake appears to be effective independent of the 
macronutrient composition of the low-energy diet [48]. 
• Observational and intervention studies strongly suggest that the Mediterranean 
diet [49-51], vegetarian diet [52, 53], and the ‘prudent’ diet; synonymous with the 
US dietary guidelines [54-56] , reduces chronic low-grade inflammation and 
improves endothelial function.   
• The review by Calder et al. details individual components of the diet and 
micronutrients associated with lower inflammatory markers. These include whole 
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grains, fibre, vegetables, fruit, fish, vitamin C, vitamin E and carotenoids. 
Moderate consumption of wine and beer also decreases low-grade inflammation. 
It is not clear whether such effects are due to the alcohol content or to other 
components, such as phenolic compounds in these fermented beverages [41, 57]. 
• A number of excellent reviews have addressed the positive influence of physical 
activity and fitness on low-grade inflammation [58-60]. It is unclear whether the 
anti-inflammatory benefits of a physically active lifestyle are due to exercise per 
se or changes in body composition. It has been hypothesized that these  
anti-inflammatory effects may be mediated by increased insulin sensitivity and/or 
improved concentrations of HDL-C, reactive oxygen species (ROS) or endothelial 
function [61]. 
 
1.5.2. Dietary fatty acids and inflammation 
 
Dietary fatty acids have received considerable attention for their ability to regulate 
cytokine gene expression and secretion [41, 62, 63]. It has been proposed that 
dietary fatty acids affect inflammatory processes through the modulation of 
transcription factors such as NFκB and peroxisome proliferator-activated receptor 
gamma (PPARγ) [62, 64]. PPARγ inhibits NFκB, and both transcription factors are 
sensitive to dietary fatty acids [65]. Polyunsaturated fatty acids (PUFA), especially 
marine omega-3 (n-3) PUFA protects against inflammation, whereas oxidized lipids, 





1.5.3. Saturated fat  
 
There is general agreement that increasing dietary SFA intake, especially in 
overweight or obese individuals, is associated with raised inflammatory markers [41], 
predominately by activating the toll-like receptor 4 (TLR4) pathway. The TLR4 
pathway is expressed in both subcutaneous adipose tissue (SAT) and VAT. SFAs 
serve as ligands for TLR4, inducing inflammatory changes in both adipocytes and 
macrophages through NFκB activation [66], increasing adipocytokine gene 
expression and production [67, 68]. It has been shown that when adipocytes are 
exposed to the SFA, palmitic acid, IL-6 messenger ribonucleic acid (mRNA) 
expression and protein production increased, most likely through activation of NFκB 
[69, 70]. Similarly, monocytes were directly activated when exposed to SFA, 
especially lauric acid [68, 71]. 
 
1.5.4. N-6 PUFAs: linoleic acid and arachidonic acid  
 
The omega-6 (n-6) PUFA, linoleic acid (LA), constitutes the majority of PUFA intake 
in the western diet. LA is the precursor of the n-6 PUFA arachidonic acid (AA). A 
high LA intake has on occasion been considered pro-inflammatory, however the 
evidence to support this is contradictory and not conclusive [41, 72-74]. AA intake in 
the diet is low relative to LA intake, its metabolic precursor. AA is the most prevalent 
n-6 PUFA in inflammatory cell membranes and is the substrate for the synthesis of 
the pro-inflammatory eicosanoids, including prostaglandin E2 (PGE2) and 4-series 
leukotrienes, associated with inflammatory processes [41]. In addition, AA regulates 
cellular receptors such as NFkB, PPAR and sterol regulatory element-binding protein 
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(SREBP), thereby modulating the expression of inflammatory proteins, including IL-6 
and TNFα [75]. Despite this, studies investigating the impact of AA on inflammatory 
markers are inconclusive, and few human intervention studies have reported on the 
effect of dietary intake of AA on low-grade inflammation [76-78]. 
 
1.5.5. N-3 PUFAs: α-linolenic acid, eicosapentanoic acid and decosahexanoic acid 
 
The n-3 PUFA, alpha-linolenic acid (ALA) is an 18-carbon n-3 essential fatty acid 
common in canola, soybean oil and some nuts, but in greatest concentrations in 
flaxseed and flaxseed oil [79]. ALA is elongated and desaturated to eicosapentanoic 
acid (EPA) and further to decosahexanoic acid (DHA), however the efficiency of this 
conversion has been debated [80]. Association studies between dietary intake of 
ALA and inflammatory markers suggest a modest anti-inflammatory effect of ALA 
[41, 72, 74, 81-83].  
 
The long chain n-3 PUFAs, EPA and DHA are found in seafood, especially oily 
fish and in some algal oils. Is it proposed that n-3 PUFAs affect inflammation 
mainly through altered eicosanoid production, but potentially also impacting 
cell signalling and gene expression [41, 81]. When EPA and DHA are 
incorporated into human inflammatory cells, this is partly at the expense of AA, 
providing less substrate for eicosanoid production [41]. Culture systems, 
animal models and human intervention studies are generally consistent in 





1.6. Ethnicity as a confounder 
 
As discussed in sections 1.1.2. and 1.2. for SA populations, and described here in 
African Americans [25, 87], the prevalence of obesity may be high in a given 
population, but the prevalence of obesity-associated co-morbidities may differ 
between ethnic groups [25, 87-90]. As an example; while both African American and 
black SA women have a higher prevalence of obesity [7, 25, 91, 92], they have less 
atherogenic lipid profiles than their white counterparts; characterized by low TAG,  
T-C, and LDL-C concentrations [21-23, 88]. Furthermore, the association established 
between insulin sensitivity and serum lipids, which has seen the TAG:HDL-C ratio 
recommended as a tool to predict insulin resistance in overweight women, appears 
to differ by ethnicity [23, 93].  While the ratio predicts insulin resistance in white 
women, it is ineffective in African American, black SA and West African women [23, 
29, 93, 94].  
 
Differences between ethnicities comprise complex aetiologies. Ethnicity incorporates 
a variety of different components including; genetic variation, diet and lifestyle, as 
well as cultural, behavioural and socio-demographic conditions [87]. In the example 
of ethnic differences in lipid profiles described above, ethnic variability may be 
observed in dietary intake, body fat distribution (VAT vs. SAT)[19, 95], distribution of 
polymorphisms and genotype frequencies in genes such as apolipoprotein E (APOE) 
[96], and inflammatory gene expression (TNFA and IL-6)[97, 98]. In addition, dietary 
intake and physical activity [99], as well as diet-gene interactions may differ between 
ethnic groups [96]. In considering differences between ethnic groups resident in 
developed and developing countries, attitudes to food as well as the quality of the 
urban environment will also pay a role [87]. 
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1.6.1. Body fat distribution 
 
There is considerable heterogeneity among the various AT depots as both the 
physical and physiological properties of VAT and SAT differ [100-104]. VAT is 
associated with increased risk for metabolic syndrome, insulin resistance, diabetes, 
dyslipidaemia and atherosclerosis compared to SAT depots [100, 105, 106]. While 
the exact mechanisms are not clearly known, even the anatomic location of the 
different fat depots affects endocrine function [107]. Endocrine hormones from VAT 
are secreted into the portal system, affecting hepatic metabolic function, whereas 
those derived from SAT are secreted into the systemic circulation [100, 107]. VAT 
also exhibits greater expression of the receptors; β3-adrenergic, glucocorticoid, and 
androgen receptors relative to SAT [100, 107].  Furthermore, these fat depots differ 
in cytokine expression and secretion. For example, VAT has greater expression and 
secretion of TNFα, IL-6 and plasminogen activator inhibitor-1 (PAI-1), whereas leptin 
and adiponectin secretion are greater in SAT. It has also been shown that deep SAT 
(DSAT), a sub-compartment within the abdominal SAT depot, has a greater 
inflammatory gene expression profile than superficial SAT (SSAT), and in the case of 
TNFα expression, similar to that of VAT [98, 108]. These differences in AT depots 
are particularly relevant in countries with ethnic diversity such as the United States of 
America (USA) and SA. Both African American women and black SA women present 
with less VAT for the same waist or body fat than do their respective white 





1.6.2. Adipose tissue and systemic inflammation 
 
Both obesity [30, 111-113] and CAD [113-117] have been described as a state of low 
grade inflammation, attributed to excess adipose tissue, adipose tissue inflammation, 
increased release of free fatty acids and increased secretion of adipokines from 
enlarged fat cells [6, 7]. It is interesting to note that even though VAT is regarded as 
more inflammatory than SAT, black SA women have greater SAT [102], and a higher 
SAT inflammatory gene expression profile compared to white SA women, despite 
showing no ethnic differences in circulating inflammatory markers [118]. In contrast, 
Albert et al. found significantly higher levels of C-reactive protein (CRP) in African 
American women compared to Caucasian women [119]. It has also been reported 
that the levels of leptin, CRP and fibrinogen were higher in black compared to white 
South Africans, after adjusting for central obesity [120]. These variations in findings 
may be partly due to the fact that cytokines act in a paracrine and autocrine manner 
making it difficult to capture an accurate measurement [88, 98].  
 
1.6.3. Inflammatory gene expression 
 
Only a few studies have examined the effect of ethnicity on cytokine gene and 
protein expression. In morbidly obese African American and white American women 
undergoing bariatric surgery, there were no differences in mRNA levels or in vitro 
release of IL-6, interleukin-8 (IL-8) and PGE2 from VAT between ethnic groups [121]. 
In contrast, when comparing black and white SA women, black women had higher 
abdominal and gluteal SAT inflammatory gene expression then white women, which 
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was independent of age, total adiposity and VAT. This was characterized by 
increased chemokine (C-C motif) ligand 2 (CCL2), and its receptor, C-C chemokine 
receptor type 2 (CCR2), cluster of differentiation 68 (CD68), TNFα, colony 
stimulating factor-1 (CSF-1), and macrophage inhibitory factor (MIF) [98].  
 
1.6.4. Genotype frequency 
 
Functional polymorphisms have been reported in the promoter regions of the TNFA, 
IL-1, IL-6 and lymphotoxin-α (LTA) inflammatory genes, altering cytokine production 
[122-125]. Several of these polymorphisms have been shown to interact with dietary 
fatty acids to regulate production and secretion of cytokines, predisposing an 
individual to inflammation and altering obesity and associated comorbidity risk [40, 
126].  
 
In a recent review article by Phillips [127], it has been suggested that inconsistencies 
in previous studies on the influence of cytokine polymorphisms on the risk for 
obesity, diabetes and the metabolic syndrome (MetS), may be, in part, explained by 
the fact that cytokines act in a complex network, and that studying single genes may 
not provide full insight [127]. The recent LIPGENE-SU.VI.MAX MetS case control 
study reported by Phillips et al. examined the relationship between LTA, IL-6 and 
TNFA gene variants and MetS. They reported that the G allele of the TNFA -308 
G>A polymorphism and the minor A allele of the LTA rs915654 polymorphism were 
associated with a 20-40% higher MetS risk [128], but the combined effect of carrying 
both risk genotypes further increased MetS risk. It was also shown that total plasma 
PUFA:SFA levels exacerbated the observed additive genetic effects of IL-6, TNFA 
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and LTA [128], highlighting the importance of studying nutrigenetic single nucleotide 
polymorphism (SNP)-SNP or gene-gene interactions. 
 
A number of studies have investigated the relationship between cytokine 
polymorphism frequencies and ethnicity. The consensus from these studies is that 
African Americans have a greater frequency of alleles associated with high 
production of pro-inflammatory cytokines and a low production of anti-inflammatory 
cytokines [97]. Specifically, interleukin-1 (IL-1) A -889 T, IL-1 B, -3957 C and -511A, 
IL-6 -174 G, interleukin-18 (IL-18) -137 G, and TNFA -308 A alleles have been 
associated with an increase in cytokine production and are found more frequently 
among African Americans [97, 129-131]. There is a scarcity of cytokine genotype 
studies in Sub-Saharan and Southern African populations [132], and none examining 
differences in genotype frequencies between black and white South Africans. 
Genotype and allele frequencies of polymorphisms included in this thesis have been 
compared in Table 1.1 for European, British in England and Scotland, African, and 
African American populations (Ensemble public database; 
http://browser.1000genomes.org). These polymorphisms are polymorphic in all these 
populations, however there is a very low frequency of the IL-6 -174 C allele in 
populations of African descent [133]. Furthermore, it is not yet known if these ethnic 






Table 1.1. TNFA and IL-6 genotype and minor allele frequencies 
 Ensemble 1000 Genomes: phase 1  
 EUR GBR AFR ASW 
TNFA -308 G>A rs1800629 
GG 0.75 0.80 0.81 0.87 
GA 0.24 0.17 0.18 0.13 
AA 0.02 0.03 0.00 0.00 
A allele 0.14 0.12 0.10 0.10 
TNFA -238 G>A rs361525 
GG 0.87 0.81 0.93 0.90 
GA 0.13 0.19 0.07 0.10 
AA 0.00 0.00 0.00 0.00 
A allele 0.07 0.10 0.03 0.05 
IL-6 174 G>C rs1800795 
GG 0.36 0.39 0.95 0.78 
GC 0.44 0.42 0.05 0.21 
CC 0.20 0.19 0.0 0.0 
C allele 0.41 0.40 0.02 0.11 
IL-6 IVS3+281 G>T rs1554606 
GG 0.34 0.36 0.48 0.39 
GT 0.45 0.44 0.46 0.57 
TT 0.20 0.19 0.05 0.03 
T allele 0.43 0.41 0.28 0.32 
IL-6 IVS4+869 A>Grs2069845 
AA 0.34 0.36 0.46 0.37 
GA 0.45 0.44 0.47 0.57 
GG 0.20 0.19 0.05 0.04 
G allele 0.43 0.41 0.29 0.33 
Population frequencies are from the Ensemble public database (http://browser.1000genomes.org) 
[134]. Abbreviations: EUR, European; GBR, British in England and Scotland; AFR, African; ASW, 




1.6.5. Dietary intake in black and white South Africans 
 
In evaluating dietary intake in SA, it is important to consider the health and nutrition 
transition caused by growing urbanisation [9, 15, 135, 136]. The health transition is 
characterised by a decrease in physical activity, changes in diet and eating patterns, 
tobacco use and increased alcohol use [9]. The changes in dietary intake are largely 
due to urban exposure and availability of fast foods and drinks replacing leisurely 
meal times of home grown and indigenous foods [15, 135-137]. Many of the food 
items in urban areas are high in fat and sugar, having a high energy density, but a 
low nutrient density [9]. Specifically, rural dwellers have a higher intake of cereals 
and vegetables, however for all other food groups, urban intake is greater. This is 
particularly true for sugar, meat, vegetable oil, dairy, fruit, roots, tubers and alcohol 
consumption [9, 138].  
 
This thesis focuses on dietary intake of SA urban whites and urban blacks residing in 
townships. Figure 1.2 compares macronutrient distribution between the Coronary 
Risk Factor Study in blacks (BRISK) (black urban) and Vanderbijlpark Information 
Project on Health, Obesity and Risk Factors (VIGHOR) (white urban) dietary studies 
in SA [139, 140]. In summary, black and white urban populations appear to consume 
similar amounts of sugar and protein, however total fat and SFA intake is higher in 
white urban compared to black urban diets, and carbohydrate (CHO) intake is 





Figure 1.2. Mean macronutrient intake as a % of total energy intake from BRISK (black urban) and 
VIGHOR (white urban) studies [139, 140]. Abbreviations: CHO, carbohydrate; PUFA, polyunsaturated 
fatty acid; SFA; saturated fat; BRISK, Coronary Risk Factor Study in blacks; VIGHOR Vanderbijlpark 
Information Project on Health, Obesity and Risk Factors 
 
While it is known that a high and increasing dietary fat (PUFA and SFA) intake is 
cause for concern in both black and white South Africans, these studies are 20 years 
old and have not been replicated recently, nor have new studies been conducted. 
Furthermore, in these studies only total fat intake and groupings of dietary fatty acids 
such as PUFA, monounsaturated fatty acids (MUFA) and SFA were analysed, while 
individual dietary fatty acids being consumed were not identified. Knowing the intake 
of individual fatty acids in different populations is valuable in order to investigate and 
understand their impact on inflammation, and the aetiology of dietary fatty acids in 
lipid metabolism.  
 
1.6.6. Diet-gene interactions 
 
In a systematic review, Patel et al. investigated the influence of ethnicity on the 
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African American, Inuit and Eskimo, Italian, South Asian, Eastern Asian, and 
indigenous white populations of Europe, the USA and Australia)[99]. They concluded 
that studies have not shown consistency in the effects of n-3 PUFA on CVD risk and 
that ethnicity is a factor that can account for some of this variation. This includes an 
ethnic groups actual dietary intake of n-3 PUFAs, as well as their ability to absorb 
and utilise n-3 PUFAs from the diet [99]. Another key consideration in reviewing 
dietary intake and diet-gene interactions is the impact that certain genes have on 
dietary fatty acid metabolism, and how these may differ between ethnic groups. Of 
interest is the fatty acid desaturase gene (FADS), which codes for enzymes in PUFA 
metabolism. Lu et al. reported how genetic variation in the FADS1 gene interacted 
with dietary intake of both n-3 and n-6 PUFA to affect T-C and HDL-C concentrations 
[141]. Furthermore, it has recently been shown that FADS polymorphisms altered the 
capacity of different ethnic groups to synthesize long-chain fatty acids [75, 142]. 
Specifically, Sergeant et al. found that FADS genotype frequencies differed 
significantly between African Americans and European Americans, and FADS 
polymorphisms in African Americans were associated with the ability to more 
efficiently convert the n-6 fatty acid LA to the pro-inflammatory fatty acid AA, 
resulting in higher circulating AA levels, and potentially a more deleterious impact of 
a diet high in LA in this ethnic group [75].  
 
1.7. Gender as a confounder 
 
Like ethnicity, it is likely that the gender of study participants may impact  
genotype-phenotype interactions. A number of studies have observed  
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gene–diet–gender interactions, whereby an interaction was identified in one sex, but 
not another. For example, the FINGEN study, which examined the effect of long 
chain n-3 PUFA supplementation and APOE genotype on plasma lipids, reported 
greater TAG lowering effects following dietary intervention in APOE4 males than in 
females [143]. Further, results from the Framingham Heart Study showed that 
dietary PUFA intake modulates the effect of the apolipoprotein A1 (APOA1) −75 G>A 
polymorphism (rs670) on plasma HDL-C concentrations in women but not in men 
[144, 145]. In addition, Phillips et al. has shown that the transcription factor 7-like 2 
(TCF7L2) rs7903146 polymorphism influences MetS risk, and is impacted by both 
gender and dietary SFA intake [145]. Phillips et al. have also identified associations 
between genetic variants of the apolipoprotein B and APOA1 gene and MetS risk, 
however the modulation of MetS risk by dietary fat intake observed in the entire 
cohort was observed in the male high-fat consumers only [146]. 
 
For the remainder of this review genetic variation in the cytokine genes TNFA and  
IL-6 will be discussed in detail, including their association with obesity and serum 
lipids, and their interaction with dietary fatty acids. 
 
1.8. Tumour necrosis factor-α    
 
1.8.1. TNFα and obesity  
 
TNFα was the first cytokine associated with inflammation [125]. TNFα is 
overexpressed in the AT of obese individuals, with greater expression in VAT than in 
SAT [113, 147]. TNFα acts in a paracrine manner, suggesting that circulating TNFα 
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levels may not be indicative of actual TNFα levels [148]. Despite this caution, 
elevated circulating levels of TNFα have been observed in the obese phenotype, 
which decrease with weight loss [149]. It was originally proposed that adipocytes 
were the principle source of raised TNFα levels in obesity, however, it is now well 
recognized that TNFα is abundantly produced by macrophages in the SVF [33, 113, 
147, 148]. TNFα has numerous effects in AT including regulating adipogenesis, lipid 
metabolism and insulin signaling [34, 40]. In addition to its ability to increase other 
pro-inflammatory cytokines [147, 150], TNFα has also been associated with a 
reduction in anti-inflammatory adipokines such as adiponectin [151, 152]. 
Conclusively, TNFα plays a powerful role in regulating inflammatory pathways, 
favouring an overall inflammatory state [40]. 
 
1.8.2. TNFα and serum lipids 
 
The influence of TNFα on lipid metabolism is complex with the underlying 
mechanisms still unclear. However, Chen et al. in his review describes four signal 
pathways involved in TNFα-mediated lipid metabolism [153]. The effects of TNFα on 
lipid metabolism occurs in different cells, tissues, and organs and includes a number 
of metabolic processes. TNFα induces lipolysis, increasing free fatty acid (FFA) 
production. In addition, TNFα regulates cholesterol metabolism and other  
adipocyte-derived adipokines such as leptin, adiponectin, etc. which may also alter 
lipid metabolism [153]. 
 
A number of studies, in cell culture, rodent and human clinical models have 
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confirmed the relationship between TNFα and lipid metabolism [153]. In clinical 
patients with dyslipidaemia, TNFα levels were altered. Compared with healthy 
subjects, patients with hyperlipoproteinaemia showed higher TNFα levels and raised 
T-C, TAG, and LDL-C concentrations. Furthermore, after treatment with fenofibrate, 
T-C, TAG and VLDL-C decreased, which correlated with decreasing TNFα 
concentrations [154]. It has also been shown that cholesterol-lowering drugs such as 
simvastatin and atorvastatin decrease TNFα concentrations [155, 156], and that 
blockading TNFα production improves lipid metabolism [157]. Lastly, administration 
of TNFα interferes with plasma lipid levels [153, 158, 159]. Feingold et al. has shown 
that an increase in hepatic VLDL-TAG secretion induced by TNFα is due to both the 
stimulation of hepatic de novo fatty acid synthesis and an increase in lipolysis [158]. 
 
1.8.3. TNFα and dietary fatty acids 
 
Several studies have investigated the effect of dietary fatty acids on TNFα 
concentrations and TNFA gene expression in cell, animal and human models (Table 
1.2.). Plasma TNFα levels and TNFA gene expression increased in 3T3-L1 
adipocytes incubated with the SFA palmitic acid, whereas incubation with the MUFA, 
oleic acid and the n-3 PUFA, DHA had no effect [160]. In rodent studies, 
supplementing the diet with n-3 PUFA decreased TNFA gene expression in mice 
[161]. In another study, rats were fed a standard diet (18% energy from protein, 76% 
as CHO and 6% of energy as lipid) or a high-fat cafeteria diet (9% energy as protein, 
29% as CHO and 62% as lipid). The high fat diet increased both body weight and fat 
mass, however when these rats were supplemented with EPA they gained less 
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weight, decreased their food intake and increased leptin production. TNFA gene 
expression was also increased by the high fat diet, but not in the rats supplemented 
with EPA [162].  
 
Similar results were reported in human studies; Caucasians supplemented with ALA 
in the form of flaxseed oil in domestic food preparation for four weeks, experienced a 
30% reduction in TNFα production. When these subjects were exposed to further 
supplementation with fish oil (9g/d) for an additional four weeks, TNFα production 
was reduced by up to 70%. There was a significant inverse exponential relationship 
between TNFα synthesis and mononuclear cell content of EPA [163]. Similarly, 
Endres et al. used a radioimmunoassay to measure TNFα produced in vitro by 
stimulated peripheral-blood mononuclear cells. They reported that supplementation 
with n-3 PUFA (18g/d) for six weeks decreased TNFα levels but these levels 
returned to baseline levels once supplementation was stopped [164]. However, 
Grimble et al. demonstrated that the change in TNFα production in response to n-3 
PUFA supplementation depended on the subjects’ plasma TNFα levels prior to 
supplementation, with subjects with lower pre-supplementation TNFα levels showing 
the greatest decrease in TNFα levels post-supplementation [165]. It is possible that 
the inherent inflammatory status, potentially due to a pre-existing condition such as 
obesity, could determine the extent of the inflammatory response to different dietary 
fatty acids. In addition to the independent influence of dietary fatty acids on TNFα 
production, variation in the TNFA gene may also contribute to the individual 
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1.8.4. TNFA gene variants, obesity and serum lipids 
 
Several polymorphisms have been identified in the promoter region of the TNFA 
gene, however the TNFA -308 G>A (rs1800629) and -238 G>A (rs361525) 
polymorphisms are most commonly associated with measures of adiposity, obesity 
risk and serum lipids (Table 1.3). The A allele of the functional -308 G>A 
polymorphism results in a 2-fold increase in TNFA transcription, with a subsequent 
increase in TNFα production [125]. Several studies have reported that carriers of the 
pro-inflammatory -308 A allele (AA and GA genotypes) reported a higher BMI and/or 
percent body fat than those with the GG genotype [167-172]. In a recent meta-
analysis by Yu et al. including 48 eligible studies, the -308 GA+AA genotypes were 
associated with an increased risk of obesity (odds ratio (OR), 1.19; 95% CI,  
1.02–1.39) [126]. This result was consistent with the study by Sookoian et al., who 
performed a meta-analysis of 31 observational studies with a total of 3562 
individuals and showed that individuals with the GA+AA genotypes had a 23% 
elevated risk of obesity compared with the GG genotype (OR, 1.23; 95% CI,  
1.05–1.45) [173]. Not all studies have however shown an association between the  
-308 G>A polymorphism and obesity [173-177]. In comparison to the -308 G>A 
polymorphism, only two studies have investigated the association between the -238 
G>A polymorphism and obesity, and neither found an association between the -238 
G>A polymorphism and BMI [177, 178].  
 
To our knowledge only two papers have found an independent association between 
the -308 G>A polymorphism and serum lipid concentrations. In Caucasian men, the  
-308 A allele was associated with increased TAG [179], and in Polish Caucasian 
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men and women the AA genotype was associated with lower HDL-C concentrations 
compared to the GG genotype [180]. Furthermore, to our knowledge, no 
independent associations have been reported between the -238 G>A polymorphism 
and serum lipid concentrations.  
 
No studies have reported on associations between TNFA polymorphisms, obesity 
and serum lipids in African populations. While the A allele of the -308 G>A and -238 
G>A polymorphisms appear to be associated with the obese phenotype and serum 
lipid concentrations, it is highly likely that genetic variation in the TNFA gene may 
provide only a partial explanation with regards the inter-individual variability observed 
and the heterogeneity of the results in these studies. Other variables such as 
ethnicity, gender, diet, lifestyle and environmental factors may modulate these 
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1.8.5. TNFA gene and diet interactions on obesity and serum lipids 
 
The TNFA -308 G>A and -238 G>A polymorphisms have been shown to modulate 
the relationship between dietary fat intake on obesity and serum lipid profiles (Table 
1.4). Despite studies showing independent associations between the TNFA 
polymorphisms and obesity (Table 1.3.), to our knowledge only one study has 
investigated interactions between diet and the TNFA -308 G>A polymorphism. 
Nieters et al. found that German Caucasian men and women with the -308 A allele, 
who were in the highest tertile for intake of the n-6 PUFAs LA and AA (%E), had an 
increased obesity risk [170]. To date, no studies have reported on diet-gene 
interaction between the -238 G>A polymorphism, dietary intake and obesity (Table 
1.4.).  
 
In contrast, Fontaine-Bisson et al. have shown interactions between the -308 G>A 
and -238 G>A polymorphisms and dietary fat intake on serum lipid profiles (Table 
1.4.). In ethnically diverse diabetic Canadians, PUFA intake was inversely 
associated with HDL-C concentrations in -308 A allele carriers, but positively 
associated with HDL-C concentrations in -238 A allele carriers [182]. In a combined 
analysis in healthy non-diabetic Canadians, they also reported that in individuals with 
the -308 GA + AA & -238 GG genotypes, an inverse relationship was observed 
between HDL-C concentrations and n-3, n-6 and total PUFA intake [183]. These 
diet-gene interactions have not been investigated in African populations, and would 
be of interest due to the higher inflammatory genotype observed, as well as 
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1.9.1. IL-6 and obesity 
 
During an acute incident, the cytokine IL-6 acts as an anti-inflammatory cytokine, but 
in a chronic inflammatory condition, IL-6 is pro-inflammatory, as well as being a key 
regulator of hepatic CRP production [187, 188]. IL-6 is secreted by a variety of cells, 
however approximately 30% of total IL-6 is produced by AT, and macrophages that 
have infiltrated WAT produce approximately 50% of AT-derived IL-6 [187-189]. 
Higher circulating concentrations of IL-6 have been associated with obesity, 
especially VAT deposition [190-192], and decrease in response to weight loss [190, 
193]. One should however cautiously interpret circulating IL-6 levels as both 
adipokines and myokines contribute to IL-6 concentrations. A number of studies 
have reported that contracting muscle fibers secrete IL-6, exerting a local effect 
within the muscle, as well as releasing IL-6 into the circulation [194]. 
 
1.9.2. IL-6 and serum lipids 
 
IL-6 is associated with lipid metabolism and plays a role in the development of 
atherosclerosis through a number of different mechanisms causing metabolic and 
endothelial dysfunction. [36, 189]. IL-6 impairs insulin action, elevating lipolysis, and 
increasing FFA release [195]. The increase in FFAs reduces nitric oxide (NO) 
bioavailability and impairs vasodilation [196]. Insulin resistance and subsequent 
hyperglycaemia also increases lipoprotein oxidation and subsequent increased 
expression of adipocytokines [115]. In rats administered IL-6, serum TAG, T-C levels 
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and hepatic TAG secretion increased [197]. Similarly, in human studies, increased 
IL-6 levels have been associated with an increase in serum TAG and FFAs, and low 
HDL-C concentrations [198, 199]. 
 
1.9.3. IL-6 and dietary fatty acids 
 
Several studies have investigated the effect of different dietary fatty acids on IL-6 
production and IL-6 gene expression in cell, animal and human models, with all 
studies showing similar results (Table 1.5). An in vitro study reported that IL-6 
plasma levels and IL-6 gene expression increased when 3T3-L1 adipocytes were 
incubated with the SFA, palmitic acid, whereas no effect was observed for lauric acid 
(C12:0) and the n-3 PUFA, DHA [69]. Similarly, macrophages treated with EPA or 
DHA showed a decrease in lipopolysaccharide-stimulated (LPS) IL-6 mRNA and IL-6 
production. In agreement with these findings, rats fed a diet high in n-6 PUFA-rich 
sunflower oil showed moderate IL-6 release from adipocytes, which was less than 
when fed a SFA-rich diet, but greater than when fed a MUFA-rich diet [200]. In 
addition, in mice fed a low fat diet or one of two high-fat diets, consisting of either 
unsaturated soybean oil or saturated palmitic acid for 16 weeks, MCP-1 expression 
in AT tissue increased for both high-fat diets compared to the low-fat diet. However, 
the high saturated fat diet also showed a three-fold increase in IL-6 expression in AT 
not observed in the soybean oil diet [201]. 
 
In human studies (Table 1.5.), increased long-chain n-3 PUFA intake and fish 
consumption were associated with decreased plasma IL-6 concentrations and other 
inflammatory markers (matrix metalloproteinase-3, CRP, soluble intercellular 
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adhesion molecule-1) in men from the Multi-Ethnic Study of Atherosclerosis cohort 
[202]. Furthermore, Ferrucci et al. reported that plasma levels of PUFAs, especially 
n-3 PUFAs, were independently associated with lower levels of pro-inflammatory 
markers and higher levels of anti-inflammatory markers [203]. A controlled feeding 
trial investigating the effects of SFA and MUFA–rich diets on serum lipid 
concentrations and whole-genome microarray gene expression profiles of AT, found 
that consuming a SFA-enriched diet for eight weeks resulted in increased expression 
of genes involved in inflammatory processes in AT including IL-6, and NFκB 
signaling, whereas the MUFA-enriched diet led to a more anti-inflammatory gene 
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1.9.4. IL-6 gene variants, obesity and serum lipids 
 
There is growing scientific evidence reporting associations between deoxyribonucleic 
acid (DNA) sequence variants within the IL-6 gene and increased risk of obesity and 
dyslipidaemia (Table 1.6) [187, 189, 206-208]. The most frequently studied IL-6 
polymorphism is -174 G>C (rs1800795). This is a functional polymorphism, with 
most studies showing the -174 C allele to be associated with raised IL-6 and CRP 
concentrations in mostly Caucasian populations [126, 209-212]. Association studies 
between the -174 G>C polymorphism, obesity and dyslipidaemia have yielded 
conflicting results. A recent meta-analysis found the -174 G>C polymorphism was 
associated with obesity [126]. However, this finding was not reproduced in two other 
meta-analyses [210, 213]. The relationship between the -174 G>C polymorphism 
appears to be complex in that while the -174 C allele appears to be the risk allele 
associated with obesity [126], it is the -174 G allele that is associated with raised 
serum lipids concentrations [206, 208, 214], despite the -174 C allele being shown to 
be associated with raised IL-6 and CRP levels [126, 209-212]. The lack of consistent 
results in these association studies may be due to interactions between multiple 
polymorphisms on the IL-6 gene that may modulate these relationships. This was 
illustrated by Qi et al. who found no independent association between the -174 G>C 
polymorphism and obesity, but did identify an association between an IL-6 haplotype 
containing the -174 G>C polymorphism and adiposity in healthy American men and 
women [210].  
 
A number of studies have reported associations between the -174 G>C 




studies [214], for most, in Caucasian men and women the -174 G allele was 
associated with higher T-C, LDL-C, VLDL-C and TAG concentrations compared to 
the C allele [186, 206, 208]. Riikola et al. suggested several possible reasons that 
may explain the inconclusiveness of study results, including differences in body 
mass and body composition, as well as metabolic and pharmacological interference 
in the different study cohorts. They also suggested that the effect of IL-6 on serum 
lipids might differ depending on the phase of development of atherosclerosis. Age 
might also impact these associations as subtle allelic effects observable in young 
populations may be masked by stronger life-long diet and lifestyle covariates in older 




Table 1.6 Studies investigating associations between IL-6 polymorphisms and 
obesity and serum lipids.   









GG: 19.3%; GC: 
51.3%; CC: 29.3% 
In men BMI was higher in the -174 CC 





 • The C allele was associated obesity when 
using allelic comparisons, the recessive 
genetic model and the dominant genetic model 
with OR (95% CI) of 1.95 (1.37-2.77), 1.44 







 • No evidence for association between -174 G>C 
SNP and BMI. 
[213] 
IL-6 -174 











 • No association between -174 G>C SNP and 
adiposity. 
• T allele of the IVS3+281 G>T SNP associated 







men (245) and 
women (252) 
Women, GG: 28%; 
GC: 47%; CC: 24% 
Men, GG: 30%; GC: 
46%; CC: 24% 
• The CC genotype was associated with lower 





GG: 19.3%; GC: 
51.3%; CC: 29.3% 
• In men, serum T-C and LDL-C was higher in 




men (15) and 
women (17) 
GG: 25%; GC: 40.6%; 
CC: 34.4% 
• G allele associated with high carriers TAG, 
VLDL-C and slightly lower HDL-C compared to 





GG: 20.8%; GC: 
50.4%; CC: 28.8% 
• In men for HDL cholesterol was higher for −174 
GG compared to GC or CC  
[214] 
Genotype frequency is expressed as a percentage. The number of subjects (n) is in parentheses. 
Abbreviations: IL, interleukin; SFA; N-W; Normal-weight; WHR, waist-hip ratio; TAG, triglycerides; T-
C, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; T-C:HDL-C ratio 
 
1.9.5. IL-6 gene and diet interactions on obesity and serum lipids 
 
As previously described, studies have shown that dietary fat intake modulates the 
relationship between TNFA gene variants and obesity and serum lipid profiles (Table 
1.4.). However, to our knowledge, only two published studies have reported on the 
relationship between any IL-6 polymorphism and dietary intake, and both studies 




oxidation after a high fat load was increased in obese European Caucasians with the 
-174 C allele [184]. In Spanish men and women with a high CVD risk, the -174 CC 
genotype was associated with higher levels of adiposity at baseline, however after 
three years of nutritional intervention, those with the -174 CC genotype following a 
Mediterranean-style diet, had the greatest reduction in body weight [185].  
 
To our knowledge only a single study has reported an interaction between the -174 
G>C polymorphism and dietary intake on serum lipids concentrations in a Caucasian 
population. In this study, those individuals with the G allele had higher post-glucose 
load TAG and VLDL-C concentrations, and higher post-glucose load FFA levels than 
C allele carriers [186].  
 
No studies have reported on IL-6 associations, or on diet-IL-6 gene interactions with 
obesity and serum lipids in African populations. The -174 G>C polymorphism is rare 
in individuals of African ancestry, is not informative, and has therefore not been 
studied in African populations. However, it would be valuable to identify and 
investigate IL-6 polymorphisms that are representative in these populations. 
 
1.10. Literature summary and conclusions  
 
Both black and white SA women present with a high prevalence of overweight and 
obesity, however the co-morbidities associated with excess AT in these two groups 
appear to be different. Despite black SA women being more obese than white SA 
women, they have a less atherogenic lipid profile than the white women. Obesity and 




multifactorial aetiology. Obesity is considered a chronic low-grade inflammatory 
condition. Hypertrophic AT is associated with macrophage infiltration and 
subsequent raised inflammatory markers. Elevated inflammatory markers are 
associated with oxidative modification of serum lipids and all stages of 
atherosclerosis. Therefore, low-grade inflammation is a plausible mechanism 
underlying both obesity and dyslipidaemia.  
 
Different dietary fatty acids, as well as genetic sequence variants of inflammatory 
genes have been shown to alter inflammatory gene expression and protein 
production. This review suggests that polymorphisms involved in inflammation may 
interact with environmental exposures such as dietary intake, to modulate an 
individual’s susceptibility to developing obesity and dyslipidaemia. 
 
Two key and well-researched inflammatory cytokines are TNFα and IL-6, which have 
been discussed in detail in this review. In summary, dietary fatty acids, in particular 
SFAs and the n-3 and n-6 PUFAs impact the expression of the cytokine genes TNFA 
and IL-6, and alter TNFα and IL-6 production. In addition, polymorphisms in these 
genes have also been shown to alter their gene expression and plasma levels, and 
are associated with obesity, measures of adiposity and serum lipid concentrations.  
 
To our knowledge, only a few studies have examined interactions between dietary 
fatty acids and the TNFA -308 G>A and -238 G>A polymorphisms on obesity [170], 
and serum lipid concentrations [182, 183], and interactions between dietary fatty 
acids and the IL-6 -174 G>C polymorphism on obesity [184, 185], and serum lipids 






In summary, Nieters et al. found that German Caucasians with the TNFA -308 A 
allele, who were in the highest tertile for intake of the n-6 PUFAs had an increased 
obesity risk [170]. In ethnically-diverse diabetic and non-diabetic Canadians, 
Fontaine-Bisson et al. reported interactions between n-3, n-6 and total PUFA intake 
and the TNFA -308 G>A and -238 G>A polymorphisms on HDL-C concentrations 
[182, 183].  
 
Corpeleijn et al. reported that obese European Caucasians with the IL-6 -174 C 
allele exhibited an ability to increase fat oxidation after a high fat load [184]. In a 
Spanish population, the IL-6 -174 CC genotype was associated with higher levels of 
adiposity at baseline, but these individuals had the greatest reduction in body weight 
after following a Mediterranean-style diet [185]. In another Spanish Caucasian 
population, individuals with the IL-6 -174 G allele had higher post-glucose load TAG 
and VLDL-C concentrations, and higher post-glucose load FFA levels than C allele 
carriers [186].  
 
To our knowledge, there are no studies that have examined these polymorphisms, 
and their association with obesity and serum lipids, nor the impact of diet-gene 
interactions on obesity and serum lipids in African populations.  This is of interest 
due to the higher inflammatory genotype observed in black populations, as well as 






The inter-individual and ethnic variability in the obese phenotype and serum lipid 
profiles, and inconsistencies in study results may be better understood by 
researching diet-gene interactions more extensively, and understanding further the 
role of ethnicity as a confounder. Understanding the complexity of obesity and its co-
morbidities in SA will require a greater understanding of dietary intake, especially 
intake of individual dietary fatty acids, the frequency of polymorphisms in different 
populations and how these factors may interact in different ethnic groups in SA. 
 
1.11. Aims and objectives  
 
In a convenience sample of urbanized black and white SA women, the primary aim 
of the thesis was to investigate associations between TNFA and IL-6 sequence 
variants and obesity and serum lipid concentrations. Only women were included 
because of the high prevalence of obesity reported in black and white SA women [3, 
7]. Only black and white SA populations were compared, due to the disparities in 
obesity risk and risk for dyslipidaemia and CAD observed in these two groups[8]. 
 
The candidate genes (TNFA and IL-6) were selected based on the biological function 
of their encoded proteins (TNFα and IL-6), and the role they play in both systemic 
and adipose tissue inflammation. The objectives of the specific gene association 
studies that addressed the primary aim of this thesis were as follows: 
 
• Characterise ethnic differences in measures of adiposity and serum lipid 
levels between black and white SA women (Chapter 3). 




polymorphisms and obesity, measures of adiposity and serum lipid 
concentrations in both black and white SA women (Chapters 3 & 4). 
• In addition to the commonly researched polymorphism IL-6 -174 G>C, which 
has a low frequency in black populations; identify sequence variants in the  
IL-6 gene with a reported high heterozygosity in both the white and black SA 
populations (rs1554606: IVS3+281 G>T, intron 3 and rs2069845: IVS4+869 
A>G, intron 4) (Chapter 5).   
• Determine if the IL-6 polymorphisms (-174 G>C, IVS3+281 G>T, IVS4+869 
A>G), were associated with obesity, measures of adiposity and serum lipid 
concentrations in black and white SA women (Chapter 5). 
• A secondary objective of these studies was to investigate if these associations 
differed between black and white SA ethnic groups (Chapters 3,4 & 5). 
 
The secondary aim of this thesis was to investigate interactions between TNFA and 
IL-6 polymorphisms (TNFA -308 G>A and -238 G>A & IL-6 -174 G>C, IVS3+281 
G>T, IVS4+869 A>G) and dietary fatty acids on obesity, measures of adiposity and 
serum lipid concentrations. The objectives of the interaction studies that addressed 
the secondary aim of this thesis were as follows: 
 
• Determine dietary intake, in particular dietary fatty acid intake of black and 
white SA women (Chapter 3). 
• Investigate interactions between the TNFA -308 G>A polymorphism and 
dietary fatty acids on obesity and serum lipids in black and white SA women 
(Chapter 3). 




dietary fatty acids on obesity and serum lipids in black and white SA women 
(Chapter 4). 
• Investigate interactions between the IL-6 -174 G>C, IVS3+281 G>T, 
IVS4+869 A>G polymorphisms and dietary fatty acids on obesity and serum 
lipids in black and white SA women (Chapter 6). 
• A secondary objective of these studies was to investigate if interactions 


















2.1. Subject selection 
 
A convenience sample of 107 normal-weight (BMI ≤ 18.5- 24.9 kg/m²) and 120 
obese (BMI ≥ 30 kg/m²) urban black and 89 normal-weight and 62 obese 
urban white SA women between the ages of 18 and 45 years were recruited in 
the greater Cape Town area, from 2004 to 2006. White and black subjects 
were recruited from church groups, community centres, and universities. 
Racial identity was self-reported. Subjects who reported both parents as black, 
or both parents as white, where included in the study. The majority of the 
black participants reported being of Xhosa ancestry (n=186, 78%), the 
remaining women were either of Zulu (n=4, 1.6%), Pedi (n=4, 1.6%), Tswana 
(n=3,1.2%), or mixed SA tribal ancestry (n=25, 10%), other black ancestries 
each represented less than 1%. Other inclusion criteria included: no previous 
diagnosis or undergoing therapy for diabetes, hypertension, dyslipidaemia, 
HIV or other metabolic diseases, and not currently pregnant or lactating. Only 
women were included because of the high prevalence of overweight and 
obesity seen in both black and white SA women, and because of the 
differences in serum lipids between black and white women previously 
described [19]. Only 73 normal-weight and 74 obese black, and 73 normal-
weight and 48 obese white adequate reporters, according to the Goldberg cut-
offs, were included in the analysis, as described below [215]. Specific 
numbers are given in each chapter as study group numbers differ for each 
chapter according to the number of subjects that were successfully genotyped 





2.2. Ethics approval 
 
Approval was obtained from the Human Research Ethics Committee of the 
Faculty of Health Sciences at the University of Cape Town (REC REF: 101/2004) 
(Chapter 10, appendix), and written informed consent was obtained from all 
participants prior to participation. The study was performed in accordance with 
the principles of the Declaration of Helsinki, ICH Good Clinical Practice (GCP). 
 
2.3. Assessment Methods  
 
2.3.1. Body Composition 
 
Basic anthropometric measurements included weight (in light-weight clothing 
without shoes), height, waist circumference (at the level of umbilicus) and hip 
circumference (largest gluteal area). Whole body composition was measured 
using dual-energy X-ray absorptiometry (DXA) (Hologic QDR 4500 Discovery-W 
dual-energy X-ray absorptiometer, software version 4.40, Hologic Inc., Bedford, 
MA, USA) according to standard procedures. In vivo precision (%CV) was 
determined for fat-free tissue mass (0.7%) and fat mass (1.7%) by measuring 
thirty individuals twice on the same day with re-positioning. The arm-replacement 
method was used to determine body composition in individuals who exceeded 
the scanning area (n=16) [216]. This method requires the radiographer to use the 
data from one arm for both arms. This method has been shown to be more 




half-body method proposed by Tataranni et al. [217].  A single slice computerised 
tomography (CT, Toshiba Xpress Helical Scanner, Japan) scan was taken at the 
level of the L4-L5 lumbar vertebrae to determine abdominal VAT and SAT [104]. 
Basic anthropometry was completed before measurement of body fat percentage 
by DXA.  
 
2.3.2. Blood sampling and analysis 
 
Blood samples were drawn from the antecubital vein after an overnight (10-12 
hours) fast for the determination of TAG, T-C, HDL-C, and LDL-C concentrations, 
and for DNA extraction. Serum TAG, T-C, and HDL-C concentrations were 
measured on the Roche Modular Auto Analyzer using enzymatic colorimetric 
assays. LDL-C was calculated using the Friedewald equation [218].  
 
2.3.3. Dietary assessment  
 
Dietary intake was estimated using a food frequency questionnaire from Steyn 
and Senekal that represents monthly intake [219] (Chapter 10, appendix), and 
has been validated in black SA women by De Villiers et al. [220]. The 
questionnaire comprises 100 food items with food photographs to determine 
portion size. The questionnaire was administered by registered dieticians. 
Nutrient intake was calculated by means of the software program FoodFinder, 
III™ (SA Medical Research Council, Cape Town, SA)[221]. Under-reporting and 
over-reporting were detected on the basis of the ratio of energy intake 




equation [215]). Upper and lower cut-points were calculated assuming a 
sedentary lifestyle of 1.55 x basal metabolic rate as defined by the physical 
activity level values from the World Health Organisation (WHO) recommended 
energy requirements [222]. Participants were defined as adequate reporters if 
this ratio was between 1.05 and 2.28 [215]. They included 42 under-reporters, 
268 adequate reporters, and 73 over-reporters. Only adequate reporters were 
included in the diet analyses. All subject characteristics, body composition, serum 
lipids and dietary intake of the reporters groups, both as a combined group (Table 
2S I), and separately for black (Table 2S II) and white (Table 2S III) women, are 
described in Chapter 9 (Supplementary data). 
 
The Goldberg cut-offs [215] were used to classify individuals into energy intake 
reporting groups as it removes bias in energy intake based on size. Resting 
energy expenditure varies considerably between individuals with a low and high 
body mass, markedly affecting their energy intake requirements. The effect of 
body size on energy intake reporting is of particular relevance in the SA 
population as it has recently been shown that in a study including 198 SA 
women, 45% of black women under-reported their energy intake, of which 83% of 
these black under-reporters were obese (Personal communication, Z. Mciza, 
Human Science Research Council, Nutrition Unit. Research done with the 
University of Cape Town, SA, Human Biology Department). As this study focused 
on obesity and the sample comprised normal-weight and obese women, it was 






2.4. Genotyping  
 
2.4.1. DNA extraction  
 
Approximately 5 ml of venous blood was collected from the antecubital vein of the 
subjects into an ethylenediaminetertaacetic acid (EDTA) vacutainer tube. 
Samples were stored at 4°C for no longer than one week until DNA was 
extracted using a modification of the method of Lahiri and Nurnberger [223]. In 
brief, the blood samples were transferred into sterile 15 ml polypropylene tubes 
with 10 ml of TKM1 buffer (10 mM Tris-HCl, pH 7.6; 10 mM KCl; 10 mM MgCl2; 2 
mM EDTA) containing 2.5% Nonidet P-40 to lyse the red blood cells. After a 10 
minute incubation period at room temperature, the white blood cells were 
centrifuged at 1200 X g for 10 minutes at room temperature. The supernatants 
were discarded and the pellets resuspended in 5 ml of TKM1 buffer without 
NP40, by vortexing for 2 minutes. The samples were then centrifuged at 1200 X g 
for 10 minutes at room temperature, the supernatants were discarded and the 
pellets resuspended in 800 µl of TKM2 buffer (10 mM Tris-HCl, pH 7.6; 10 mM 
KCl; 10 mM MgCl2; 2 mM EDTA; NaCl 0.4 M) containing 0.6% sodium-dodecyl-
sulphate (SDS) by vortexing for 4 minutes. The samples were then incubated at 
55°C in a water bath for 1 hour or until the pellets had completely dissolved, after 
which 150 µl of 5 mM NaClO4 and 500 µl of analytical grade chloroform were 
added to the dissolved pellets. After vortexing for 15 seconds, the solutions were 
transferred into sterile 1.5 ml microfuge tubes and centrifuged at 600 X g for 10 
minutes at room temperature. The top aqueous phases (approximately 500 µl) 




was added to precipitate the DNA. The samples were then centrifuged at 600 X g 
for 10 minutes at room temperature, forming a pellet of DNA in the bottom of the 
tubes. The supernatants were removed and the DNA was left to air dry for up to 
10 hours. The DNA was resuspended in 200 µl of Tris-EDTA buffer (10 mM  
Tris-HCl 10, pH 8.0; 1 mM EDTA). The samples were incubated for 15 minutes at 
65°C and stored at 4°C until PCR analysis.  
 
2.4.2. Genotype analysis  
 
For all polymorphisms genotyped, several negative control samples (containing no 
DNA), and positive controls were included on each 96 well polymerase chain 
reaction (PCR) plate in order to detect PCR contamination. The positive controls 
included a known sample for each of the three genotypes and the negative controls 
included three sample with no DNA included in the reaction. In addition, several DNA 
samples were randomly selected and re-analysed to confirm genotype results. All 
the negative and positive control samples gave the same results during all the 
analyses.  
 
2.4.2.1. TNFA -308 G>A  
 
DNA samples were genotyped for the functional -308 G>A polymorphism 
(rs1800629) within the proximal promoter of the TNFA gene by restriction 
fragment length polymorphism (RFLP) analysis using a nested PCR based 




forward primers F1 (5’-CTG AAG CCC CTC CCA GTT CTA-3’) and F2 (5’-AGG 
CAA TAG GTT TTG AGG GCC-3’), and reverse primers R1 (5’-GCT CAT CTG 
GAG GAA GCG GTA-3’) and R2 (5’-TCC TCC CTG CTC CGA TTC CG-3’) 
(Figure 2.1). The F2 primer contains a modified nucleotide (underlined C), which 
creates a NcoI restriction recognition site in the secondary wild type PCR 
product. 
 
Figure 2.1. A 600 bp genomic sequence within the proximal promoter of the human TNFA gene 
is shown to indicate the position of the outer forward (F1) and reverse (R1) primers (solid arrows) 
designed to amplify the primary 326 bp fragment. The positions of the nested forward (F2) and 
reverse (R2) primers (dashed arrows) designed to amplify the secondary 107 bp PCR fragment, 
which contains the -308 G>A transition (rs1800629), is also indicated. In addition the primer 
sequences are also in bold. The F2 primer contains a modified nucleotide, which is in lower case 
(c) and introduces a NcoI restriction recognition site (5’-CCATGG-3’) in the amplified wild type 
sequence. Polymorphism rs1800629 is indicated with an R and the NcoI site is underlined with a 
dashed line. The G to A substitution eliminates the NcoI restriction site, therefore the 107 bp 
fragment is only digested when the G allele is present (87 bp and 20 bp). The sequence was 
obtained from Ensembl Transcript TNF-001 ENST00000448781 (www.ensembl.org). 






The primary PCR reaction included approximately 100 ng genomic DNA, 20 pmol 
of the F1 and R1 primers, 20 mM Tris-HCl (pH 8.4), 10 mM KCl, 2 Mm MgCl2, 20 
Mm MgSO4, 125 µM each dATP, dCTP, dTTP, and dGTP, and 0.5 U of Taq 
polymerase (New England Biolabs, Ipswich, Massachusetts, USA) in a final 
volume of 50 µl. The nested PCR reaction was as described above, except; 10 µl 
of the primary 326 bp PCR product was used and the F2 and R2 primers, in a 
final volume of 50 µl. 
 
Both the primary and secondary PCR amplifications were performed with an (i) 
initial denaturing step for two minute at 94°C; (ii) followed by 35 cycles of 
denaturing for 1 minute at 94°C, annealing for 1 minute at 55°C, and extension 
for 1 minute at 72°C; (iii) and a final extension at 72°C for 5 minutes (BIOER XP 
Thermal Cycler PCR machine, Bioer technology Co. Ltd. Tokyo, Japan). 
 
The 107 bp secondary PCR products were digested with 5U of the restriction 
endonuclease NcoI (New England Biolabs, Ipswich, MA, USA) at 37°C for 4 
hours following the manufacturers instructions. The resultant fragments together 
with a 100 bp molecular weight marker (Promega Corporation, Madison, 
Wisconsin, USA), and SYBER® Gold nucleic acid stain (Invitrogen Molecular 
probes™, Oregon, USA) were separated on 8% non-denaturing polyacrylamide 
gels. The gels were photographed under UV light using the Uvitec photo 
documentation system (Uvitec Limited, Cambridge, UK) and the size of the DNA 
fragments determined. The A allele (restriction site absent) produces a 107 bp 






Figure 2.2. A typical 8% non-denaturing polyacrylamide gel showing the genotypes of the TNFA -
308 G>A single nucleotide polymorphism. The 107 bp secondary PCR product was digested with 
NcoI to produce 87 bp and 20 bp fragments for the G allele. NcoI is unable to digest the 107 bp 
PCR product when the A allele is present. The genotype of the samples is indicated at the top of 
the lane. The left lane contains the 100 bp molecular weight marker (MW) and the appropriate 
fragment sizes are given in base pairs. Abbreviations: bp, base pair; PCR, polymerase chain 
reaction; TNFA, tumour necrosis alpha gene. 
 
2.4.2.2. TNFA -238 G>A 
 
DNA samples were genotyped for the -238 G>A polymorphism (rs361525) within 
the proximal promoter of the TNFA gene by RFLP analysis as previously 
described [225] using the following forward (5’-AAA CAG ACC ACA GAC CTG 
GTC-3’) and reverse (5’-CTC ACA CTC CCC ATC CTC CCG GAT C-3’) primers 
(Figure 2.3.). The reverse primer contains two modified nucleotides (underlined G 
and A), which creates a BamHI restriction site in the amplified wild type 
sequence. The PCR reactions included approximately 100 ng genomic DNA, 10 




dATP, dCTP, dTTP, and dGTP, and 0.5 U of Taq polymerase (New England 
Biolabs, Ipswich, Massachusetts, USA) in a final volume of 50 µl.  
 
Figure 2.3. A 600 bp genomic sequence within the proximal promoter of the human TNFA gene. 
The positions of the forward (F1) and reverse (R1) primers are indicated with solid arrows. In 
addition the primer sequences are also in bold. The reverse primer contains two modified 
nucleotides, which are in lower case (t and c) and creates a BamHI (5’-GGATCC-3’) restriction 
site in the amplified wild type sequence. The forward and reverse primers were used to amplify a 
155 bp PCR fragment which contains the -238 G>A transition (rs361525). Polymorphism 
rs361525 is indicated with an R. The G to A substitution eliminates the BamHI restriction site. 
Therefore only the 155 bp wild type PCR fragment is cleaved into 129 and 25 bp with BamHI. The 
sequence was obtained from Ensembl Transcript TNF-001 ENST00000448781 
(www.ensembl.org). Abbreviations: bp, base pair; PCR, polymerase chain reaction; TNFA, tumour 
necrosis alpha gene. 
 
The PCR amplifications were performed with an (i) initial denaturing step for two 
minute at 94°C; (ii) followed by 35 cycles of denaturing for 30 seconds at 94°C, 
annealing for 1 minute at 59°C, and extension for 2 minute at 72°C; (iii) and a 
final extension at 72°C for 5 minutes (BIOER XP Thermal Cycler PCR machine, 




The 155 bp PCR products were digested with 5 U of the restriction endonuclease 
BamHI (New England Biolabs, Ipswich, MA, USA) at 37°C for 4 hours following the 
manufacturers instructions. The resultant fragments together with a 100 bp 
molecular weight marker (Promega Corporation, Madison, Wisconsin, USA), and 
SYBER® Gold nucleic acid stain (Invitrogen Molecular probes™, Oregon, USA) 
were separated on 2% agarose gels. The gels were photographed under UV light 
using the Uvitec photo documentation system (Uvitec Limited, Cambridge, UK) and 
the size of the DNA fragments determined. The G to A substitution eliminates a 
BamHI restriction site. The digested G allele produces 129 bp and 25 bp fragments, 
while the A allele remains uncut (155 bp) (Figure 2.4.).  
 
Figure 2.4. A typical 2% agarose gel showing the GG and GA genotypes of the TNFA -238 G>A 
polymorphism. The 155 PCR products were digested with BamHI to produce 129 bp and 25 bp 
fragments with the G allele. BamHI is unable to digest the 155 bp PCR product when the A allele 
is present. The genotype of samples is indicated at the top of each lane. The left lane contains 
the 100 bp molecular weight marker (MW) and the appropriate fragment sizes are given in base 






2.4.2.3. IL-6 polymorphism selection 
 
The IL-6 gene spans a physical region of 4.8 kb located on chromosome 7p21 
and includes five exons and four introns.  The information from the databases 
hosted by the National Centre for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/) and Ensemble Genome Data Centre 
(www.ensembl.org) were used to construct a schematic representation of the 
exon and intron boundaries of IL-6 and selected polymorphisms mapped to this 
region (Figure 2.5.).  
 
Figure 2.5. A schematic representation of the IL-6 gene. The relative sizes and positions of the 
exons (boxes), introns (vertical lines) and proximal promoter (vertical line) are shown. The 5’- and 
3’-UTRs are indicated as clear boxes, while the translated exons or part of the exons are 
indicated as black boxes. The number of SNPs identified within the UTRs and introns are 
indicated in Table 2S IV (Chapter 9) in Supplementary data. The accession numbers, amino acid 
substitutions and/or nucleotide changes of selected polymorphisms are annotated. Specifically 
the accession numbers as well as the RFLPs of the three IL-6 polymorphisms used in this study 
(rs1800795, rs1554606, rs2069845) (boxed) are also annotated. All the information used to 
construct this figure was obtained from databases hosted by the National Centre for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov/) and Ensemble Genome Data Centre 
(www.ensembl.org). Abbreviations: IL-6, interleukin 6; RFLP, restriction fragment length 
polymorphism analysis; SNP, single nucleotide polymorphism; TNFA, tumour necrosis alpha 





Polymorphisms with the highest heterozygous frequencies (potentially informative 
polymorphisms) within both the Caucasian and black populations were identified 
(Table 2S IV, Chapter 9 (Supplementary data)) Preference was given to 
functional polymorphisms or nonsynonomous coding variants, i.e. polymorphisms 
that change the amino acid sequence.  The most extensively studied 
polymorphism within the IL6 gene is the G>C functional promoter polymorphism 
at position -174 has a low frequency (<5%) in the black population [133], and was 
therefore expected to be low in the SA black population.  Only four 
polymorphisms were identified within the coding region of IL-6 of which three 
were non-synonomous. However, the heterozygote frequencies of all four 
polymorphisms within the black population were either low (<10%) or not 
determined and were therefore not selected. These four polymorphisms were 
therefore considered non-informative in the black population and were not 
selected for this study.  The large majority of the polymorphisms mapped to the 
non-coding regions of the IL-6 gene; 19 polymorphisms were located within intron 
two, 11 polymorphisms within intron three, and eight polymorphisms within intron 
four. Two of these polymorphisms (rs1554606, rs2069845) had a high 
heterozygous frequency within both the black and Caucasian populations (Table 
2S IV, Chapter 9 (Supplementary data)). In addition, these polymorphisms 
altered restriction enzyme recognition sequences, which facilitated RFLP analysis 
and they were therefore considered suitable for this genetic association study 







2.4.2.4. IL-6 -174 G>C 
 
Genotyping of the -174 G>C polymorphism (rs1800795) within the promoter of 
the IL-6 gene was performed by PCR amplification and digested with the SfaN1 
restriction enzyme as previously described [186] (Figure 2.6.). A 227 bp fragment 
corresponding to the -246 to -473 bp region of the IL-6 gene promoter region, 
was PCR amplified using the forward primer 5’-TTT TCT CTT TGT AAA ACT 
TCG TGC ATC ACT T-3’ (the modified nucleotide is underlined), in which an 
SfaN1 site was created, and reverse primer 5’-TGG GGC TGA TTG GAA ACC 
TTA TTA AG-3’ as previously described with slight modifications (Fishman et al. 
1998). The PCR reactions were carried out in a final volume of 50 µl containing at 
least 100 ng genomic DNA, 20 pmol of the forward and reverse primers, 20 mM 
Tris-HCl (pH 8.4), 10 mM KCl, 2 mM MgCl2, 20 mM MgSO4, 125 µM each dATP, 
dCTP, dTTP, and dGTP, and 0.5 U of Taq DNA polymerase (New England 







Figure 2.6. A 540 bp genomic sequence within the proximal promoter of the human IL-6 gene. 
The positions of the forward (F) and reverse (R) primers are indicated with solid arrows. In 
addition the primer sequences are also in bold. The forward primer contains a modified nucleotide 
(lower case c) in which an internal SfaN1 (5’-GCATG-3’) site in the PCR fragment was created 
(positive digestion control). The naturally occurring positive digestion control NlaIII (5’-CATG-3’) 
site with the PCR fragment is also indicated. In addition the reverse complement sequences of 
the SfaN1and NlaIII restrictions sites, which includes polymorphism rs1800795 (C>G) are also 
indicated. polymorphism rs1800795 is indicated with an S. The 228 bp PCR product was digested 
with SfaN1 to produce fragments of 196 bp and 32 bp for the C allele and 137 bp, 59 bp and 32 
bp for the G allele. The NlaIII enzyme produced 123 bp, 56 bp and 49 bp fragments for the C 
allele and 172 bp and 56 bp fragments for the G allele. The sequence was obtained from 
ensemble (www.ensembl.org) IL-6 gene product ENSG00000136244. Abbreviations: bp, base 
pair; IL-6, interleukin 6; PCR, polymerase chain reaction. 
 
The samples were amplified with a BIOER XP Thermal Cycler PCR machine 
(Bioer technology Co. Ltd. Tokyo, Japan), using the following conditions: (i) an 
initial denaturing step for 5 minutes at 94oC; (ii) followed by 35 cycles of 
denaturing for 1 minute at 94oC, annealing for 105 seconds at 60oC, and 






The 228 bp PCR product was digested with SfaN1 (New England Biolabs, 
Ipswich, MA, USA) at 37°C for 4 hours to produce fragments of 196 bp and 32 bp 
for the C allele and 137 bp, 59 bp and 32 bp for the G allele (Figure 2.7.).  
Genotypes were confirmed by also digesting the PCR products with NlaIII (New 
England Biolabs, Ipswich, MA, USA) at 37°C for 4 hours to produce 123 bp, 56 
bp and 49 bp fragments for the C allele and 172 bp and 56 bp fragments for the 
G allele (Figure 2.8.).  The resultant fragments together with a 100 bp molecular 
weight marker (Promega Corporation, Madison, Wisconsin, USA), and SYBER® 
Gold nucleic acid stain (Invitrogen Molecular probes™, Oregon, USA) were 
separated on 8% non-denaturing polyacrylamide gels. The gels were 
photographed under UV light using the Uvitec photo documentation system 







Figure 2.7. A typical 8% non-denaturing polyacrylamide gels showing the genotypes of the IL-6  
-174 G>C polymorphism. The 228 bp PCR product was digested with SfaN1 to produce 196 bp 
and 32 bp fragments for the C allele and 137 bp, 59 bp and 32 bp for the G allele. The genotype 
of samples is indicated at the top of the lane. The left lane contains the 100 bp molecular weight 
marker (MW) and the appropriate fragment sizes are given in base pairs (bp). Abbreviations: bp, 
base pair; IL-6, interleukin 6; PCR, polymerase chain reaction. 
 
 
Figure 2.8. A typical 8% non-denaturing polyacrylamide gels showing the genotypes of the IL-6 -
174 G>C polymorphism. The 228 bp PCR product was digested with NlaIII to produce 123 bp, 56 
bp and 49 bp fragments for the C allele and 172 bp and 56 bp fragments for the G allele. The 
genotype of samples is indicated at the top of the lane. The left lane contains the 100 bp 
molecular weight marker (MW) and the appropriate fragment sizes are given in base pairs . 





2.4.2.5. IL-6 IVS3+281 G>T  
 
DNA samples were genotyped for the IVS3+281 G>T (rs1554606) polymorphism 
in intron 3 of the IL-6 gene (Figure 2.9.). The 472 bp fragment of intron 3 of the 
human IL-6 gene was PCR amplified using forward primer 5’-GTA CCA ACT TGT 
CGC ACT CA-3’ and reverse primer 5’-GGA TCC TTC TCT GAT TGT CC-3’ 
(Figure 2.11). The PCR reactions were performed in a final volume of 50 µl 
containing at least 100 ng of genomic DNA, 10 mM Tris-HCl (pH 8.3), 10 mM 
KCl, 1.5 mM MgCl2, 2.5 mM each of dATP, dTTP, dCTP and dGTP, 0.5 U Taq 







Figure 2.9. A 540 bp genomic sequence, including nucleotides 1 to 540, of the 707 bp intron 3 of 
the human IL-6 gene. The positions of the forward (F) and reverse (R) primers are indicated with 
solid arrows. In addition the primer sequences are also in bold. The 472 bp PCR fragment, 
contains the IL-6 IVS3+281 (G>T) polymorphism (rs1554606), which is indicated with a K. The G 
to T substitution creates a DdeI restriction site (5’-CTCAG-3’) in the amplified 472 bp fragment. 
The G allele eliminates the DdeI restriction site, therefore the 472 bp fragment is only digested 
when the T allele is present (191 bp, and 281 bp). The sequence was obtained from ensemble 
(www.ensembl.org) IL-6 gene product ENSG00000136244. Abbreviations: bp, base pair; IL-6, 
interleukin 6; PCR, polymerase chain reaction. 
 
 
Samples were amplified with a BIOER XP Thermal Cycler PCR machine (Bioer 
technology Co. Ltd. Tokyo, Japan), using the following conditions: (i) 5 minutes at 
94˚C; (ii) 30 cycles of denaturing for 30 seconds at 94˚C, annealing for 30 
seconds at 58˚C, and extension for 40 seconds at 72˚C; (iii) followed by a final 
extension step for 5 minutes at 72˚C. Twenty-five µl of PCR product was digested 
with 5U of the restriction endonuclease DdeI in a final volume of 30 µl overnight 




together with a 100 bp molecular weight marker (Promega Corporation, Madison, 
Wisconsin, USA), and SYBER® Gold nucleic acid stain (Invitrogen Molecular 
probes™, Oregon, USA) were separated on 8% non-denaturing polyacrylamide 
gels. The gels were photographed under UV light using the Uvitec photo 
documentation system (Uvitec Limited, Cambridge, UK) and the size of the DNA 
fragments determined. The digested 472 bp PCR product produced fragments of 








Figure 2.10. A typical 8% non-denaturing polyacrylamide gels showing the genotypes of the IL-6 
IVS3+281 G>T polymorphism. The 472 bp PCR products were digested with DdeI to produce 34 
bp, and 438 bp for the G allele, and 34 bp, 191 bp, and 247 bp for the T allele. The genotype of 
samples is indicated at the top of the lane. The left lane contains the 100 bp molecular weight 
marker (MW) and the appropriate fragment sizes are given in base pairs. Abbreviations: bp, base 
pair; IL-6, interleukin 6; PCR, polymerase chain reaction. 
 
 
2.4.2.6. IL-6 IVS4+869 A>G 
 
DNA samples were genotyped for the IVS4+869 A>G (rs 2069845) polymorphism 
in intron 4 of the IL-6 gene (Figure 2.11.). The 383 bp fragment corresponding to 
the 694 to 1076 region of intron 4 of the human IL-6 gene was PCR amplified 
using the forward primer 5’-GAG TCT GAC TTA GCA AGC CTC CGG T-3’ and 
the reverse primer 5’-CCA AGC CTG ACC AGC ATC ACT ATC-3’ (Figure 2.11.). 
The forward primer contains a modified nucleotide (underlined C), which creates 














Figure 2.11. A 540 bp genomic sequence, including nucleotides 601 to 1140, of 1745 bp intron 4 
of the human IL-6 gene. The positions of the forward (F) and reverse (R) primers are indicated 
with solid arrows. In addition the primer sequences are also in bold. The forward primer contains 
a modified nucleotide, which is indicated by a lowercase c, to create an internal MspI (5’-CCGG-
3’) restriction site in the amplified PCR product. The forward and reverse primers were used to 
amplify a 383 bp PCR fragment, which contains the IL-6 IVS4+869 (A>G) polymorphism 
(rs2069845). Polymorphism rs2069845 is indicated with an R. The A to G substitution creates a 
MspI restriction site in the amplified product. The digested 383 bp PCR product produced 
fragments of 21 bp, 155 bp, and 207 bp for the G allele, and 21 bp and 362 bp for the A allele. 
The sequence was obtained from ensemble (www.ensembl.org) IL-6 gene product 
ENSG00000136244. Abbreviations: bp, base pair; IL-6, interleukin 6; PCR, polymerase chain 
reaction. 
 
The PCR reactions were performed in a final volume of 50 µl containing at least 
100 ng of genomic DNA, 10 mM Tris-HCl (pH 8.3), 10 mM KCl, 1.5 mM MgCl2 , 
2.5 mM each of dATP, dTTP, dCTP and dGTP, 0.5 U Taq polymerase, and 20 
pmol each of the forward and reverse primers. Samples were amplified with a 
BIOER XP Thermal Cycler PCR machine (Bioer technology Co. Ltd. Tokyo, 
Japan), using the following conditions: (i) 5 minutes at 94˚C; (ii) 30 cycles of 
denaturing for 30 seconds at 94˚C, annealing for 30 seconds at 58˚C, and 
extension for 40 seconds at 72˚C; (iii) followed by a final extension step for 5 
minutes at 72˚C. Twenty five µl of PCR product was digested with 5U of the 
restriction endonuclease MspI in a final volume of 30 µl overnight at 37˚C 
following the manufacturers instructions. The resultant fragments together with a 




USA), and SYBER® Gold nucleic acid stain (Invitrogen Molecular probes™, 
Oregon, USA) were separated on 8% non-denaturing polyacrylamide gels. The 
gels were photographed under UV light using the Uvitec photo documentation 
system (Uvitec Limited, Cambridge, UK) and the size of the DNA fragments 
determined. The digested 383 bp PCR product produced fragments of 21 bp, 155 
bp, and 207 bp for the G allele, and 21 bp and 362 bp for the A allele (Figure 




Figure 2.12. A typical 8% non-denaturing polyacrylamide gels showing the AA and AG genotypes 
of the IL-6 IVS4+869 A>G polymorphism. The 383 bp PCR product was digested with MspI to 
produce 21 bp, 155 bp, and 207 bp fragments for the G allele, and 21 bp and 362 bp fragments 
for the A allele. The genotype of the samples is indicated at the top of the lane. The left lane 
contains the 100 bp molecular weight marker (MW) and the appropriate fragment sizes are given 






2.5. Statistical analysis 
 
2.5.1. Study groups 
 
In order to explore the metabolic effects of extreme ranges in BMI and hence 
most other measures of obesity and body fat distribution, while maintaining a 
unimodal distribution for the lipid profile, only normal-weight and obese women 
were recruited.  Accordingly, 107 normal-weight and 120 obese black and 89 
normal-weight and 62 obese white SA women were included in the analyses. 
However, for all diet and diet-gene analyses only adequate responders where 
included.  
 
2.5.2. Summary statistics 
 
Genotype and allelic frequency distributions are summarised as counts and 
percentage, according to BMI group, separately in black and white women 
(Tables 3.3., 4.1. and 5.1.). Exact tests of Hardy Weinberg Equilibrium (HWE), as 
well as linkage disequilibrium (LD) between polymorphisms were assessed for 
women of each BMI group and ethnic group.  
 
Subject characteristics and body composition are summarised as mean ± SD. 
Serum lipid concentrations and dietary intake are summarised as median 





2.5.3. Modelling  
 
Logistic regression (a binomial model with logit link) was used to model the 
dichotomous outcomes, BMI group (belonging to the normal-weight or obese 
group) and ethnicity (belonging to the white or the black group). Numerical 
outcomes (subject characteristics, body composition, serum lipids and dietary 
intake), were either left untransformed, or transformed  (adding a constant, then 
log transformed), when required to approximate normality for analysis. General 
linear models were used for numerical data. Modelling enabled adjustment for 
confounders, testing for associations with genotype, and also testing the 
interaction between genotype and dietary intake on outcomes by including them 
as terms in the models. Tests of the above associations and interactions on body 
composition variables were adjusted for age, whereas the tests of association 
and interaction on serum lipid variables were adjusted for age and fat mass. 
Associations and interactions were tested in white and black women separately 
and combined in one group, while covarying for ethnic group. In order to 
determine whether interaction effects differed between ethnic groups, three-way 
interactions between ethnic group and dietary intakes and polymorphisms were 
modeled in the combined group (of black and white women). In order to 
determine whether interaction effects were the same in the two ethnic groups, an 
indicator of ethnic group was included and tested in models of the two-way 
interaction between dietary intake and polymorphisms on outcome (body 
composition or serum lipids) in the combined group.   







Genotype (2 degrees of freedom) models and additive allelic (number of minor 
alleles, 1 degree of freedom) models were tested, and based on only those 
estimates provided by significant models, other transition models, additive, 
dominant or recessive for the minor allele were investigated. The best model 




Different confounders were adjusted for in different parts of this study. As the 
obese women were older than the normal-weight, all analyses were adjusted for 
age. All joint (combined) analyses (including women from both ethnic groups) 
were adjusted for ethnic group. Tests for interaction between dietary intake and 
genotype on serum lipids were further adjusted for a measure of body fat, 
specifically BMI for the TNFA polymorphisms and fat mass for the IL-6 
polymorphisms. The models provided the effect estimates and p-values in the 
tables.  
 
2.5.6. Interpreting interactions  
 
Graphs are presented in this thesis to aid in the interpretation of significant 
interactions, because interaction effects, especially between transformed 





 A significant interaction between dietary intake and polymorphisms on a 
numerical outcome suggests that there is a significant difference in rates of 
change in the outcome between the genotype groups.  There are two 
possibilities:  either only the difference is significant, but none of the individual 
rates of change are, or one or both of the ‘slopes’ change significantly. In this 
thesis only the significant genotype effects are described.   
 
Boxplots are sometimes used to illustrate the interaction between genotype and 
BMI group on outcomes. Plots show predicted outcome, back-transformed if 
necessary, versus genotype, for a woman of average age.  
 
The significant interaction between genotype and dietary fat intake as a 
percentage of total energy intake (%E) on risk of obesity (BMI group, a 
dichotomous outcome) were illustrated by graphing estimated OR of obesity with 
specific genotypes compared to other genotype, as a function of dietary fat intake 
(%E). The odds of being obese increases with age, but the OR (odds ratios) are 
the same for all ages. The term ‘odds of being obese’ was used to mean the odds 
of being obese relative to being of normal body weight. The study design  
(case-control study) did not enable the estimation of the odds of being obese, 
only the estimation of the obesity OR. 
 
Significant interactions between genotype and dietary fatty acid intake (%E) on 
numerical outcomes are illustrated by plotting the observed raw values, as well 
as the modelled relationships (back transformed where necessary) for the 




adjusted for. Some outcomes were modelled with transformed values, with the 
result that the modelled relationships of the untransformed values (which we 
graph) are curves, not straight lines.  The curves will move up or down with 
different values of the confounders, but the relative positions will remain the 
same. For example the curves will be slightly higher for older, but lower for 
younger (than average age) women.    
 
2.5.7. Multiple testing 
 
Results corresponding to p-values below 5% are described as significant. There 
was no adjustment for multiple testing because it has been suggested that 
corrections, such as Bonferroni, are too conservative when several associations 
are tested in the same group of individuals [226], and might not be appropriate in 
a situation such as this, where there is prior evidence that such effects exist 
[227]. Nyhold’s correction is not appropriate for this thesis, where there are only 5 
linked polymorphisms [226-228]).  Furthermore, It is impossible to rule out a false 
positive result, whether one does a single or multiple tests. The Bonferroni, 
Benjamini-Yekutieli [4, 6] (and all other corrections for multiple testing) entails a 
decrease of the critical or cutoff p-value. Decreasing the critical p-value, 
decreases the probability of a type 1 error (false positives), while it increases the 
probability of missing a true association (false negatives).   
 
Most ‘correction for multiple testing’ approaches are based on an assumption of 
statistically independent tests.  Approaches such as the Bonferroni corrections 




SNPs and the three IL-6 SNP's are located close together on the same gene and 
in some cases are in linkage disequilibrium with each other, so it is expected to 
obtain similar associations with all outcomes. There is no consensus on the 
appropriate critical p-value for testing associations with multiple outcomes with 




R, a free language and environment for graphics and statistical computing, freely 
available from http://www.R-project.org [229] was used for statistical analysis. 
The R package genetics [229], available from the same site, was used for allele 
and genotype frequencies, HWE and LD testing. Power analysis was done with 
Quanto ( http://hydra.usc.edu/gxe/ ). 
 
An example demonstrating the statistical analysis described above is included in 
Chapter 9 (Supplementary data). This example, which is taken from Chapter 4, 
assesses the interaction between a diet variable and a genetic factor on a 
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3.1. INTRODUCTION  
 
Excess adipose tissue associated with obesity has been linked with a low-grade, 
chronic inflammatory response, characterised by altered production of adipokines 
and raised inflammatory markers such as TNFα [32, 230]. The proinflammatory 
cytokine TNFα has also been shown to have important effects on whole-body lipid 
metabolism. Raised circulating levels of TNFα have been associated with increased 
serum TAG, VLDL-C and low levels of HDL-C [231]. Moreover, circulating soluble 
TNF receptor levels, a surrogate marker of previous TNFα effects, have been shown 
to circulate in proportion to LDL-C concentrations in apparently healthy subjects 
[232]. The link between obesity, inflammation and dyslipidaemia may be mediated 
through different pathways; one of which may include interactions between dietary 
fat intake and polymorphisms within the TNFA gene, potentially modulating the 
phenotype [170, 182, 183].  
 
The A allele of the functional TNFA -308 G>A polymorphism has been shown to 
increase transcription and subsequently increase TNFα production [40, 125, 187]. A 
number of studies have reported higher BMI and/or percent body fat [167-169, 233], 
lower HDL-C [179] and higher TAG [180], in carriers of the pro-inflammatory -308 A 
allele compared to those with the G allele (Table 1.3. in Chapter 1). In addition, the 
TNFA -308 A allele has been shown to modulate the relationship between dietary fat 
intake and obesity risk and dyslipidaemia in different populations. Nieters et al. found 
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that white German men and women with the TNFA -308 A allele, who were in the 
highest tertile for intake of the n-6 fatty acids LA and AA (%E), had increased risk of 
obesity [170]. In an ethno-racially diverse Canadian diabetic population,  
Fontaine-Bisson et al. showed that dietary PUFA intake (%E) was inversely 
associated with HDL-C concentration in carriers of the TNFA -308 A allele, but not in 
those with the GG genotype [182].  
The interactions between dietary fat intake (%E) and the TNFA -308 G>A 
polymorphism may be of particular relevance in the SA context, given the high 
prevalence of obesity in black and white SA women [3], as well as the higher 
prevalence of dyslipidaemia and CVD in white women compared to black women 
[234]. Black SA women typically present with a more favourable lipid profile than 
white SA women, with lower TAG, T-C and LDL-C concentrations [22, 235]. 
However, in a cohort of black SA women of Xhosa ancestry (African tribe residing in 
southern and eastern SA), it was recently found that approximately 45% had low 
HDL-C levels [236]. The increased risk for obesity and low HDL-C in black SA 
women may be compounded by an increase in dietary fat intake associated with the 
nutrition transition in the country [135]. In addition, differences in the distribution of 
inflammatory gene polymorphisms and inflammatory gene expression between black 
and white populations may contribute to ethnic differences in phenotype [19, 118, 
237]. Genetic studies have shown that African-American and sub-Saharan 
populations are more likely to carry allelic variants that up-regulate inflammation 
compared to white women [97]. Further, in a SA population, black women had a 
higher SAT inflammatory gene expression profile, including higher TNFα mRNA 
levels, than white SA women [118].  
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Given these reported differences, it is important to investigate these diet-genotype 
interactions that have not as yet been examined in a black population. Therefore, the 
aims of this study were to i) characterise the body composition, serum lipid 
concentrations and dietary intake of black and white SA women; ii) explore the 
relationships between the TNFA -308 G>A polymorphism and obesity and serum 
lipid concentrations; and iii) to determine whether these relationships are modulated 





3.2.1. Subject characteristics  
 
The study group included 107 normal-weight and 120 obese urban black women, 
and 89 normal-weight and 62 obese urban white SA women between the ages of 18 
and 45 years. Basic subject characteristics of the black and white women are 
summarised by ethnicity and BMI group in Table 3.1. The white women were older 
than the black women, and the obese women older than the normal-weight women; 
as a result all analyses were adjusted for age (P< 0.001).  
 
The white women were taller and heavier than the black women (P<0.001), but 
because of their shorter stature the black women had a higher BMI than the white 
women (P=0.002). The white women also had greater waist (P=0.003), waist hip 
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ratio (WHR), and VAT (P<0.001, respectively) than the black women, and the black 
women had higher body fat % (P=0.004), and SAT (P=0.028) than the white women. 
Irrespective of ethnicity, and by design of the study, all body composition variables 
were higher in the obese women compared to the normal-weight women 
 
After adjusting for age and BMI group, TAG, T-C, HDL-C and LDL-C were higher in 
the white women compared to the black women (P<0.001). Only the total cholesterol 
: high-density lipoprotein cholesterol (T-C:HDL-C) ratio was not different (P=0.618). 
In addition, T-C (P=0.047), TAG, LDL-C and T-C:HDL-C ratio were all higher and 
HDL-C lower (P<0.001 for all variables), in the obese compared to the normal-weight 
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3.2.2. TNFA -308 G>A genotype and allele frequencies 
 
The TNFA -308 G>A genotype (P=0.011) and allele frequencies (P=0.016) differed 
between the black and white women, after adjusting for BMI group (Table 3.2.). 
When the BMI groups were analysed, there were no significant differences in the 
TNFA -308 G>A genotype (P=0.287) or allele frequencies (P=0.115) between the 
normal-weight and obese women, after adjusting for ethnicity. Similarly, when the 
GA and rare AA genotypes were combined, the combined genotype differed 
between the black and white women (P=0.005) after adjusting for BMI group, 
whereas there was no significant difference on average between the normal-weight 
and obese women (P=0.139) after adjusting for ethnicity. Subsequently, because of 
the low frequency of the -308 AA genotype, the GA and AA genotypes were 
combined for all further analyses.  
 
Similar genotype distributions were obtained for the black women when the normal-
weight and obese women of only Xhosa ancestry were compared (P=0.914), 
indicating that there was reduced likelihood of population stratification in the black 
group. The TNFA genotype distribution of the normal-weight and obese black 
women were in Hardy-Weinberg equilibrium (HWE) (P=0.718), as were the white 
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3.2.3. TNFA -308 G>A polymorphism, body composition and serum lipids 
 
The normal-weight and obese subjects were divided into two groups based on their 
TNFA -308 G>A genotype in order to investigate associations between genotype 
and phenotype. Those who were homozygous wild type (GG) were included in one 
group, while those who were heterozygous and homozygous for the variant A allele 
were combined in the second group. The physical characteristics, body composition 
and serum lipid concentrations, according to TNFA -308 G>A genotype for black and 
white women are presented in Tables 3.3. and 3.4. In the black and white women 
there were no independent genotype effects for any measures of body composition, 
nor serum lipid concentrations. There was however an interaction between BMI 
groups and TNFA -308 G>A genotypes on BMI. BMI was greater in the obese white 
women with the GA+AA genotypes compared to those with the AA genotype 















hysical characteristics and body com
position of norm
al-w
eight and obese black and w
hite w
om




















































23 ± 5 
25 ± 7 
29 ± 8 







161 ± 5 
160 ± 7 
161 ± 6 





eight, kg  
57.4 ± 6.3 
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3.2.4. Dietary intake of adequate reporters 
 
A further aim of this chapter was to assess whether dietary fatty acids modified the 
relationship between TNFA -308 genotypes, obesity and serum lipid concentrations. 
When examining dietary intake, only those who were classified as adequate 
reporters according to the Goldberg cut-offs, were included in the analysis. 
Accordingly, 73 normal-weight and 74 obese black, and 73 normal-weight and 48 
obese white women were studied and their dietary intake is summarised in Table 
3.5. The black women consumed more energy (kJ), CHO (%E)(P< 0.001) and total 
fat (%E)(P=0.002) than the white women. When individual dietary fatty acid intake 
was analysed, the black women consumed more total PUFAs (%E) and n-6 PUFAs 
(%E), including greater amounts of LA and AA (%E)(P=0.001), and the n-3 PUFAS; 
EPA and DHA (%E)(P<0.001), than the white women. The polyunsaturated 
fat:saturated ratio (PUFA:SFA ratio) and n-6:n-3 PUFA ratio were also higher in the 
black women compared to the white women (P<0.001). In contrast, the white women 
consumed more protein, SFA and ALA (P<0.001) compared with the black women. 
MUFA (%E)(P=0.844) and total n-3 PUFA (%E)(P=0.997) intake were not different 
between the ethnic groups. All results presented in this paragraph were adjusted for 
age and BMI group. 
 
When comparing dietary intake of the BMI groups, the obese group consumed more 
energy (kJ; P<0.001), total fat (%E)(P=0.023), SFA (%E)(P=0.041) and PUFA 
(%E)(P=0.007) compared to the normal-weight group. When individual dietary fatty 
acids were analysed, the obese group also had a greater intake of total n-6 PUFAs 
(%E)(P=0.010), the n-6 PUFA’s LA (%E)(P=0.011) and AA (%E)(P<0.001), and the 
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n-3 PUFA’s EPA (P=0.037) and DHA (P=0.043), compared to the normal-weight 
group. Intake of protein (%E), CHO (%E), MUFA (%E), n-3 PUFA (%E), ALA (%E), 
and the PUFA:SFA and n-6:n-3 PUFA ratios did not differ between the obese and 
normal-weight groups. All results presented in this paragraph were adjusted for age 
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3.2.5. Diet-genotype interactions 
 
3.2.5.1. Diet-genotype interactions on body composition 
 
In black women, there was a significant interaction observed between total dietary fat 
intake (%E) and TNFA -308 G>A genotypes on obesity risk, (P=0.036) (Figure 3.1.). 
Figure 3.1. shows the obesity OR for genotype GA+AA versus genotype GG, at each 
fat intake value (%E). At low relative dietary fat intakes (%E), the odds of being 
obese for the GA+AA genotype were lower than for the GG genotype. However, the 
increase was greater for the GA+AA genotype so that when dietary fat intake was  
= 40.6 (%E) the estimated odds of obesity for the GA+AA genotype was equal to the 
odds of obesity with the GG genotype. For those with the GG genotype the OR for 
obesity was 1.12 and 1.26 for fat = 35 and 40 (%E) compared to 30 %E.  For those 
with the GA+AA genotype, the obesity OR was 3.02 and 9.12 for fat = 35 and 40 




Figure 3.1. The modelled relationship between the odds of being obese (odds of being obese versus 
being normal weight), TNFA -308 genotype and dietary fat intake (%E) for black women. The graph 
gives the modelled obesity OR for genotype GA+AA versus genotype GG, at each fat intake (%E). 
Lines shows the dietary fat intake (%E) of equal odds (OR=1, for the genotype groups), namely 40.6 
(%E), the OR for fat = 30 (%E) namely 0.12 and the OR for fat intake = 35 (%E), namely 0.33. 





In the white women there was a significant interaction between the intake of the n-3 
PUFA, EPA (%E) and TNFA -308 G>A genotypes on WHR (P=0.043) (Table 3S III). 
With increasing EPA intake (%E), WHR decreased in the white women with the -308 
GA+AA genotype, whereas there was no effect in those with the GG genotype.  
 
The ethnic-specific nature of these diet-genotype interactions was investigated by 
examining three-way interactions between the ethnic group, dietary fat intake (%E) 
and the TNFA -308 G>A polymorphism on obesity (Table 3S V), as well as by 
including both black and white women in the same model and adjusting for ethnicity 
(Tables 3S IV and 3S VIII). 
 
When the black and white women were combined and adjusted for age and ethnicity, 
interactions between ALA (%E) intake and TNFA -308 genotypes on SAT, and EPA 
(%E) intake and TNFA -308 genotypes on most measures of body composition were 
identified (weight, BMI, body fat %, fat mass, waist and SAT). In addition, the n-3 
PUFA, DHA (%E) interacted with the TNFA -308 genotypes on weight, BMI, fat mass 
and waist (Table 3S IV). Of these, only the interaction between EPA (%E) intake and 
TNFA -308 genotypes on WHR was significant in the white women (P=0.043), but 
not in the black women. This suggests that the interactions identified in the combined 
group were not different for the black and white women, and were observed only 
because there was more power in this larger group to detect effects. No diet-gene 




3.2.5.2. Diet-genotype interactions on serum lipid concentrations 
 
In the black women, the interaction between the n-3 PUFA, ALA (%E) and TNFA  
-308 G>A genotypes on the T-C:HDL-C ratio was significant (P=0.028) (Table 3S VI) 
(Figure 3.2.). With increasing ALA intake (%E), T-C:HDL-C ratio decreased in those 
with the -308 GA+AA genotype, and increased in the GG genotype.  
 
In the white women, a significant interaction between dietary SFA intake (%E) and 
TNFA -308 G>A genotypes on serum T-C concentrations (P=0.047) was observed 
(Table 3S VII) (Figure 3.3.). Serum T-C levels decreased for the GG genotype and 







Figure 3.2. Interaction between TNFA -308 G>A genotype and dietary ALA intake (%E) on  
T-C:HDL-C ratio in normal weight and obese black women. Symbols represent, for each woman, 
observed values.  The regression curves are modelled relationships for a woman of average age 
(27.5 years). Abbreviations: ALA, α-linolenic acid; T-C:HDL-C ratio, total cholesterol:HDL-cholesterol 





Figure 3.3. The relationship between dietary SFA, serum T-C and TNFA -308 G>A genotype in 
normal-weight and obese white women. The modelled relationship is for white women adequate 
reporters with mean age (30.6 years) and BMI (26.7 kg/m2). With increasing dietary SFA (%E), T-C 
concentration decreases in those with the GG genotype and increases in those with the GA+AA 
genotype. The difference in rates of change is statistically significant (P=0.047). Curves (because of 
the logs being modelled) will shift up or down according to age and BMI. Abbreviations: BMI, body 
mass index; SFA, saturated fat; T-C, total cholesterol; TNFA, tumour necrosis factor-α gene. 
 
  

























Table 3S IX, which lists p-values for three-way interactions between ethnic group, 
dietary fat intake (%E) and the TNFA -308 G>A polymorphism on serum lipid 
concentrations, shows a significant interactions between ALA (%E) intake and the 
TNFA -308 genotypes on LDL-C (P=0.026) and T-C:HDL-C ratio (P=0.044). These 
interactions were therefore different for the black and white women. However, only 
the interaction between ALA (%E) intake and TNFA -308 genotypes on T-C:HDL-C 
ratio was significant in the black women, the interaction on LDL-C was not (P=0.120) 
(Table 3S VI). Neither interaction was significant in the white women (Table 3S VII). 
When the black and white women were combined and adjusted for age and ethnicity, 
only the interaction between EPA (%E) intake and TNFA -308 genotypes on T-C was 
significant (P=0.046) (Table 3S VIII). This interaction was not significant in the black 
or white women when analysed separately, suggesting that the interaction identified 
was not different for the black and white women, and was observed only because 
there was more power in the larger combined group to detect the effect.  
 
3.3. DISCUSSION  
 
This study has reported ethnic differences in body composition, serum lipid 
concentrations, dietary intake and TNFA -308 G>A genotype frequencies between 
black and white SA women. In addition, although no independent genotype 
associations between the TNFA -308 G>A polymorphism and obesity and serum 
lipid concentrations were observed, for the first time, interactions between dietary fat 
intake (%E) and the TNFA -308 G>A polymorphism on obesity risk, adiposity and 
serum lipid concentrations in a black and white SA population were identified. These 
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results highlight the complexity of understanding the role these many factors play in 
the development and prevalence of obesity and associated co-morbidities in black 
and white SA populations. It is therefore important to understand these ethnic 
differences in the development of effective interventions. 
 
CAD and dyslipidaemia are important co-morbidities associated with obesity, but 
their prevalence differs by ethnicity, with white women being at greater risk for CAD 
than black women [8, 13]. In this study, serum lipid concentrations were higher in the 
white compared to the black women. Black SA women, similar to African Americans, 
have previously been shown to have a less atherogenic lipid profile than white 
women [21-23], potentially attributable to relatively low levels of VAT [21], also 
reported in this study. Studies in SA women have generally reported no ethnic 
difference in HDL-C levels [22], however, in this study, similar to that reported by 
Goedecke et al. [19, 24], HDL-C was lower in black women compared to white 
women. The reasons for this are not clear, but could relate to their lower total 
cholesterol levels.  
 
Ethnic differences in the obese phenotype and serum lipid profiles may also be due, 
in part, to differences in the genotype or allele distribution of TNFA polymorphisms 
[97, 98]. Specifically, several studies have reported associations between 
polymorphisms in the TNFA gene and obesity and dyslipidaemia [40, 187]. The  
pro-inflammatory A allele of the TNFA -308 G>A polymorphism has been associated 
with a higher BMI and/or percent body fat [167-169, 233], lower HDL-C [179] and 
higher TAG [180], than those with the G allele. These studies are summarised in 
Table 1.3. in Chapter 1. Although the white women in this study had higher TNFA -
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308 GA+AA genotype and A allele frequencies than the black women, this study 
found no independent genotype effects of the TNFA -308 G>A polymorphism on 
obesity risk, adiposity or serum lipid concentrations in the black or white women, nor 
in the combined group (Table 3S I). This is unlikely to be due to differences in 
genotype frequency, as the frequency of the A allele in this study was between 14% 
and 24% (Table 3.3.), not different from those reported in Caucasian, African 
American, and other African populations, summarised in Table 1.1. in Chapter 1 
[170, 182, 233, 238-240].  
 
TNFA polymorphisms have been shown to interact with dietary fatty acids [40, 187]. 
When dietary fat intake was included in the study analyses, interactions between 
dietary fat intake (%E) and the TNFA -308 G>A polymorphism on obesity risk, 
adiposity and serum lipid concentrations in both black and white women were 
observed. In the black women, the obesity odd ratio (OR) of those with the -308 A 
allele compared to the GG genotype, was higher with increasing fat intake (%E). 
Those with the A allele appeared to be more responsive to an increase in dietary fat 
intake (%E) in their risk of being obese versus normal-weight.  
 
In the white women in this study there was a significant interaction between the 
intake of the n-3 PUFA, EPA (%E) and TNFA -308 G>A genotypes on WHR, a 
measure of central adiposity (P=0.043) (Table 3S III). With increasing EPA intake 
(%E), WHR decreased in those with the -308 GA+AA genotype, there was no effect 
in the GG genotype. The identification of this diet-gene interaction on WHR and not 
waist circumference or VAT suggests that it may be the ratio of central to peripheral 
adiposity that is important, with peripheral fat being more protective. Whereas this 
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result showed an interaction between higher n-3 PUFA intake and reduced central 
adiposity, in German Caucasian men and women Nieters et al. identified an 
increased OR for the risk of obesity (based on BMI) with a higher intake of n-6 
PUFAs (LA and AA (%E)) [170], both these interactions were only observed in those 
with the -308 A allele. These findings are of relevance in the white SA women, who 
present with greater levels of central adiposity compared to the black women [241].  
 
In addition to the effects on body composition, diet-gene interactions have also been 
shown to impact serum lipid concentrations [96]. In the black women in this study; 
with increasing ALA intake (%E), the T-C:HDL-C ratio decreased, and with 
increasing PUFA (%E) intake, LDL-C concentrations increased, but only in subjects 
with the TNFA -308 A allele. In the white women, with increasing SFA intake (%E), 
T-C concentrations increased for the –308 GA + AA genotype and decreased for the 
GG genotype. These interactions between PUFA intake (%E) and LDL-C in the black 
women, and SFA intake (%E) and T-C in the white women are notable, in that the 
dietary analysis reported that black women consumed greater amounts of PUFAs 
compared to the white women, and the white women consumed greater amounts of 
SFA compared to the black women (Table 3.3). 
 
Only the studies by Fontaine-Bisson et al. have previously investigated interactions 
between dietary fat intake and the -308 G>A polymorphism on serum lipids [182, 
183]. In an ethno-racially diverse Canadian population they found that PUFA intake 
(%E) was inversely associated with HDL-C concentrations in TNFA -308 A allele 
carriers, but not in those with the GG genotype [182]. However, in a subsequent 
study using a diabetes-free population, with participants being mostly lean and 
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younger, they found that the association between PUFA (%E) intake and HDL-C 
amongst each genotype were in the opposite direction [183]. While this study did not 
show an interaction between the TNFA -308 G>A polymorphism, PUFA intake (%E) 
and HDL-C, the results of this study, and those of Nieters et al. [170] and  
Fontaine-Bisson et al. [182, 183] suggest that individuals with the pro-inflammatory 
TNFA -308 A allele may be more responsive to changes in dietary fat intake (%E) 
than those with the GG genotype (33), and that different dietary fatty acids impact 
the phenotype in different ways.  
 
Grimble et al. has suggested that the inherent underlying inflammatory status of a 
population may alter the impact of different dietary fats on inflammation [165, 183, 
242]. An individual’s inherent inflammatory status may be due to an individual’s 
genotype and / or dietary intake or a pre-existing condition such as obesity [41]. The 
-308 A allele has been shown to increase transcription and subsequently increase 
TNFα production [125]. In this study, the -308 A allele frequency was greater in the 
white women compared to the black women. However, dietary fat intake was also 
different between the black and white women. It is therefore possible that these 
differences in genotype frequency and dietary fat intake may contribute to the ethnic 
variability in diet-gene interactions observed in this study, and the differences in lipid 
profiles between these two groups.  
 
Interpreting the diet-genotype interactions reported in this study would be enhanced 
by knowing the impact of dietary fatty acids on the release of different cytokines [40, 
41]. Unfortunately, circulating levels of TNFα or TNF-R, were not measured in this 
study. However, previous studies have reported that SFAs have been shown to have 
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a pro-inflammatory action, increasing TNFα concentration [160], whereas cell culture 
and human studies have demonstrated that n-3 PUFAs act in an anti-inflammatory 
manner, inhibiting the production of a number of cytokines, including TNFα [40, 41]. 
Discussed in detail in Chapter 1, section 1.8.3. 
These differences in the inflammatory impact of different dietary fatty acids are 
relevant to the results in this study as most dietary fat intake variables investigated in 
this study differed between the white and black SA women (Table 3.3). The black 
women consumed more total PUFAs (%E) and n-6 PUFAs (%E), and showed a 
greater n-6:n-3 PUFA ratio compared to the white women. In contrast, the white 
women consumed more SFA (%E) compared with the black women. Total n-3 PUFA 
(%E) intake was not different between the ethnic groups. In contrast to the study of 
Nieters et al. in which the relative total dietary fat intake was higher [170] than this 
study, their n-6:n-3 PUFA ratio was almost 3 times lower than that reported in the 
white SA women and 4 times lower than that reported in the black SA women in this 
study. Further, their reported n-3 (% E) intake was two times greater than in the 
white and black SA women in this study [170]. Dietary fat intake in the black SA 
women in this study are a cause for concern, highlighted by the very high n-6:n-3 
PUFA ratio (28.2:1 and 29.9:1 in the obese and normal weight groups, respectively), 
far exceeding the WHO recommendation of a 5–10:1 ratio [243].   
It is generally believed that multiple genes, each with modest effects, may underlie 
the obesity phenotype and associated risk factors [96, 244, 245]. This study was 
limited to the examination of only one polymorphism from a single gene [170] [182]. 
It has also been shown that there is constancy in TNFα production in post-
menopausal women and men but not pre-menopausal women, suggesting that 
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TNFα production may be regulated by sex hormones [246]. This study included only 
pre-menopausal women, which may also affect the study results. Furthermore, the 
study group was small and therefore may not have been able to detect differences 
that may exist in the black and white population. For example, only when the black 
and white women were combined, an interaction between EPA (%E) intake and 
TNFA -308 genotypes on T-C concentrations was identified. An interaction that was 
not significant in the black or white women when analysed separately, suggesting 
that the interaction may only have been observed because there was more power in 
the larger combined group to detect the effect.  
 
In order to improve the validity of the dietary data in this study, a validated food 
frequency questionnaire was used, developed specifically for the SA population, and 
included only adequate reporters in the analysis [215]. The results, like the results of 
all genetic association studies, should be treated with caution until independently 
replicated.  
 
In conclusion, although the TNFA -308 G>A polymorphism was not independently 
associated with obesity risk or serum lipid concentrations in this sample of black and 
white SA women, dietary fat intake modified the relationship between the TNFA -308 
G>A polymorphism, obesity risk and serum lipid concentrations. In light of these 
findings, the results of this and other similar studies should be confirmed in larger 
cohorts. Additional polymorphisms within the TNFA gene such as TNFA -238 G>A, 
as well as polymorphisms in other genes involved in inflammation such as IL-6 -174 
G>C should be investigated. Results from diet-gene studies such as these will 
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4.1. INTRODUCTION  
 
The previous chapter has shown that dietary fat intake modifies the relationship 
between the TNFA -308 G>A polymorphism (rs1800629), obesity, adiposity, and 
serum lipid concentrations. Common to the results of Chapter 3 and those of other 
studies [170, 182] was that the pro-inflammatory A allele of the functional TNFA -308 
G>A polymorphism was associated with increased risk for obesity and 
dyslipidaemia, and appeared to be more responsive to dietary fat intake. Notably, 
these associations differed between black and white SA women. Differences in these 
relationships may be explained, in part, by ethnic differences in obesity risk, dietary 
fatty acid intake, and serum lipid concentrations [19], as well as the distribution of 
inflammatory gene polymorphisms and inflammatory gene expression between black 
and white SA women [102, 236]. 
 
The functional -308 G>A polymorphism within the promoter region of the TNFA gene 
is in close proximity to the downstream TNFA -238 G>A polymorphism (rs361525). 
While a number of studies have investigated the TNFA -308 G>A polymorphism, 
only a few have reported on the TNFA –238 G>A polymorphism and obesity [177, 
181], and only two studies have investigated the interaction between dietary fat 
intake and this polymorphism on serum lipid concentrations [182, 183]. However, 
there are no studies that have explored these associations in healthy populations of 
different ethnicity. 
 
Therefore, the aims of this study were to explore whether the TNFA -238 G>A 
polymorphism is independently associated with adiposity and serum lipid 




apparently healthy premenopausal black and white urban SA women, and if these 






The study group included 107 normal-weight and 120 obese urban black women, 
and 89 normal-weight and 62 obese urban white SA women between the ages of 18 
and 45 years. Only 72 normal-weight and 70 obese black, and 74 normal-weight and 
47 obese white women, who were classified as adequate-reporters according to the 
Goldberg cutoffs were included in the diet-gene analysis. Subject characteristics and 
dietary intake for normal-weight and obese, black and white women in this study are 
the same as those described in the previous chapter, sections 3.2.1 and 3.2.4, 
respectively, and can be found in Tables 3.1. and 3.6. 
 
4.2.2. TNFA -238 G>A genotype and allele frequencies 
 
The genotype and minor allele frequency distribution for normal-weight and obese, 
black and white women are presented in Table 4.1. There were no significant 
differences in the TNFA -238 G>A genotype (P=0.285) or allele frequencies 
(P=0.352) between the normal-weight and obese women, after adjusting for 
ethnicity. However, the differences in genotype distribution and allele 
frequency between black and white women were highly significant after adjusting for 




The normal-weight and obese white and the normal-weight black groups were in 
HWE (P=0.600, P=1.00 and P=0.113 respectively), but the black obese group was 
not (P<0.001). As reported in Table 4.1., the TNFA -238 G>A polymorphism was in 
tight LD with TNFA -308 G>A only in the normal-weight white women (D’=0.99).  
 
There was only one black normal-weight woman with the TNFA -238 AA 
homozygous genotype. For all analyses, she was grouped with those with a GA 
genotype, thus assuming a dominant effect of the A allele for this polymorphism, as 
done previously by other authors such as Fontaine-Bisson et al. [182, 247].   
 
Table 4.1. TNFA -238 G>A genotype and allele frequency in black and white women  
 
Values are expressed as frequency (%). TNFA -238 G>A genotype frequency distribution, minor 
allele frequency and p-values for tests of association with ethnicity and BMI group, respectively, each 
adjusted for the other.  P-values for exact tests of HWE. Summary statistics for LD with TNFA -308 
G>A. Abbreviations: BMI, body mass index; HWE, Hardy Weinberg equilibrium; LD, linkage 
disequilibrium; TNFA, tumour necrosis factor-α gene. 
 





weight Obese Ethnicity 
BMI 
group 
n 107 120 89 62   
GG 63% 52% 76% 81% <0.001 0.285 
GA 36% 48% 24% 19%   
AA 1% - - -   
A allele 19% 24% 12% 10% <0.001 0.352 
HWE p-value 0.113 < 0.001 0.600 1.000   
LD between TNFA -238 G>A and TNFA -308 G>A 
n 107 111 88 59   
D' 0.05 0.10 0.99 0.03   
r 0.05 0.07 -0.20 -0.01   




4.2.3. TNFA -238 G>A polymorphism, body composition and serum lipids 
 
Summaries of body composition and serum lipid concentrations, according to TNFA  
-238 G>A genotypes and BMI group are presented in Tables 4.2. and 4.3., 
respectively, with age-adjusted p-values comparing the outcomes between BMI 
groups and the TNFA -238 G>A genotypes.  
 
In the black women, those with the TNFA -238 GA genotype had a greater body fat 
% than the GG genotype group (P<0.001), independent of age and BMI group 
(Table 4.2.). In the black and white women there were no other independent 
genotype effects for all measures of body composition or serum lipid concentrations 
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4.2.4. Diet-genotype interactions 
 
4.2.4.1. Diet-genotype interactions on body composition  
 
In black women, a number of interactions between dietary fat intake and the TNFA  
-238 G>A polymorphism on measures of adiposity were identified (Table 4S II). With 
increasing total fat and SFA intake (%E), weight (P=0.034 and P=0.017), waist 
(P=0.036 and P=0.012), and fat mass (P=0.047 for SFA only) increased for those 
with the GA genotype, but not the GG genotype. With increasing MUFA intake (%E), 
weight (P=0.044) increased for the GA genotype, but not the GG genotype, and with 
increasing ALA intake (%), the rates of change in waist (P=0.007), BMI (P=0.012), 
body fat % (P=0.006), waist (P=0.044), and fat mass (P=0.005) also differed, but 
neither individual rate was significant. As an example, the interaction between SFA 
intake, the TNFA -238 G>A polymorphism and waist in black women is illustrated in 
Figure 4.1.  
 
No diet-genotype interactions with obesity or body composition were identified in the 






Figure 4.1.The relationship between adiposity, TNFA -238 G>A genotype, and dietary saturated fat 
intake in normal-weight and obese black adequate reporter women. Symbols represent, for each 
woman, observed values. The lines are modelled relationships for a woman of average age (27.3 y). 
With increasing saturated fat intake (%E), adiposity increased for the A allele, while the GG genotype 
did not. 
 
The ethnic-specific nature of these diet-genotype interactions was identified by 
examining three-way interactions between ethnic group, dietary fat intake (%E) and 
the TNFA -238 G>A polymorphism on obesity (Table 4S V), as well as by including 
both black and white women in the same model and adjusting for ethnicity (Tables 





The association showing a greater body fat % in those with the TNFA -238 GA 
genotype compared to subjects with the GG genotype was observed in black 
women, as well as in the combined black and white group, independent of ethnicity 
(Table 4S I). This suggests that this association was not different for the black and 
white women, and was observed only because there was more power in this larger 
group, and the white group may have been too small to detect the effect. No  
diet-gene interactions on obesity were identified in the combined group (Table 4S IV) 
nor in the 3-way interactions on obesity (Table 4S V). 
 
4.2.4.2. Diet-genotype interactions on serum lipid concentrations 
 
In black women, interactions between dietary fat intake and the TNFA -238 G>A 
polymorphism on serum lipid concentrations were identified (Table 4S VI). With 
increasing P:S ratio, HDL-C concentrations decreased in those with the GA 
(P=0.013) but not the GG genotype, and as expected T-C:HDL-C ratio increased in 
those with the GA genotype but not the GG genotype (P=0.032). With increasing  
n-6:n-3 PUFA ratio, the rates of change in HDL-C concentration (P=0.032) and  
T-C:HDL-C ratio (P=0.004) differed between GG and GA, but did not change 
significantly with either of the genotypes. In addition, with increasing n-3 PUFA 
(P=0.012) intake (%E), T-C:HDL-C ratio decreased in those with the GA, but not in 
those with GG genotype (Table 4S VI). As an example, interactions between n-6:n-3 
PUFA ratio, the TNFA -238 G>A polymorphism, HDL-C and T-C:HDL-C ratio are 





In white women, with increasing EPA (P=0.020)(%E) intake, LDL-C decreased in 
those with the GG genotype but not the GA genotype (Table 4S VII). Similarly, with 
increasing EPA (%E) (P=0.041) and DHA (%E) intakes (P=0.040), T-C decreased in 
those with the GG genotype and not the GA genotype, but the individual rates were 
not significant (Table 4S VII).   
 
When the black and white women were combined and adjusted for age and ethnicity 
(Table 4S VIII), the interactions between MUFA (%E), n-3 PUFA (%E) and ALA (%E) 
intake and TNFA -238 genotypes on T-C:HDL-C ratio were significant (P=0.038, 
P=0.019, and P=0.015, respectively). Of these, only the interaction between n-3 
PUFA (%E) intake and TNFA -238 genotypes on T-C:HDL-C ratio was significant in 
the black women (P=0.012), but not in the white women. This suggests that the 
interactions identified in the combined group were not different for the black and 
white women, and were observed only because there was more power in this larger 
group to detect effects.  
 
Table 4S IX, which reports the p-values for three-way interactions between ethnic 
group, dietary fat intake (%E) and the TNFA -238 G>A polymorphism on serum lipid 
concentrations, identified significant interactions between the n-6:n-3 PUFA ratio and 
the TNFA -238 G>A genotypes on T-C:HDL-C ratio (P=0.015), and between EPA 
(%E) and DHA (%E) and the TNFA -238 genotypes on T-C (P=0.019 and P=0.004, 
respectively) and LDL-C (P=0.014 and P=0.006, respectively). This suggests that 






Figure 4.2. The relationship between serum lipids, TNFA -238 G>A genotype, and n-6:n-3 PUFA ratio 
in normal-weight and obese black adequate reporter women. Symbols represent, for each woman, 
observed values. The curves on each graph are from general linear models of age, fat mass, and the 
interaction between TNFA -238 G>A genotype and specific dietary fat intake for a woman aged 27.3 y 
with fat mass 29.4 kg.  
(A) With increasing n-6:n-3 PUFA ratio, HDL-C concentrations increased in those with the GG 
genotype and decreased in those with the GA genotype. 
(B) With increasing n-6:n-3 PUFA ratio, T-C:HDL-C ratio increased in those with the GA 
genotype and decreased in those with the GG genotype.  
Abbreviations: HDL-C, high-density lipoprotein cholesterol; n-6:n-3 PUFA ratio, omega-6:omega-3 






4.3. DISCUSSION  
 
The main findings of this study were that black women with the TNFA -238 GA 
genotype had a greater body fat % than those with the GG genotype, and that 
interactions between the -238 G>A polymorphism and serum lipid concentrations 
differed depending on dietary fat intake; moreover, these interactions differed 
between the black and white women.   
 
Previous studies have found no association between the TNFA -238 G>A 
polymorphism and BMI [177, 181]. This is the first study to report that the -238 GA 
genotype is associated with greater body fat % than the GG genotype. This effect 
was demonstrated in black women, as well as in the combined black and white 
group, independent of ethnicity. In Chapter 3, the proinflammatory A allele of the 
TNFA -308 G>A polymorphism was discussed as being independently associated 
with obesity risk [167, 169], but this has not been reported in all studies [175, 176]. 
Obesity is associated with chronic sub-clinical systemic inflammation, characterized 
by increased production of pro-inflammatory cytokines, such as TNFα, released by 
adipose tissue [248]. Unlike with the TNFA -308 G>A polymorphism [125], there is 
controversy regarding the functional significance of the TNFA -238 G>A 
polymorphism. Studies have reported that the -238 A allele either increases [249], 
decreases [250, 251] or has no effect on TNFA transcription [252, 253], depending 
on the conditions of the experiment. The inflammatory impact of this polymorphism 
needs to be confirmed. Measures of circulating TNFα or TNFα receptor levels may 





It is notable that the A allele frequency in this study, particularly in the black women 
is higher than that reported in the Ensemble database in Caucasian, African 
American, and other African populations, summarised in Table 1.1. in Chapter 1. 
There are however no studies that have reported this genotype in Southern African 
populations (as opposed to Sub-Saharan Africans, which refers to West Africans).  
 
Human studies have also shown that TNFα expression is regulated by dietary fatty 
acids [163-165]. Results presented in Chapter 3, as well as previous studies on the 
TNFA -308 G>A polymorphism, have shown that the relationship between this 
polymorphism and obesity risk differed depending on dietary fat intake [170]. In 
agreement with this, this study is the first to show that with increasing dietary fat 
intake, irrespective of the type and quality, select measures (weight, BMI, body fat 
%, fat mass, and waist) of body composition increased in black women with the 
TNFA -238 GA genotype and decreased or did not change in those with the GG 
genotype (Figure 4.1.). These findings suggest that the A allele of the -238 
polymorphism may be responsive to dietary fatty acid intake, as has been shown for 
the -308 A allele [167-170]. 
 
This chapter also showed that the relationship between the TNFA -238 G>A 
polymorphism and serum HDL-C concentration differed depending on the intake of 
specific PUFAs in black, but not white women (Figure 4.2.). Similarly,  
Fontaine-Bisson et al. reported that PUFA (%E) intake was positively associated with 
serum HDL-C concentrations in carriers of the -238 A allele within a mixed ethnicity, 
diabetic Canadian population [182]. The greatest contribution to PUFA intake is from 




are contradictory and inconclusive [254, 255]. Nonetheless, n-6 PUFAs have been 
shown to reduce LDL-C concentrations and T-C:HDL-C ratio, although some studies 
have also reported  a decrease in HDL-C [254, 256]. A high n-6:n-3 PUFA ratio is 
more consistently regarded as pro-inflammatory and has been associated with 
cardiovascular, inflammatory and autoimmune diseases [203, 255, 257, 258]. 
Notably, the intake of n-6 PUFAs (%E) and the n-6:n-3 PUFA ratio in the black 
women were higher than that of the white women in this study (8.3% vs. 5.6%, and 
26.4:1 vs. 16.1:1, for black and white women, respectively), and that reported in 
other populations (4.0 – 6.0% for n-6 PUFA (%E) [254], and ≈15:1 for n-6:n-3 PUFA 
ratio [259]). In this study the interaction between the TNFA -238 G>A polymorphism 
and n-6:n-3 PUFA ratio on T-C:HDL-C ratio was only observed in the black women. 
These findings are relevant in this context as the black women in this study had 
lower HDL-C concentrations than the white women. These findings need to be 
replicated in other African populations as it has been shown that other African 
populations, as well as African Americans have higher HDL-C concentrations than 
their white counterparts [13, 21, 22]. 
 
Apart from the higher HDL-C concentrations, white women in this study had a more 
atherogenic lipid profile than black women, characterised by higher TAG, T-C, and 
LDL-C concentrations in the white women compared to the black women [21, 234]. 
This study reported that the relationship between the TNFA -238 G>A polymorphism 
and serum LDL-C and T-C concentrations differed depending on the intake of the  
n-3 PUFA’s EPA and DHA, in white, but not black women. The intake of n-3 PUFA 
(%E) in this study was the same for the black and white women, but is approximately 




non-diabetic Canadian population [183]. These differences are relevant and worth 
exploring further as n-3 PUFAs have been shown to attenuate inflammation. In 
particular, EPA and DHA regulate inflammatory processes and have been shown to 
improve serum lipid concentrations and vascular endothelial function [62, 260]. As 
evidenced by the findings of this study and others, dietary fatty acids affect 
inflammation and serum lipids in different ways, for this reason the inclusion of 
individual FAs in diet-genotype studies is important. The differences in dietary fat 
intake, as well as differences between serum lipid profiles [93] between black and 
white SA women, may partly explain the ethnic differences in these diet-gene 
interaction findings.  
 
This study is novel and adds to the literature as it is the first to highlight differences in 
the associations between the TNFA -238 G>A polymorphism, body composition and 
serum lipid concentrations, and their interaction with dietary fat intake in different 
ethnic groups. There are however limitations to this study that should be considered. 
Accuracy of diet reporting is always difficult. As mentioned in Chapter 3, the validity 
of the dietary intake data was improved by using a validated FFQ developed 
specifically for the SA population, and by including only adequate reporters in the 
analyses. Other lifestyle factors, such as physical activity and socioeconomic factors 
may also interact with these variables, but were not included in this study. The 
sample size was small, included no men and had fewer white than black women. 
Therefore, small associations that were detected in the black women may not be 
detected in the white women, as demonstrated by the independent genotype 
association between the -238 G>A polymorphism and body fat % that was shown in 





This study also investigated the -238 G>A and -308 G>A polymorphisms as a 
haplotype. Although these polymorphisms are only 69 bp apart 
(http://www.ensembl.org), they were only in LD in the white normal-weight women 
and not in the obese white women, nor the black groups. For this reason the 
haplotypes were not informative, and were not reported here. It is not surprising that 
the two variants were not in LD in the black populations, as rapid decay in LD has 
been shown to be more associated with populations of African descent compared to 
populations of non-African descent [261].  It is also not surprising to note the 
differences in the frequency distribution of the genotypes and alleles for these two 
variants within the various populations. This study therefore highlights the 
importance of exploring this particular genetic interval defined by these two variants 
in populations of African descent to unravel the functional significance of TNFA in 
modulating an individuals’ response to dietary fat intake.  
 
In conclusion, a novel association between the TNFA -238 G>A polymorphism and 
body fat % was observed, as well as responsiveness of the -238 A allele to 
increasing dietary fat intake for adiposity in black SA women. This thesis has also 
shown that the relationship between the TNFA -238 G>A polymorphism and serum 
lipid concentrations differed depending on PUFA intake, in both black and white SA 
women, but that these interactions were ethnic-specific. While the results of this 
study provides new insight into the TNFA -238 G>A polymorphism, they also 
highlight the need for further research to study the functional significance of this 
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In previous studies and in Chapters 3 and 4 of this thesis, polymorphisms in the 
cytokine gene TNFA have been associated with obesity, measures of adiposity and 
serum lipid concentrations. Furthermore, it has been shown that total dietary fat 
intake, as well as individual dietary fatty acids, in particular SFAs and the n-3 and n-6 
PUFAs, interact with TNFA polymorphisms to modulate these relationships. In 
addition to the TNFA gene, IL-6 was also selected for investigation as a candidate 
gene for association with obesity and dyslipidaemia, based on the biological function 
of the encoded IL-6 protein, and the role it plays in both systemic and adipose tissue 
inflammation. 
 
The cytokine IL-6 is known to regulate inflammation [189]. Higher circulating 
concentrations of IL-6 have also been associated with obesity and VAT deposition 
[190-192], lipid metabolism [189] and increased risk for CVD [209]. In addition, there 
is a growing body of evidence linking polymorphisms within the IL-6 gene to 
increased risk of obesity and dyslipidaemia [187, 189, 206-208].  
 
Within the IL-6 gene, the most frequently studied polymorphism is IL-6 -174 G>C 
(rs1800795). This polymorphism has been shown to be functional, with most studies 
showing the C allele to be associated with raised concentrations of IL-6 and the 
acute phase protein, CRP [126, 209-212]. However, association studies between this 
IL-6 gene polymorphism, obesity and dyslipidaemia have yielded conflicting results.  
A recent large meta-analysis by Yu et al. found the -174 G>C polymorphism to be 




meta-analyses [210, 213]. Although Qi et al. found no association between the -174 
G>C polymorphism and obesity, they identified an IL-6 haplotype to be associated 
with adiposity in healthy American men and women [210].  
 
Conversely, several studies have found an association between the -174 G>C 
polymorphism and serum lipid concentrations, independent of obesity, with most 
showing the IL-6 -174 G allele to be associated with higher T-C, LDL-C and TAG 
concentrations [186, 206, 208], and lower HDL-C concentrations [208, 214].  
 
Taken together, these findings suggest that this polymorphism is a strong candidate 
for obesity and dyslipidaemia. However, the -174 G>C polymorphism has been 
shown to be rare in persons of African descent [262]. Therefore, the aim of this study 
was to identify informative (more common) polymorphisms in both black and white 
SA populations, and to investigate associations between these IL-6 polymorphisms 
(IL-6 -174 G>C, IVS3+281 G>T and IVS4+869 A>G) and obesity and dyslipidaemia 
in black and white SA women. 
 




The study group included 107 normal-weight and 120 obese urban black women, 
and 89 normal-weight and 62 obese urban white SA women between the ages of 18 
and 45 years. Subject characteristics for normal-weight and obese, black and white 




and summarised in Table 3.1. The white women were older than the black women, 
and the obese women older than the normal-weight women; as a result all analyses 
were adjusted for age (P< 0.001).  
 
5.2.2. IL-6 genotype and allelic frequency distributions  
 
The genotype and minor allele frequency distribution of the IL-6 polymorphisms 
investigated in this study for normal-weight and obese, black and white women are 
presented in Table 5.1. There were no significant differences between the  
normal-weight and obese women, after adjusting for ethnicity, for the IL-6 -174 G>C 
genotype (P=0.104) or allele frequencies (P=0.515), IL-6 IVS3+281 G>T genotype 
(P=0.914) or allele frequencies (P=0.950), and IL-6 IVS4+869 A>G genotype 
(P=0.293) or allele frequencies (P=0.474). 
 
However, the difference in the IL-6 -174 G>C and IVS3+281 G>T genotype 
distribution and allele frequency between black and white women was highly 
significant after adjusting for BMI group (P<0.001). Although the IVS4+869 A>G 
genotype distribution between black and white women was also significant after 
adjusting for BMI group (P<0.001), the allele frequency was not different (P=0.688). 
The frequency of the minor allele of the -174 G>C and IVS3+281 G>T 
polymorphisms were higher in the white compared to the black women. All genotype 
frequencies reported in this study were similar to European and African populations 
reported in the Ensembl database (Chapter 1, Table 1.1), however none of the 
African populations reported in the Ensembl database were representative of 





Deviations from HWE were detected for the -174 G>C polymorphism in the black 
obese group and for the IVS4+869 A>G polymorphism in both the normal-weight and 
obese white women (Table 5.1.). Only one individual was homozygous for the 
IVS4+869 G allele, despite the frequency of the minor G allele being over 30% in the 
white SA women (Table 5.1.). In the white women, all the polymorphisms were in 
high LD in both the normal-weight and obese groups. In the black women, of the 
three pairs of polymorphisms genotyped, only IVS4+869 A>G and IVS3+281 G>T 






Table 5.1. Genotype and minor allele frequencies of normal-weight and obese black 
and white women 
 Normal-weight Obese P-values 
 Black White Black White Ethnicity BMI group 
IL-6 174 G>C      
n 106 89 123 63   
GG 97 30 95 32   
GC 3 58 3 46   
CC 0 12 2 22 < 0.001 0.104 
C 1 40 3 45 < 0.001 0.515 
HWE p-value 1.000 0.077 0.003 0.613   
IL-6 IVS3+281 G>T    
n 100 89 115 63   
GG 54 35 5 30   
GT 38 48 37 51   
TT 8 17 9 19 < 0.001 0.914 
T 27 41 27 44 < 0.001 0.950 
HWE p-value 0.799 1.000 0.477 1.000   
IL-6 IVS4+869 A>G    
n 99 88 112 63   
AA 51 42 54 37   
GA 39 57 40 3   
GG 10 1 6 1 < 0.001 0.293 
G 30 30 26 32 0.688 0.474 
HWE p-value 0.630 0.001 0.811 < 0.001   
Values are expressed as percentage (%). IL-6 -174 G>C, IVS3+281 G>T, and IVS4+869 A>G 
genotype frequency distribution, minor allele frequency and p-values for tests of association with 
ethnicity and BMI group, respectively, each adjusted for the other.  P-values for exact tests of HWE. 







Figure 5.1. LD structure of IL-6 polymorphisms (n, number of women; D’, Lewontin’s D; r, coefficient 
of correlation) for IL-6 polymorphisms of normal-weight and obese black and white women. LD plots 
showing A: Normal Black; B Obese Black; C Normal White; D Obese White.  Shading determined by 
value of D’ – light indicates high value. 
 
5.2.3. Body composition and genotype 
 
Physical characteristics and body composition of normal-weight and obese black and 
white women according to IL-6 -174 G>C, IVS3+281 G>T, and IVS4+869 A>G 
genotypes are described in Tables 5.2., 5.3. and 5.4., respectively. 
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 The IVS4+869 A>G was the only polymorphism to be associated with body 
composition. In the black women, waist circumference was 3.38 cm (95%CI:  
0.79-5.98) higher in those with the AG and GG genotypes compared to the AA 
genotype (P=0.011, dominant model).  An interaction between this polymorphism 
and BMI group on fat mass in black women (P=0.034) is illustrated in Figure 5.2. The 
differences in fat mass between genotypes in the normal-weight group were not 
significant, but in the obese group, each G allele added, on average, 4.28 kg 
(95%CI: 1.90-6.65) to fat mass (P=0.010, additive allelic model). 
 
The ethnic-specific nature of these genotype-phenotype associations were examined 
by including both black and white women in the same model and adjusting for 
ethnicity (Table 6S I). The associations between the IVS4+869 A>G polymorphism 
and waist and fat mass described above were significant in the black women, but not 
in the white group, nor in the combined group (Table 6S I), suggesting that these 







Figure 5.2. Interaction between IL-6 IVS4+869 A>G polymorphism and BMI group on fat mass in 
black women.  Figure contains boxplots of fat mass in black women, separated by BMI group and 
genotype.  Boxplots indicate the median, the quartiles and the minimum and maximum values for 
each group. Predicted fat mass (*) from the additive allelic interaction model, for a woman of average 
age, is also indicated for each genotype by BMI group combination. Abbreviations: BMI, body mass 
index; IL-6, Interleukin-6. 
 
5.2.4. Serum lipid concentrations and genotype  
 
Serum lipid concentrations of normal-weight and obese black and white women 
according to IL-6 -174 G>C, IVS3+281 G>T, and IVS4+869 A>G genotypes are 
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The only association identified between the IL-6 polymorphisms and serum lipid 
concentrations, was in the white women, between the IVS3+281 G>T polymorphism 
and serum TAG concentrations (P=0.024) (Figure 5.3). White women with a 
IVS3+281 T allele (GT and TT genotype), had lower TAG concentrations than those 
with a G allele; the estimated effect of any T allele was 82% of the GG genotype 
(P=0.008, dominant model). The association was also significant in the combined 
group (Table 6S I), suggesting that this association was not different for the black 
and white women. 
 
 
Figure 5.3. Association of IL-6 IVS3+281 G>T polymorphisms with triglyceride concentration in white 
women.  The figure contains boxplots of triglyceride concentrations in white women, separated by 
BMI group and genotype, as well as predicted triglyceride concentration (*) for a white woman of 
average age per IL-6 IVS3+281 G>T genotype and BMI group, from the dominant model. 
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5.3. DISCUSSION  
 
This study identified associations between the G allele of the IL-6 IVS4+869 A>G 
polymorphism and increasing adiposity in the black women, and the T allele of the 
IL-6 IVS3+281 G>T polymorphism and lower TAG concentrations in the white 
women. Although the functional nature of the IVS4+869 A>G and IVS3+281 G>T 
polymorphisms have not been determined, these polymorphisms are in strong LD in 
both black and white SA women, identifying a region of the IL-6 gene that may 
contribute to obesity and dyslipidaemia.  
 
Previous studies in varied populations have shown the C allele of the IL-6 -174 G>C 
polymorphism to be associated with increased adiposity [126], and the T allele of the 
IVS3+281 G>T polymorphism to be associated with adiposity when part of a 
haplotype [210]. However, in agreement with previous studies in black populations, 
the black SA women had a very low -174 C allele frequency [97, 262, 263], which 
may explain why no association was found with this allele. It is notable that black SA 
women have a higher prevalence of obesity [3], greater SAT [102], and a higher SAT 
inflammatory gene expression profile compared to white SA women [118]. The 
findings of the present study are supported by the previous studies in Chapters 3 
and 4 examining polymorphisms within the pro-inflammatory cytokine gene TNFA. In 
these chapters it was reported that for both the TNFA -308 G>A and -238 G>A 
polymorphisms, the -308 A allele and the -238 A allele were associated with obesity 
risk and adiposity in black, but not white SA women. 
 
Conversely, the association between the IVS3+281 G>T polymorphism and lower 




atherogenic lipid profile than black women [19], which may be related to their higher 
levels of VAT [21]. Limited data is available concerning the role of IL-6 
polymorphisms in lipid metabolism [214, 264] in Caucasian and African American 
populations [264-266]. Most studies, but not all [214], found -174 G allele carriers to 
have higher T-C, LDL-C and TAG concentrations, [186, 206, 208] and lower HDL-C 
concentrations [208, 214]. Henningson et al. reported the -174 CC genotype was 
associated with lower TAG, T-C and LDL-C concentrations in Swedish women, 
however in men, C allele carriers displayed elevated TAG concentrations [206]. In 
contrast, Riikola et al. reported that T-C and LDL-C concentrations were higher in 
Finnish men with the -174 GG genotype compared to the CG and CC genotypes, but 
not in women. These conflicting results highlight the complexity of these associations 
[187, 208]. 
 
Unfortunately, little is known about the biological function and therefore the 
inflammatory nature of the IVS4+869 A>G and IVS3+281 G>T polymorphisms 
analysed in the present study, which limits the interpretation of these results. 
Circulating levels of IL-6 were not measured in this study, but in all studies these 
should be cautiously interpreted due to the contribution of both adipocytes and 
myocytes to IL-6 concentrations [194]. Studies on the -174 G>C polymorphism have 
yielded conflicting results. Specifically, the majority of studies show the -174 C allele 
results in greater gene expression and higher IL-6 concentrations [209, 212, 265, 
267], while others have reported a positive association between the G allele and IL-6 





A limitation of the study is the small subjects numbers. In addition, we focused solely 
on the IL-6 gene and the three polymorphisms analysed. However, these were 
included because of their high reported heterozygosity frequency in both white and 
black SA populations, and their established LD in both the black and white SA 
populations. Studies need to be undertaken in larger, more representative samples 
and need to explore the functional nature and biological relevance of these 
polymorphisms. Furthermore, the IL-6 gene contains a number of polymorphisms 
that may interact with each other, and other inflammatory genes should also be 
considered. It is also important to consider that genotype-phenotype relationships 
may be impacted by environmental factors such as dietary intake. Previous studies 
have shown that dietary fatty acid intake impacts IL-6 production and IL-6 gene 
expression, thereby influencing inflammatory status [40]. A few studies have also 
identified interactions between IL-6 polymorphisms and dietary fatty acid intake on 
obesity and serum lipid concentrations [184, 185]. Therefore, studies that include 
dietary intake data, investigating diet, IL-6 genotype and phenotype interactions 
should be undertaken. 
 
In conclusion, IL-6 genotype findings in this study were associated with obesity in 
black SA women and serum lipids in the white women. These findings are novel in 
that, no other studies have reported on the association between the IVS4+869 A>G 
polymorphism and adiposity. This study is also the first to report on ethnic-specific 
associations between IL-6 genotypes, obesity and associated risk in different SA 









INTERACTIONS BETWEEN DIETARY FAT INTAKE AND INTERLEUKIN-6 GENE 
POLYMORPHISMS ON OBESITY AND SERUM LIPID CONCENTRATIONS IN 
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DNA sequence variants within the IL-6 gene, in particular the functional -174 G>C 
polymorphism, have been extensively studied, but inconclusively associated with 
obesity and dyslipidaemia [187, 189, 206-208]. In the previous chapter the IL-6 
IVS4+869 A>G polymorphism was associated with adiposity in black SA women and 
the IVS3+281 G>T polymorphism with serum lipids in the white women. Differences 
in study findings may relate to differences in environmental factors, such as dietary 
intake. Chapters 3 and 4 in this thesis have described how dietary fatty acid intake, 
in particular, total fat, SFA and the n-3 and n-6 PUFAs modulate the relationship 
between polymorphisms in the TNFA gene and obesity and dyslipidaemia.  
 
To our knowledge, only two studies have reported on the relationship between IL-6 
polymorphisms and dietary intake, and both studies investigated only the -174 G>C 
polymorphism. Corpeleijn et al. reported that the ability to increase fat oxidation after 
a high fat load was increased in obese European Caucasians with the IL-6 -174 C 
allele [184]. In Spanish men and women with a high CVD risk, the -174 CC genotype 
was associated with higher levels of adiposity at baseline, however after three years 
of nutritional intervention, those with the -174 CC genotype following a 
Mediterranean-style diet, had the greatest reduction in body weight [185].  
 
In Chapter 5, the IL-6 -174 G>C polymorphism was shown not to be informative in a 
black SA population as the minor C allele is rare [133, 262]. For this reason, the two 
IL-6 intronic polymorphisms, IVS3+281 G>T and IVS4+869 A>G were identified, 
which were common in both black and white women. The G allele of the IL-6 




in black SA women, whereas the T allele of IVS3+281 G>T (rs1554606) was 
associated with lower TAG in white women (Chapter 5). However, it is not known 
whether these relationships are impacted by dietary fat intake, which has been 
shown to alter an individuals’ inflammatory profile [41]. The aim of this study was to 
investigate the impact of dietary fat intake on the relationship between the IL-6 -174 
G>C, IVS3+281 G>T and IVS4+869 A>G polymorphisms and obesity and serum 





6.2.1. Subjects  
 
The study group included 107 normal-weight and 120 obese urban black women, 
and 89 normal-weight and 62 obese urban white SA women between the ages of 18 
and 45 years. Only 73 normal-weight and 74 obese black, and 73 normal-weight and 
48 obese white women classified as adequate-reporters according to the Goldberg 
cut-offs were included in the analysis. Subject characteristics and dietary intake for 
normal-weight and obese, black and white women in this study are the same as 
those described in Chapter 3, sections 3.2.1 and 3.2.4 and summarised in Tables 
3.1. and 3.5. The white women were older than the black women, and the obese 
women older than the normal-weight women; as a result all analyses were adjusted 





In Chapter 5, physical characteristics and body composition of normal-weight and 
obese black and white women according to IL-6 -174 G>C, IVS3+281 G>T, and 
IVS4+869 A>G genotypes are described in Tables 5.2., 5.3. and 5.4., respectively. 
Serum lipid concentrations of normal-weight and obese black and white women 
according to IL-6 -174 G>C, IVS3+281 G>T, and IVS4+869 A>G genotypes are 
described in Chapter 5 in Tables 5.5., 5.6. and 5.7., respectively. Genotype 
frequency distributions and allele frequencies are discussed in Chapter 5 (section 
5.2.2) and summarised in Table 5.1.  
 
6.2.2. Diet-genotype interactions on BMI and body composition 
 
Diet-genotype interactions on body composition are summarised in Table 6.1, and 





Table 6.1. Summary of IL-6 diet-gene interactions on body composition 
  Black White 

















 GG or GT  
 TT 
 GG or GT  
 TT 
 GG or GT  
 TT 
 GG or GT  
 TT      
IVS4+869 
A>G 
AG or AAa 
 GGa 
 AG or AAa 
 GG a 
 AG or AAa 
 GGa 
 AG or AA  






 GG or Gb 
 TTb 
 GG or GT  
 TT        
IVS4+869 
A>G 
 AG or AAa 
 GGa 
 AG or AAa 
 GGa 
 AG or AAa 
 GGa 
 AG or AAa 




 IVS3+281 G>T   TT  
 GG or GT  
 TT       
IVS4+869 
A>G 
 AG or AAa 
 GGa 
 AG or AAa 
 GGa 
 AG or AAa 
 GGa 
 AG or AAa 







 GG or GT  
 TT 
 GG or GTb 
 TTb 
 GG or GT  
 TT  
 GG or GT  









 GG or GT  
 TT 
 GG or Gb 
 TTb 
 GG or GT  




 GG or GT  
 TT 
 GG or Gb 
 TTb 
 GG or GT  






 GG or GT  
 TT 
 GG or GTb 
 TTb 
 GG or GT  
 TT        
IVS4+869 







-174 G>C      C allele     
IVS4+869 















G>T      T allele    T allele  T allele 
IVS4+869 
A>G      
 AG or GGb 







 -174 G>C      C allele      
IVS3+281 
G>T      T allele
b   T allele  T alleleb  
IVS4+869 
A>G       AG or GG
c    
The interactions are described as follows: With increasing dietary fat variable, the body composition outcome 
either  (increases) or  (decreases) for a particular genotype or allele. All interactions are diet-genotype unless 
stated as being allelic. Dietary fat intake is calculated as a percentage of total energy intake. a These interactions 
were significant but the individual rates of change were not significant; b These interactions were ethnic specific; c 
This interaction was not different for black and white women. Abbreviations: WHR, waist:hip ratio; SFA, saturated 
fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; n-3 PUFA, omega-3 
polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, omega-6 : 
omega-3 polyunsaturated fatty acid ratio; ALA, α-linolenic acid; LA, linoleic acid; AA, arachidonic acid; EPA, 




6.2.2.1. IL-6 -174 G>C  
 
In white women, interactions between the IL-6 -174 G>C polymorphism and the 
intake of different dietary fatty acids (%E) on BMI were found (Table 6S II A & 6S IV 
A, and summarised in Table 6.1.). With increasing total n-3 PUFA (P=0.027) (Figure 
6.1A), EPA (P=0.040) and DHA (P=0.043) intake (%E), a decrease in BMI was 
observed in individuals with a -174 C allele (CC or GC genotypes, dominant). In 
addition, as the n-6:n-3 PUFA ratio increased, BMI increased equally with each 
additional -174 C allele (additive, P=0.028) (Figure. 6.1B). Diet-genotype 
interactions, as well as the impact of ethnicity for the -174 G>C polymorphism on 
body composition were not analysed due to the rare frequency of the C allele in the 





Figure 6.1. The relationship between BMI and fat mass, IL-6 -174 G>C, IVS3+281 G>T and 
IVS4+869 A>G polymorphisms and dietary fat intake in white women. Symbols represent, for each 
woman, observed values. The lines are modelled relationships for a woman of average age (27.3 y).  
A. With increasing n-3 PUFA intake (%E), BMI decreased in those with the -174 CC or GC 
genotypes. 
B. With increasing n-6:n-3 PUFA ratio, BMI increased equally with each additional -174 C allele. 
C. With increasing ALA intake (%E), BMI decreased with each additional IVS3+281 T allele. 
D. With increasing n-6:n-3 PUFA ratio, BMI increased with each additional IVS3+281 T allele.   
E. With increasing ALA intake (%E), fat mass decreased in those with the IVS4+869 AG or GG 
genotype. 
F. With increasing n-6:n-3 PUFA ratio, fat mass increased in those with the IVS4+869 AG or GG 
genotype; compared to those with the AA genotype. 
Abbreviations: ALA, α-linolenic acid; BMI, body mass index; IL-6, Interleukin-6 gene; n-6:n-3 PUFA, 











































































































































































































































































































6.2.2.2. IVS3+281 G>T 
 
Interactions were also observed in white women between IVS3+281 G>T and ALA 
intake (%E) on BMI (P=0.032), waist (P=0.038) and WHR (P=0.037), as well as 
between IVS3+281 G>T and n-6:n-3 PUFA ratio on BMI (P=0.030), waist (P=0.048), 
and body fat % (P=0.044) (Table 6SII B & 6SIV B, and summarised in Table 6.1.).  
More specifically, with increasing ALA intake (%E), BMI decreased with each T allele 
(Figure. 6.1C); while with increasing n-6:n-3 PUFA ratio, BMI increased with each 
additional IVS3+281 T allele (additive models) (Figure. 6.1D).  In all cases, the rate 
of change (increase and decrease) was significant for the minor homozygotes, TT. 
Similar to the -174 G>C interactions described above, slopes were in the opposite 
direction depending on the fatty acids consumed.  
 
In black women, we also identified interactions between IVS3+281 G>T and dietary 
fat intake (P=0.006), PUFA (P=0.004), SFA (P=0.010), MUFA (P=0.046), n-6 PUFA 
(P=0.004), LA (P=0.006), and AA (P=0.005), intake (%E) on BMI (Table 6SII B & 
6SIV B, and summarised in Table 6.1). With increasing dietary fat intake, BMI 
decreased in those with the IVS3+281 TT genotype and increased in those with the 
GG or GT genotype (recessive). With increasing MUFA intake (P=0.046), BMI also 
decreased in those with the IVS3+281 TT genotype, but the increase in those with 
the GG or GT genotype was not significant. Similar effects were detected for weight 
(total dietary fat (P=0.012), PUFA (P=0.007), n-6 PUFA (P=0.009), LA (P=0.009) and 
AA (P=0.008)), waist (for total dietary fat (P=0.019) and PUFA (P=0.013)), and for fat 
mass (total fat (P=0.005), SFA (P=0.010), MUFA (P=0.013), PUFA (P=0.004), n-6 




increasing dietary fat intake, adiposity decreased in those with the IVS3+281 TT 
genotype and increased in those with the GG or GT genotype.  
 
The ethnic-specific nature of these diet-genotype interactions was identified by 
examining three-way interactions between ethnic group, dietary fat intake (%E) and 
the IL-6 polymorphisms on body composition (Table 6S X A (genotype) and 6S XII A 
(allelic), as well as by including both black and white women in the same model and 
adjusting for ethnicity (Tables 6S VI A and 6S VII A (genotype) and Tables 6S VIII A 
and 6S IX A (allelic)). 
 
Tables 6S X A (genotype) and XII A (allelic), which report the p-values for three-way 
interactions between ethnic group, dietary fat intake (%E) and the IVS3+281 G>T 
polymorphism on body composition, identified significant interactions between 
ethnicity and SFA (P=0.045), PUFA (P=0.024), n-6 PUFA (P=0.027), LA (P=0.029), 
AA (P=0.005), and n-6:n-3 PUFA ratio (P=0.023) and the IVS3+281 G>T genotypes 
on BMI. Interactions between ethnicity, n-6:n-3 PUFA ratio and IVS3+281 G>T 
genotypes (P=0.015) and alleles (P=0.049) on waist were also observed. This 
suggests that these interactions, reported above, were different between the black 
and white women. Significant diet-gene interactions identified for the IVS3+281 G>T 
polymorphism, but not found to be significant in the three-way interactions, were also 
not significant in the combined group (Tables 6S VI A and 6S VII A (genotype) and 





6.2.2.3. IVS4+869 A>G 
 
In white women, we also detected interactions between IVS4+869 A>G 
polymorphism and ALA (%E) (P=0.048, Figure. 6.1E), n-3 PUFA (%E) (P=0.034) 
and n-6:n-3 PUFA ratio (P=0.034, Figure. 6.1F) on fat mass (Table 6SII C & 6SIV C, 
and summarised in Table 6.1.). With increasing n-3 PUFA (%E) intake, fat mass 
decreased in those with AG or GG genotype, while with increasing n-6:n-3 PUFA 
ratio, fat mass increased in those with an AG+GG genotype; compared to those with 
the AA genotype (Figure. 6.1F).  With increasing ALA (%E) intake, fat mass 
increased in those with the AA genotype and decreased in those with the AG+GG 
genotype, however the individual rates were not significant (Figure.. 6.1E). These 
interactions are similar to -174 G>C and IVS3+281 G>T in the white women where 
opposite slopes were observed for n-3 PUFA and n-6:n-3 PUFA ratio.  
 
In black women, we also observed a number of diet-gene interactions with the 
IVS4+869 A>G polymorphism on adiposity (Table 6S II C & S6 IV C, and 
summarised in Table 6.1), which where similar to interactions shown for the 
IVS3+281 G>T polymorphism. With increasing total dietary fat (P=0.009), MUFA 
(P=0.010), and SFA (P=0.007) intake (%E), BMI, (as well as weight, waist and fat 
mass) increased in those with the IVS4+869 AA+AG genotype and decreased in 
those with the IVS4+869 GG genotype. However, the individual rates of change 
were not significant. With increasing AA intake (%E), BMI (P=0.010), weight 
(P=0.016) and fat mass  (P=0.014) increased for the AA+AG genotypes (recessive 





Tables 6S X B (genotype) and XII B (allelic), which reports the p-values for  
three-way interactions between ethnic group, dietary fat intake (%E) and the 
IVS4+869 A>G polymorphism on body composition, identified significant interactions 
between ethnicity, ALA intake and the IVS4+869 A>G genotypes (P=0.010) and 
alleles (P=0.036) on fat mass. This suggests that these interactions, reported above, 
were different between the black and white women.  
 
When the black and white women were combined and adjusted for age and ethnicity 
(Tables 6S VI B and VIII B), the interactions between total fat (%E) and SFA (%E) 
and the IVS4+869 A>G polymorphism on weight, BMI, waist and fat mass were 
significant (P=0.009, P=0.029, P=0.011 and P=0.018, for total fat intake respectively, 
and P=0.014, P=0.009, P=0.015 and P=0.049, for SFA intake respectively). These 
interactions were only significant in the black women. In the combined group an 
interaction between n-6:n-3 PUFA ratio and IVS4+869 A>G polymorphism on fat 
mass was significant (P=0.035), but this was only observed in the white women. This 
suggests that these interactions identified in the combined group were not different 
for the black and white women.  
 
6.2.3. Diet-genotype interactions on serum lipid concentrations 
 




Table 6.2. Summary of IL-6 diet-gene interactions on serum lipids. 
  Black White 
















G>T   GT   GT    
IVS4+869 
A>G 
 GG  
 AA   
 GG a  




 -174 G>C     C allele   
IVS3+281 






G>T   GT 








G>T   GT 
b  GT     
LA
 IVS3+281 
G>T   GT 












-174 G>C     C allele   CC  
IVS3+281 
G>T       TT  
IVS4+869 





 -174 G>C      C allele  CC  
IVS4+869 




 -174 G>C      C allele   
IVS3+281 











 GG  
 AA   
 GG  
 AA     
The interactions are described as follows: With increasing dietary fat variable, the serum lipid 
outcome either  (increases) or  (decreases) for a particular genotype or allele. All interactions are 
diet-genotype unless stated as being allelic. Dietary fat intake is calculated as a percentage of total 
energy intake. a These interactions were ethnic specific; b These interactions were not different for 
black and white women. Abbreviations: TAG, triglycerides; T-C, total cholesterol; HDL-C, high density 
lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; T-C:HDL-C ratio, total cholesterol: 
high density lipoprotein cholesterol ratio, SFA, saturated fatty acid; MUFA, monounsaturated fatty 
acid; PUFA, polyunsaturated fatty acid; P:S ratio, polyunsaturated fatty acid : saturated fatty acid 
ratio; n-3 PUFA, omega-3 polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acid; 
n-6:n-3 PUFA ratio, omega-6 : omega-3 polyunsaturated fatty acid ratio; ALA, α-linolenic acid; LA, 




6.2.3.1. IL-6 -174 G>C 
 
In white women, we detected interactions between -174 G>C polymorphism and the 
intake of different dietary fatty acids (%E) on T-C, TAG, HDL-C, and T-C:HDL-C ratio 
(Table 6S III A & 6S V A, and summarized in Table 6.2.). With increasing MUFA 
(P=0.015), and EPA (P=0.044) intakes, TAG decreased with each -174 C allele, and 
with increasing n-3 PUFA (P=0.047) and ALA (P=0.022) intakes (%E), HDL-C 
increased with each -174 C allele (additive effects). With increasing EPA and DHA 
intakes (%E) (P=0.021 and P=0.014, respectively), the T-C:HDL-C ratio decreased 
in those with the -174 CC compared to CG+GG genotype (recessive effect).  
Diet-genotype interactions, as well as the impact of ethnicity for the -174 G>C 
polymorphism on serum lipids were not analysed due to the rare frequency of the C 
allele in the black women. 
 
6.2.3.2. IVS3+281 G>T 
 
In white women, with increasing n-3 PUFA (P=0.015), and ALA (P=0.029) intakes 
(%E), T-C:HDL-C ratio decreased only in those with the IVS3+281 TT genotype 
compared to TG+GG genotype (recessive), and with increasing ALA intake (%E), 
HDL-C increased significantly with each additional IVS3+281 T allele (P=0.018) 
(Table 6S III B & 6S V B, and summarized in Table 6.2.). 
 
In black women, the interactions between IVS3+281 G>T and the intake of dietary 
fatty acids on serum lipids were unusual, in that with increasing dietary fat intake 




T-C:HDL-C ratio) decreased in those with a GT genotype, but there was no effect 
(increasing, but no statistical significance was observed) in those who were 
homozygous for either allele.   
 
The ethnic-specific nature of these diet-genotype interactions was investigated by 
examining three-way interactions between ethnic group, dietary fat intake (%E) and 
the IL-6 polymorphisms on serum lipids (Table 6S X A (genotype) and 6S XII A 
(allelic)), as well as by including both black and white women in the same model and 
adjusting for ethnicity (Tables 6S VI A and 6S VII A (genotype) and Tables 6S VIII A 
and 6S IX A (allelic)). 
 
No diet-gene interactions were identified in the 3-way interactions on serum lipids 
(Tables 6S XI A and XII A). When the black and white women were combined and 
adjusted for age and ethnicity (Tables 6S VII A and IX A), the interactions between 
PUFA (%E), n-6 PUFA (%E) and LA (%E) intake and IVS3+281 G>T genotypes on 
LDL-C were significant (P=0.021, P=0.026, and P=0.026, respectively), and between 
ALA intake and IVS3+281 G>T genotypes on T-C:HDL-C ratio (P=0.027). Of these, 
the interactions on LDL-C were only significant in the black women and the 
interaction on T-C:HDL-C ratio was significant in the white women. This suggests 
that these interactions described above, and identified in the combined group were 





6.2.3.3. IVS4+869 A>G 
 
In white women, with increasing EPA and DHA (%E) intakes (P=0.047 and P=0.023, 
respectively), HDL-C decreased with each IVS4+869 G allele (additive); in those the 
minor homozygote GG, the decrease in HDL-C was significant (Table 6S III C & 6S 
V C, and summarized in Table 6.2.). 
 
In black women, an interaction was observed between increasing total dietary fat 
intake (%E) and n-6:n-3 PUFA ratio, and TAG (P=0.049), and T-C:HDL-C ratio 
(P=0.029) respectively, with each IVS4+869 G allele. With increasing dietary fat 
intake, a decrease in serum lipids was noted in individuals who were homozygous 
AA, compared to increases in serum lipids in individuals who were homozygous GG.  
 
Table 6S XIII B (allelic), which reports the p-values for three-way interactions 
between ethnic group, dietary fat intake (%E) and the IVS3+281 G>T polymorphism 
on serum lipids, identified significant interactions between EPA (P=0.026) and DHA 
(P=0.013), and the IVS4+869 A>G alleles on HDL-C reported above, suggesting that 
these interactions are different between the black and white women.  
 
When the black and white women were combined and adjusted for age and ethnicity 
(Tables 6S VII B and IX B), only the interaction between total fat (%E) and IVS4+869 
A>G polymorphism on T-C:HDL-C ratio was significant (P=0.013)(Table 6S VII B), 
and only in the black women, suggesting that it is different between the black and 




6.3. DISCUSSION  
 
For the first time dietary fatty acids have been shown to modulate the relationship 
between IL-6 polymorphisms and measures of obesity and serum lipids in both black 
and white SA women. In this study, the -174 G>C, IVS4+869 A>G and IVS3+281 
G>T polymorphisms showed similar diet-gene interactions for their minor alleles, 
some of these relationships differed between the black and white women. 
 
As previously discussed, the overall prevalence of overweight and obesity in SA 
women is high, with black women being more affected than white women (58.5% vs. 
52.9%) [3]. Obesity in black women is associated with a higher prevalence of insulin 
resistance and type 2 diabetes, whereas obese white women traditionally have a 
higher prevalence of dyslipidaemia and associated CVD [8]. As ethnicity 
encompasses genetic, environmental, lifestyle (including diet) and cultural 
differences, and given that diet and environment contribute significantly to the 
pathogenesis and development of these chronic diseases, it is unlikely that genetic 
differences alone would underlie these ethnic differences [268]. SA has undergone a 
rapid diet transition from a rural diet, high in complex carbohydrates, to a more 
westernised urban intake, high in fat [135], with subsequent increases in the 
prevalence of diseases of lifestyle [8]. In contrast, polymorphism frequencies are 
unlikely to change in this time span. It is therefore hypothesized that individuals may 
take different routes in their development of obesity and comorbidities, and that the 
quantity and quality of dietary fat intake, (as well as other environmental and lifestyle 






In Chapter 5 it was reported that the IVS4+869 AG and GG genotypes were 
associated with greater waist and fat mass in black SA women and the IVS3+281 T 
allele was associated with lower TAG levels in white SA women. However, here it is 
shown for the first time that both the quality and quantity of dietary fat intake 
modulates this relationship. When dietary fat intake was included in the analyses, it 
was observed in the white women that with increasing intake of the anti-inflammatory 
n-3 PUFAs, measures of adiposity decreased, and with increasing n-6:n-3 PUFA 
ratio, adiposity increased in those with the -174 C, IVS3+281 T and IVS4+869 G 
minor alleles. These findings are supported by Razquin et al. who showed that with 
increasing n-3 PUFA intake, the -174 CC genotype was associated with lower 
measures of adiposity [185]. Further, in white women in this study, an increasing 
intake of n-3 PUFAs was associated with a decrease in TAG (only for -174 G>C) and 
T-C:HDL-C ratio, and an increase in HDL-C in those with the -174 C and IVS3+281 
T alleles. These findings suggest that anti-inflammatory n-3 PUFAs have a 
favourable effect on adiposity and serum lipids, more so in individuals with the -174 
C, IVS3+281 T and IVS4+869 G minor alleles. 
 
In contrast, in the black women it appears that an increasing intake of dietary fat, 
rather than the quality of individual fatty acids, was associated with increasing 
measures of adiposity in those with the IVS3+281 GT+GG and IVS4+869 AG+AA 
genotypes, and decreasing measures of adiposity in those with the IVS3+281 TT 
and IVS4+869 GG genotypes. Further, with increasing total fat intake and n-6:n-3 
PUFA ratio, TAG and T-C:HDL-C ratio increased with each IVS4+869 G allele. 




total dietary fat intake was associated with greater measures of obesity for the TNFA 
-308 and -238 A alleles irrespective of the quality of the dietary fat.  
 
Studies have shown that dietary fatty acids modulate IL-6 production, thereby 
influencing inflammatory status [40]. A number of studies have investigated the effect 
of different dietary fatty acids on IL-6 levels in different models, with human studies 
showing similar results to cell culture and rodent models [40]. He et al. showed that 
increased n-3 PUFA intake and fish consumption were associated with decreased 
plasma concentrations of IL-6 and other inflammatory markers [202]. Further, 
Ferrucci et al. reported that plasma levels of PUFAs, especially n-3 PUFAs, were 
independently associated with lower levels of pro-inflammatory markers and higher 
levels of anti-inflammatory markers [203]. Rats fed a diet high in n-6 PUFA-rich 
sunflower oil showed a moderate IL-6 release from adipocytes, and lower plasma  
IL-6 than when fed a SFA-rich diet, but greater than when fed a MUFA-rich diet 
[200]. Only one controlled feeding trial investigated the effect of a SFA and  
MUFA–rich diet on serum lipid concentrations and whole-genome microarray gene 
expression profiles of adipose tissue [204]. The eight week consumption of a  
SFA-enriched diet resulted in increased expression of genes involved in 
inflammatory processes in adipose tissue, including IL-6 and NF-κB signalling, 
whereas the MUFA enriched diet led to a more anti-inflammatory gene expression 
profile, accompanied by a decrease in serum LDL-C concentration [204].  
 
These findings support this study hypothesis that dietary fatty acids may modulate 
the relationship between IL-6 polymorphisms, obesity and dyslipidaemia. For the IL-6  




appears that the minor alleles of these polymorphisms may be more responsive to 
the quantity and quality of the dietary fat being consumed, compared to the major 
allele. Similar results were observed for the TNFA polymorphisms in Chapters 3 and 
4, where the minor A allele was more responsive to changes in dietary fat intake. 
Notably, in this study the individual diet-gene interactions differed between the two 
ethnic groups. The reasons for this are not known, but may relate to differences in 
the frequency of the polymorphisms and/or differences in dietary intake, specifically 
dietary fatty acid intake, between black and white women included in this study.  
 
The minor allele frequencies of the -174 G>C and IVS3+281 G>T polymorphisms 
were higher in the white compared to the black women, but all frequencies were 
similar to those from European and other African populations. In this study the  
diet-gene interactions in the white women, for both body composition and serum 
lipids, were observed only with regards the n-3 PUFA’s and the n-6:n-3 PUFA ratio, 
whereas in the black women, the diet-gene interactions were observed for total fat 
intake, SFA, MUFA and PUFA, and for all the n-6 fatty acids. The intake of n-6 
PUFAs (%E) and the n-6:n-3 PUFA ratio in the black women is alarmingly high, and 
higher than that of the white women (8.3% vs. 5.6%, and 26.4:1 vs. 16.1:1, for black 
and white women respectively), and that reported in other populations, 4.0 – 6.0% 
for n-6 PUFA (%E) [254], and ≈15:1 for the n-6:n-3 PUFA ratio [259].  
 
While the functional nature of the -174 G>C polymorphism has been investigated, 
little is known of the functional nature of the two additional intronic polymorphisms 
included in this study, especially their impact on markers of inflammation. 




other polymorphisms such as those found on the fatty acid desaturase 1 (FADS1) 
and FADS2 genes may alter PUFA metabolism and these gene-gene interactions 
may need to be considered [141]. Further limitations to this study should be 
considered, as described in the previous chapters. In brief, our sample size was 
small and included fewer white than black women. It is always difficult to report 
accurate dietary intake. To improve the validity of the dietary intake data we used a 
validated FFQ developed specifically for the SA population, and included only 
adequate reporters in the analyses. In addition, no lifestyle factors such as physical 
activity and socioeconomic factors were included, that may also impact the obese 
phenotype. 
 
In conclusion, this novel study showed that dietary fat intake, and the quality of the 
dietary fatty acids consumed, modulated the relationship between the IL-6 -174 
G>C, IVS3+281 G>T and IVS4+869 A>G polymorphisms, on measures of obesity 
and serum lipids, with different effects in black and white women. Importantly, two 
polymorphisms that are informative as markers of gene-diet interactions in both 
black and white SA women were identified. This final chapter further highlights the 
importance of understanding the inflammatory impact of different dietary fatty acids 




















The first SADHS published in 2002, highlighted the high overall prevalence of 
overweight and obesity in SA, with more than 29% of men and 56% of women 
classified as overweight or obese [3]. Black SA women had the highest prevalence 
of overweight and obesity (58.5%), higher than white SA women (52.9%)[3]. In 
addition, urban women were found to have a higher BMI than their rural counterparts. 
Although the prevalence of obesity is high in both black and white SA women, the 
prevalence of co-morbidities associated with obesity in these populations differ [8]. 
Insulin resistance and diabetes are more prevalent in black SA women, while the 
prevalence of dyslipidaemia and CAD is greater in white SA women [8]. 
 
On account of the high prevalence of overweight and obesity in women compared to 
men in SA, this thesis focused only on women, [3, 7]. Of the SA populations, only 
black and white women were compared, due to the disparities in obesity risk, serum 
lipid profiles and CAD prevalence. In line with previous studies [7], the white women 
in the study group had greater weight and central adiposity (waist, WHR, and VAT) 
than the black women, while the black women had higher BMI, body fat %, and SAT 
than the white women. The study sampling procedures also resulted in the white 
women being older than the black women; as a result all analyses were adjusted for 
age. Attempts to recruit older normal-weight black women were unsuccessful; likely 
reflective of the demographic of this population. Based on the SADHS, the mean 
BMI of SA women in the 15 to 24 year and 25 to 34 year old groups were 23.4 and 
26.8 kg/m2, respectively, compared to the 35-44 year old women who had a mean 





CAD is an important co-morbidity associated with obesity, and one that has shown 
differences in prevalence by ethnicity. In 2000, of the total age-standardised death 
rates in South Africans, CAD contributed 23% for black men and women compared 
to 41% for white men and women [8, 13], and the cholesterol-attributable mortality 
estimates were significantly lower in black than white SA women [20]. Black SA 
women, similar to African Americans have been shown to have a less atherogenic 
lipid profile than white women [21-23], potentially attributable to relatively low levels 
of VAT [21]. This was also observed in this thesis sample group. All serum lipid 
concentrations, except the T-C:HDL-C ratio were higher in the white compared to the 
black women. Studies in SA women have generally reported no ethnic difference in 
HDL-C levels [22], whereas African Americans have been shown to have higher 
HDL-C levels than their white counterparts [23]. In this study, similar to that reported 
by Goedecke et al., HDL-C was lower in black women compared to white women [19, 
24]. In addressing the healthcare burden of chronic diseases of lifestyle in SA, It is 
therefore important to identify and understand factors contributing to these 
differences, enabling the development of effective interventions.  
 
There is growing scientific evidence establishing obesity as a condition of chronic 
low-grade inflammation [191]. Adipocyte hypertrophy results in increased chemokine 
secretion, and a subsequent increase in macrophage infiltration, which in turn 
secretes cytokines such as IL-6 and TNFα [33]. Low-grade chronic inflammation also 
mediates all stages of atherosclerosis. LDL-C, VLDL-C and intermediate-density 
molecules in the intima undergo oxidative modification, inducing expression of pro-





Ethnic differences in the inflammatory phenotype may be due, in part, to differences 
in the distribution of DNA sequence variants (genotype frequencies) and gene 
expression in genes such as TNFA and IL-6 [97, 98]. Polymorphisms in these 
inflammatory genes have been shown to impact molecular processes of the 
inflammatory pathways, serum lipids and the obese phenotype. Specifically, several 
studies have reported associations between polymorphisms in the cytokine genes 
TNFA and IL-6, and obesity and dyslipidaemia [40, 187]. However, there are no 
studies that have examined these associations in Southern African populations.  
 
Accordingly, the aim of this thesis was to examine associations between TNFA and 
IL-6 polymorphisms (TNFA -308 G>A and -238 G>A & IL-6 -174 G>C, IVS3+281 
G>T, and IVS4+869 A>G) and measures of adiposity and serum lipid concentrations 
in urbanised black and white SA women, to examine the effects of dietary fatty acid 
intake on these relationships, and to determine if these relationships were ethnic 
specific. Summaries of the main findings of this thesis are presented in Tables 7.1. 
and 7.2. 
 
Association studies between the TNFA -308 G>A and -238 G>A polymorphisms with 
obesity and serum lipid concentrations are described in Chapters 3 and 4, 
respectively. No independent associations between the TNFA -308 G>A 
polymorphism and obesity and serum lipid concentrations were observed in either 
the black or white women. However, this is the first study to show that black SA 
women with the TNFA -238 GA genotype had a greater body fat percentage than 





Within the IL-6 gene, the most frequently studied polymorphism is IL-6 -174 G>C 
(rs1800795). However, it has been shown to be rare in persons of African descent, 
and as expected the -174 C allele was rare in the black women in this study, 
representing only 1% of the normal-weight and 3% of the obese black women. Two 
IL-6 polymorphisms, IVS3+281 G>T (rs1554606) in intron 3, and IVS4+869 A>G 
(rs2069845) in intron 4 (Chapter 2) were identified. Both polymorphisms showed an 
adequate heterozygosity in both the white and black SA populations in this study. 
The IVS3+281 T allele was present in 27% of the black women (both normal-weight 
and obese), and approximately 42% for the normal-weight and obese white women. 
For the IVS4+869 A>G polymorphism, the G allele was present in approximately 
30% of the normal-weight and obese, black and white women. 
 
Chapter 5 describes the genotype-phenotype associations investigated between IL-6 
174 G>C, IVS3+281 G>T, and IVS4+869 A>G polymorphisms and obesity and 
serum lipid concentrations (Table 7.1. and 7.2.). It was observed that the IVS4+869 
G allele was associated with higher adiposity in the black women This association 
was different for the black and white women. In the white women, those with the T 
allele of the IVS3+281 G>T polymorphism had lower TAG concentrations than those 
with the IVS3+281 GG genotype. This association was not different for the black and 
white women. These findings are novel in that no other studies have reported on 
associations between the IVS4+869 A>G and IVS3+281 G>A polymorphisms and 
obesity and serum lipids. 
 
Overall, this thesis reported genotype associations with obesity in the black women, 




interpreting these associations and understanding the impact of these 
polymorphisms on inflammation, the obese phenotype and serum lipids is the 
necessity of understanding the impact of these polymorphisms on TNFA and IL-6 
gene transcription, and subsequent TNFα and IL-6 plasma levels. There is 
controversy regarding the functional significance of the TNFA -238 polymorphism, 
and an absence of functional studies on the IVS4+869 A>G and IVS3+281 G>A 
polymorphisms. Studies have reported that the -238 A allele either increases [249], 
decreases [250, 251] or has no effect on TNFA transcription [252, 253], depending 
on the conditions of the experiment. Although the functional nature of the two intronic 
polymorphisms has not yet been determined, they are in strong LD in both black and 
white SA women, identifying a region of the IL-6 gene that may contribute to obesity 
and dyslipidaemia, which requires further investigation. Unfortunately, in this thesis, 
circulating levels of IL-6, TNFα or TNF-R, were not measured, which could have 
provided insight into the inflammatory phenotype of the black and white women.  
 
Dietary fatty acids also regulate cytokine gene expression and secretion, thereby 
impacting inflammation [69, 160, 162, 200, 205].  TNFA and IL-6 polymorphisms 
have been shown to interact with dietary fatty acids, modulating these relationships 
(Chapter 1) [40, 187]. Little dietary intake data of SA populations has been published 
since the early 1990’s. Data from the early BRISK (black urban) and VIGHOR (white 
urban) SA dietary studies [139, 140] found that black and white urban populations 
consumed similar amounts of PUFA, however total fat and saturated fat intake was 
higher in white urban compared to black urban diets [139, 140]. In contrast to these 
studies, it was reported in this thesis that black women consumed more total fat and 




nutrition transition may have altered these intakes over the past 20 years [135, 136]. 
Unfortunately, no previous studies have described the intake of individual dietary 
fatty acids in SA populations, making a comparison with these dietary intake results 
difficult. Nonetheless, these results reports that black SA women consumed more  
n-6 PUFA, EPA and DHA (%E), as well as had a higher n-6:n-3 PUFA ratio than the 
white women (Chapter 3). Notably, the n-6:n-3 PUFA ratio in the black women was 
alarmingly high, higher than that of the white women, and that reported in other 
populations [254, 259], and far exceeding the WHO recommendation of a n-6:n-3 
PUFA ratio of 5–10:1 [243]. 
 
In addition to the established associations between dietary fat, obesity, serum lipids 
and CVD [72, 79, 254, 255, 269, 270], dietary fatty acids interact with genetic 
variants to regulate the development and progression of obesity and serum lipids. 
These complex nutrigenetic interactions may partly explain differences observed in 
the obese phenotype and serum lipid concentrations that vary both within and across 
populations [40, 96, 187]. 
 
When dietary intake was included in the study analyses, interactions between dietary 
fat intake (%E) and the TNFA -308 G>A polymorphism on adiposity and serum lipid 
concentrations in both black and white women were observed (Chapter 3). In the 
black women, the obesity OR of those with the -308 A allele compared to the GG 
genotype, was higher with increasing fat intake (%E). Furthermore, with increasing 
dietary fat intake, irrespective of the type of fat, weight and adiposity was higher in 
black women with the -238 GA genotype and decreased or did not change in those 





With regards diet - IL-6 gene interactions, only two studies have previously reported 
on the relationship between the IL-6 -174 G>C polymorphism and dietary intake 
[184, 185], and none including the IVS3+281 G>T and IVS4+869 A>G 
polymorphisms. As described in Chapter 6 and detailed in Tables 7.1. and 7.2., for 
the first time, it is shown that both the amount and type of dietary fatty acid intake 
modulated the relationship between IL-6 -174 G>C, IVS3+281 G>T, and IVS4+869 
A>G polymorphisms and obesity and serum lipid profiles.  
 
In the white women, with increasing intake of n-3 PUFAs, measures of adiposity 
decreased, and with increasing n-6:n-3 PUFA ratio, adiposity increased in those with 
the -174 C, IVS3+281 T and IVS4+869 G minor alleles (Chapter 6). In contrast, in 
the black women it appeared that an increasing intake of total dietary fat, rather than 
individual dietary fatty acids, was associated with increasing measures of adiposity in 
those with the IVS3+281 GT+GG and IVS4+869 AG+AA genotypes, and decreasing 
measures of adiposity in those with the IVS3+281 TT and IVS4+869 GG genotypes. 
 
When analysing diet-genotype interactions on serum lipid concentrations; with 
increasing ALA intake (%E), the T-C:HDL-C ratio decreased in black women with the 
TNFA -308 A allele. In contrast, increasing PUFA intake, comprising mostly the n-6 
PUFA LA, was associated with increasing LDL-C concentrations only in black 
women with the  –308 A allele. In the white women, with increasing SFA intake (%E), 
T-C concentrations increased for the –308 GA + AA genotype and decreased for the 





Despite many studies examining the -308 G>A polymorphism, only the studies by 
Fontaine-Bisson et al. investigated interactions between dietary fat intake and the     
-308 G>A and -238 G>A polymorphisms on serum lipids in an ethno-racially diverse 
Canadian population (Chapter 1) [182, 183]. Interactions between the TNFA -238 
G>A polymorphism and dietary fatty acids on obesity and serum lipid concentrations 
are described in Chapter 4. The relationship between the -238 G>A polymorphism 
and serum lipid concentrations differed depending on the individual PUFAs 
consumed. As expected and similar to that observed for the TNFA -308 G>A 
polymorphism, the n-3 PUFAs had a favourable effect, and the n-6:n-3 PUFA ratio 
an unfavourable effect on serum lipid concentrations, but different diet-gene 
interactions were observed in the black and white women (Table 7.2.).  
 
Similar to the findings for the TNFA gene polymorphism, increasing intake of n-3 
PUFAs was associated with a decrease in TAG (only for IL-6 -174 G>C) and  
T-C:HDL-C ratio, and an increase in HDL-C in those with the IL-6 -174 C and 
IVS3+281 T alleles. Further, in black women, with increasing total fat intake and      
n-6:n-3 PUFA ratio, TAG and T-C:HDL-C ratio increased with each IL-6 IVS4+869 G 
allele.  
 
Only some of the diet-gene interactions described above for TNFA and IL-6 were 
different for the black and white women. However, a number of factors were 
common to all these interactions. In brief, in both black and white women, dietary 
fatty acids interacted in different ways; a high total fat, SFA and n-6:n-3 PUFA ratio 
produced an unfavourable effect, and the n-3 PUFAs produced a favourable effect 




interactions the minor allele of all polymorphisms showed the greatest 
responsiveness. Specifically, these thesis results reported that increasing intake of 
total fat, SFA and the n-6:n-3 PUFA ratio were associated with higher BMI, adiposity, 
TAG, T-C, LDL-C and T-C:HDL ratio, and lower HDL-C, in those with the TNFA and 
IL-6 polymorphism minor alleles. In contrast, an increase in total n-3 PUFAs, as well 
as the individual n-3 PUFAs; EPA, DHA and ALA, were associated with a decrease 
in BMI, adiposity and TAG, T-C, LDL-C and T-C:HDL ratio in those with the IL-6 
polymorphisms minor allele. This is not completely unexpected as a higher intake of 
n-3 PUFAs has been associated with a reduction in inflammation and improved 
obesity and serum lipid outcomes [41, 81]. In contrast, a higher intake of total fat and 
a greater n-6:n-3 PUFA ratio has been associated with increased inflammation and 
increased measures of obesity and serum lipid concentrations [41, 81, 84, 260, 271].  
 
The nutrigenomics literature suggests that either the wild-type or variant allele will 
exhibit a greater responsiveness to changes in dietary intake. The findings in this 
thesis suggest that both the TNFA -308 and -238 minor A alleles produce a greater 
response to changes in dietary fat intake than the G allele. Similarly, the minor 
alleles of all three IL-6 polymorphisms (-174 G>C, IVS3+281 G>T, and IVS4+869 
A>G), appear to show consistently, greater responsiveness to changes in dietary 
fatty acid intake than the wild-type alleles. While, the responsive allele was the same 
for black and white women, some of the associations and interactions observed in 
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There is little doubt that ethnicity is a significant confounder when investigating 
obesity and serum lipids. As discussed in Chapter 1, ethnicity encompasses 
genetic, environmental, diet and lifestyle, and cultural differences, highlighting 
the importance of including these variables in all studies. This thesis showed 
differences between the black and white women for body composition, serum 
lipid profiles, dietary fat intake, genotype frequency, and certain  
genotype-phenotype associations and diet-genotype interactions. These 
differences emphasise the role these factors play in the development of obesity 
and dyslipidaemia, and potentially in the differences observed in the prevalence 
of obesity-associated co-morbidities in black and white SA populations. 
 
This thesis also draws attention to the importance of including individual dietary 
fatty acid data in diet and diet-gene studies. By analysing only total fat intake or 
intake of the dietary fat sub-groups such as SFA, MUFA and PUFA; diet-gene 
interactions contributing to the development of obesity and dyslipidaemia may 
not have been identified. The thesis findings reiterate how different dietary fatty 
acids differentially impact phenotype. The diet-gene interactions identified here 
show that dietary fatty acids, especially PUFAs, differentially impact obesity and 
serum lipid profiles, but that this is not true for all individuals. Rather, individuals 
carrying certain genotypes will show a greater or lesser responsiveness to the 
beneficial or harmful effects of different dietary fatty acids, potentially impacting 
dietary requirements and recommendations. 
 
It is important to note that there are limitations to the studies in this thesis. The 
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subjects were not randomly sampled, but were recruited through local 
newspapers, church groups and universities. Therefore the data may not be 
representative of the black and white SA population. The sample size was 
small, and included no men. As discussed, only women were included because 
of their high prevalence of overweight and obesity [3, 7], and only black and 
white women were compared, due to the disparities in their obesity risk, serum 
lipid profiles and prevalence of CAD [8]. There were also fewer white than black 
women, which means that associations in the white women may not have been 
detected, which were detected in the black women.  
 
Accuracy of diet reporting is always difficult. In order to improve the validity of 
the dietary data in this study, a validated food frequency questionnaire, 
developed specifically for the SA population was used, and only adequate 
reporters were included in the analysis [215]. For future studies, the 
measurement of serum or red cell fatty acid composition will be objective and 
informative. Other lifestyle factors, such as physical activity and socioeconomic 
factors may also impact obesity and serum lipids, but were not included in this 
study.  
 
Multiple genes, each with modest effects, may underlie the obese phenotype 
and serum lipid profiles [96, 244, 245]. This thesis included only two of the 
inflammatory cytokine genes and only five polymorphisms, however many other 
adipokines, chemokines and cytokines have been associated with obesity and 
serum lipids (e.g. adiponectin, IL-1, IL-10, and MCP-1), and are sensitive to 
dietary fatty acid intake and should be studied further [187]. These results 
CHAPTER SEVEN 
 178 
should also be confirmed in larger cohorts, including additional polymorphisms 
within the TNFA and IL-6 gene, as well as polymorphisms in other genes 
involved in inflammation. Furthermore other polymorphisms such as those 
found on the FADS1 and FADS2 genes may alter PUFA metabolism and these 
interactions may need to be considered [141]. 
 
In addition to the genes and polymorphisms chosen, it is also important to 
consider the study designs selected for this thesis. The first results from a 
GWAS were reported in 2005 [272] and 2006 [273], however the 2007 
Wellcome Trust Case Control Consortium (WTCCC) paper published in Nature 
is regarded as a starting point and the first successful GWAS [272, 274]. Since 
then, GWAS have become the method of choice to identify common 
polymorphisms with small effects that are associated with complex phenotypes 
such as obesity, and diseases such as CVD. The advantage of this technique is 
that it simultaneously analyses the association of a few 100,000 to several 
millions polymorphisms with a well-defined trait without a previous hypotheses 
about potential mechanisms. The GWAS approach has yielded many 
successful discoveries [274], identifying at least 50 loci associated with BMI, 
WHR, body fat percentage and extreme obesity [272], as well as genetic 
variants associated with variation in serum lipid concentrations [275]. However, 
a major limitation of GWAS in the context of this thesis is that they have been 
conducted primarily in white European populations, with only one study 
including a population from the African continent and none from Southern Africa. 
A study of 1,931 African Nigerians and African Americans with a follow-up 
sample of 3,700 did not identify any new significant genome-wide associations 
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with anthropometric measures [276]. However, they did show variants near 
DLEU7 (deleted in lymphocytic leukemia) for height and MC4R (Melanocortin 4 
Receptor) for BMI, previously confirmed in European populations. The authors 
suggest that sample sizes comparable to European GWAS are required to 
identify replicable associations, with additional studies in African-ancestry 
populations to improve power to detect novel associations [276, 277].  
 
Notably, GWAS have also not to date been used to address gene-diet and 
gene-environment interactions, which are essential to our understanding of how 
diet and environment may modulate genotype-phenotype associations identified. 
Many important polymorphisms that interact with diet could potentially be 
missed using the GWAS approach since the role of diet and other factors in the 
development of obesity and dyslipidaemia are not taken into account in GWAS. 
 
There is therefore still a place for the use of the more traditional candidate gene 
association studies in nutrigenetic research and in clarifying the association of 
gene variants identified using GWAS. In this approach, candidate genes and 
variants are selected if there is good evidence that; i) the candidate gene is 
biologically relevant to the phenotype, ii) the genetic variant influences the 
function of the gene, and iii) that the polymorphisms of the selected genes are 
frequent enough in the population to allow meaningful statistical analysis [278]. 
These studies have however been implemented with small subject numbers 
and are susceptible to false-positives, therefore the replication of these studies 




In this thesis, although the TNFA and IL-6 genes have not been identified in 
GWAS [275, 279], they were selected for this thesis as they fulfilled the criteria 
for a hypothesis-driven candidate gene study. Their selection was based on 
established associations between TNFA and IL-6, inflammation, obesity and 
serum lipid concentrations, and the impact of different dietary fatty acids on 
TNFA and IL-6 expression and serum levels. In addition, two of the five 
polymorphisms studies have been shown to influence the function of the gene, 
and except for the IL-6 -174 G>C polymorphism in the black women, the other 
polymorphisms had adequate genotype and allele frequencies in the black and 
white SA populations included in this thesis, ethnic populations that have not 
previously been studied. 
 
Limitations of the study also include the fact that there was no adjustment for 
multiple testing. Nevertheless, it has been suggested that the Bonferroni 
correction is too conservative when several associations are tested in the same 
group of individuals [226], and might not be appropriate in a situation such as 
this, where there is prior evidence that such effects exist [227]. Based on prior 
evidence the studies in this thesis tested specific hypotheses. These results, 
like the results of all genetic association studies, should be treated with caution 
until independently replicated.  
 
Based on the findings in this thesis, it is recommended that future research 
investigating obesity and CAD should include detailed diet and genotype data, 
different ethnic populations, and both male and female subjects. Particular 
consideration should be given to the inclusion of polymorphisms and genes, 
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considering SNP-SNP and gene-gene interactions. In addition to diet-
polymorphism interactions, it is also important to understand the combined 
effect of a number of polymorphisms on the same or different genes interacting 
with the environment. For this reason, the identification and analysis of 
haplotype-diet interactions may provide additional insights in future research. 
 
It is also important that future research unravel the molecular mechanisms that 
govern the endogenous metabolism of serum lipids, which has also been shown 
to differ between black and white women, and the impact of dietary fatty acids 
on inflammation [19]. These mechanisms remain unclear, and appear to act via 
multiple pathways. It is known that different groups of dietary fatty acids (SFA, 
MUFA, and n-3, n-6 & n-9 PUFA) differ in their effect on inflammatory gene 
expression and plasma levels. The nutrigenetic interactions described in this 
thesis are complex and it is difficult to assess the magnitude of their impact in 
managing an individual or a populations’ diet. Rather than the cross-sectional 
study design employed in this thesis, randomised controlled trials with dietary 
interventions are required to measure whether nutrigenetic-driven dietary 
recommendations alter phenotypic outcomes. Furthermore, the inter-ethnic 
variability reported here should caution us with regards generalised dietary 
recommendations, as it cannot be assumed that dietary fatty acids and other 
nutrient metabolism is uniform for all populations.  
 
The future study of nutrigenomics offers the opportunity to clarify the underlying 
molecular mechanisms governing the interactions between dietary fatty acids 
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9.1. Characteristics and dietary intake of under-, adequate and over-
reporters.  
 
Table 2S I. describes subject characteristics, body composition, serum lipid 
concentrations and dietary intake of under, adequate and over-reporters. These 
variables are described separately for black (Table 2S III) and white (Table 2S III) 
women. 
 
Under-reporters were older than adequate reporters, and over-reporters 
younger than adequate reporters. Weight, BMI, waist, WHR and fat mass were 
higher in the under-reporter group compared to the adequate and over-reporter 
groups. There was a significant group*ethnicity interaction for body fat 
percentage, waist and fat mass, suggesting that the body fat measures of the 
dietary reporting groups were different between the black and white women. 
The example of body fat % is shown in the boxplots below, illustrating the 
differences (Figure 2S 1.). After adjusting for age; in white women; body fat 
percentage increased from over to under-reporters (Figure 2S 1.). In black 
women, adequate reporters had lower adiposity than under-reporters, with  
over- reporters in-between (Figure 2S 1.). It was also found that T-C and LDL-C 
concentrations were higher in the under-reporters and adequate reporters 
compared to the over-reporters.   
 
All measures of dietary fat intake differed between reporter groups, except for 
total n-3 PUFA, and ALA and DHA intake (%E). Over-reporters consumed more 





Figure 2S 1. Group*ethnicity interaction; in white women; over-reporters have lower body fat % 
than under-reporters, with adequate reporters in the middle. In black women, adequate 
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Table 2S II. Subject characteristics, body composition, serum lipids and dietary 
intake of black under, adequate and over-reporter women. 
  Under-reporters Adequate reporters Over-reporters P value 
N 17 146 68   
Age, years 34 ± 10 27 ± 7 25 ± 6) < 0.001 
Body composition    
Height, m 1.60 ± 0.07 1.60 ± 0.06 1.61 ± 0.05) 0.417 
Weight, kg  93 ± 22 75 ± 19 77 ± 22) 0.033 
BMI, kg/m2  36 ± 8 29 ± 8 30 ± 8) 0.072 
Body fat, %  43 ± 9 37 ± 8 38 ± 9) 0.207 
Fat Mass, kg 41 ± 15 29 ± 14 30 ± 15) 0.036 
Waist, cm  105 ± 18 89 ± 18 91 ± 19) 0.030 
WHR  0.85 ± 0.07 0.79 ± 0.08 0.80 ± 0.09) 0.061 
VAT, cm2  109 ± 50 73 ± 42 72 ± 35) 0.192 
SAT, cm2  561 ± 215 384 ± 219 393 ± 238) 0.188 
Serum lipids      
TAG, mmol/L 1.00 (0.50-1.10) 0.60 (0.50-0.90) 0.60 (0.50-0.80) 0.659 
T-C, mmol/L 4.05 (3.65-4.23) 3.90 (3.30-4.40) 3.85 (3.23-4.30) 0.367 
HDL-C, mmol/L  1.40 (1.05-1.50) 1.30 (1.10-1.60) 1.40 (1.10-1.80) 0.216 
LDL-C, mmol/L  2.30 (2.15-2.50) 2.30 (1.70-2.83) 2.05 (1.60-2.50) 0.204 
TC;HDL-C ratio 3.00 (2.69-3.78) 3.00 (2.47-3.84) 2.70 (2.25-3.25) 0.065 
Body composition: Summarised as mean ± SD. Serum lipids and dietary intake: Summarised as 
median (interquartile range). Other than age, all p-values are from age-adjusted linear models of 
outcomes. A significant group*ethnicity interaction for a characteristic means that the groups means 
are different between the black and white women. Abbreviations: AA, arachidonic acid; ALA,  
α-linolenic acid; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid, 
HDL-C, high-density lipoprotein cholesterol; LA, linoleic acid; LDL-C, low-density lipoprotein 
cholesterol; MUFA, mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; 
(n-6) PUFA, (n-6) polyunsaturated fatty acids; (n-3) PUFA, (n-3) polyunsaturated fatty acid; (n-6):(n-3) 
PUFA ratio, (n-6):(n-3) polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; 
SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; TAG, triacylglycerol; T-C, total 
cholesterol; T-C:HDL-C ratio, total cholesterol:HDL-cholesterol ratio; TNFA, tumour necrosis factor-α 






Table 2S II. continued 
 
  Under-reporters Adequate reporters Over-reporters P value 
Dietary intake     
Fat (%E) 30 (26-33) 34 (29-37) 36 (33-39) 0.024 
SFA (%E) 7.6 (7.0-9.5) 9.2 (8.1-10.7) 9.7 (8.8-10.9) 0.013 
MUFA (%E) 9.3 (8.0-11.5) 10.8 (9.2-12.3) 11.6 (10.2-13.4) 0.001 
PUFA (%E) 7.2 (6.1-10.9) 8.7 (7.2-10.3) 9.8 (7.8-11.2) 0.028 
P:S ratio 1.10 (0.80-1.37) 0.95 (0.77-1.16) 1.01 (0.82-1.19) 0.602 
(n-3) PUFA (%E) 0.31 (0.23-0.37) 0.31 (0.25-0.41) 0.32 (0.23-0.44) 0.884 
(n-6) PUFA (%E) 7.0 (5.8-10.6) 8.3 (6.8-10.2) 9.6 (7.5-11.3) 0.243 
(n-6):(n-3) PUFA 
ratio 28.2 (15.6-36.5) 26.4 (19.1-37.3) 27.1 (18.8-39.4) 0.654 
ALA (%E) 0.21 (0.18-0.28) 0.22 (0.18-0.25) 0.21 (0.18-0.27) 0.400 
LA (%E) 7.1 (5.9-10.8) 8.5 (6.9-10.4) 9.6 (7.6-11.6) 0.253 
AA (%E)  0.04 (0.03-0.06) 0.05 (0.03-0.07) 0.05 (0.04-0.07) 0.349 
EPA (%E) 0.02 (0.01-0.03) 0.03 (0.01-0.06) 0.03 (0.01-0.06) 0.203 
DHA (%E) 0.04 (0.04-0.06) 0.05 (0.03-0.11) 0.06 (0.03-0.11) 0.259 
Body composition: Summarised as mean ± SD. Serum lipids and dietary intake: Summarised as 
median (interquartile range). Other than age, all p-values are from age-adjusted linear models of 
outcomes. A significant group*ethnicity interaction for a characteristic means that the groups means 
are different between the black and white women. Abbreviations: AA, arachidonic acid; ALA,  
α-linolenic acid; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid, 
HDL-C, high-density lipoprotein cholesterol; LA, linoleic acid; LDL-C, low-density lipoprotein 
cholesterol; MUFA, mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; 
(n-6) PUFA, (n-6) polyunsaturated fatty acids; (n-3) PUFA, (n-3) polyunsaturated fatty acid; (n-6):(n-3) 
PUFA ratio, (n-6):(n-3) polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; 
SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; TAG, triacylglycerol; T-C, total 
cholesterol; T-C:HDL-C ratio, total cholesterol:HDL-cholesterol ratio; TNFA, tumour necrosis factor-α 





Table 2S III. Subject characteristics, body composition, serum lipids and dietary 
intake of white under, adequate and over-reporter women. 
  Under-reporters Adequate reporters Over-reporters P value 
N 25 122 5  
Age, years 35 ± 8 31 ± 8 35 ± 9 0.024 
Body composition   
Height, m 1.68 ± 0.06 1.67 ± 0.07 1.67 ± 0.06 0.558 
Weight, kg  86 ± 21 75 ± 20 62 ± 6 0.023 
BMI, kg/m2  30 ± 7 27 ± 7 22 ± 2 0.033 
Body fat, %  39 ± 10 35 ± 10 23 ± 8 0.002 
Fat Mass, kg 35 ± 15 28 ± 15 14 ± 6 0.011 
Waist, cm  98 ± 17 89 ± 17 77 ± 7 0.022 
WHR  0.84 ± 0.06 0.81 ± 0.07 0.80 ± 0.04 0.205 
VAT, cm2  117 ± 66 100 ± 63 86 ± 35 0.472 
SAT, cm2  367 ± 196 318 ± 207 175 ± 70 0.152 
Serum lipids     
TAG, mmol/L 0.80 (0.60-1.40) 0.90 (0.60-1.20) 0.80 (0.60-0.90) 0.426 
T-C, mmol/L 4.70 (4.00-5.20) 4.70 (4.10-5.30) 3.90 (3.80-5.10) 0.276 
HDL-C, mmol/L  1.60 (1.30-1.90) 1.60 (1.40-1.90) 1.50 (1.40-2.10) 0.789 
LDL-C, mmol/L  2.50 (2.10-3.40) 2.60 (2.10-3.20) 2.00 (2.00-2.70) 0.388 
TC;HDL-C ratio 3.00 (2.32-3.75) 2.81 (2.40-3.56) 2.52 (2.50-2.60) 0.361 
Body composition: Summarised as mean ± SD. Serum lipids and dietary intake: Summarised as 
median (interquartile range). Other than age, all p-values are from age-adjusted linear models of 
outcomes. A significant group*ethnicity interaction for a characteristic means that the groups means 
are different between the black and white women. Abbreviations: AA, arachidonic acid; ALA,  
α-linolenic acid; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid, 
HDL-C, high-density lipoprotein cholesterol; LA, linoleic acid; LDL-C, low-density lipoprotein 
cholesterol; MUFA, mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; 
(n-6) PUFA, (n-6) polyunsaturated fatty acids; (n-3) PUFA, (n-3) polyunsaturated fatty acid; (n-6):(n-3) 
PUFA ratio, (n-6):(n-3) polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; 
SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; TAG, triacylglycerol; T-C, total 
cholesterol; T-C:HDL-C ratio, total cholesterol:HDL-cholesterol ratio; TNFA, tumour necrosis factor-α 





Table 2S III. continued 
     
  Under-reporters Adequate reporters Over-reporters P value 
Dietary intake     
Fat (%E) 27 (25-30) 31 (26-34) 29 (26-32) 0.053 
SFA (%E) 9.6 (8.8-10.6) 11.2 (8.7-12.2) 7.9 (7.8-13.0) 0.137 
MUFA (%E) 9.5 (8.3-11.3) 10.4 (8.7-12.2) 10.2 (9.3-10.5) 0.155 
PUFA (%E) 6.0 (4.5-6.9) 6.1 (4.9-8.0) 5.3 (5.2-8.2) 0.208 
P:S ratio 0.59 (0.48-0.70) 0.57 (0.46-0.78) 0.67 (0.63-0.70) 0.785 
(n-3) PUFA (%E) 0.34 (0.28-0.42) 0.32 (0.27-0.39) 0.26 (0.25-0.35) 0.529 
(n-6) PUFA (%E) 4.8 (4.1-6.3) 5.6 (4.4-7.6) 5.0 (4.5-7.8) 0.130 
(n-6):(n-3) PUFA 
ratio 14.9 (11.9-20.2) 16.1 (12.4-25.0) 20.2 (18.9-20.9) 0.205 
ALA (%E) 0.26 (0.22-0.28) 0.25 (0.21-0.30) 0.20 (0.19-0.24) 0.402 
LA (%E) 4.7 (4.1-6.2) 5.6 (4.4-7.6) 5.0 (4.5-7.8) 0.125 
AA (%E)  0.04 (0.03-0.05) 0.03 (0.02-0.04) 0.02 (0.02-0.03) 0.301 
EPA (%E) 0.01 (0.01-0.03) 0.01 (0.01-0.02) 0.02 (0.01-0.03) 0.864 
DHA (%E) 0.05 (0.04-0.10) 0.05 (0.03-0.07) 0.05 (0.05-0.05) 0.683 
Body composition: Summarised as mean ± SD. Serum lipids and dietary intake: Summarised as 
median (interquartile range). Other than age, all p-values are from age-adjusted linear models of 
outcomes. A significant group*ethnicity interaction for a characteristic means that the groups means 
are different between the black and white women. Abbreviations: AA, arachidonic acid; ALA,  
α-linolenic acid; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid, 
HDL-C, high-density lipoprotein cholesterol; LA, linoleic acid; LDL-C, low-density lipoprotein 
cholesterol; MUFA, mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; 
(n-6) PUFA, (n-6) polyunsaturated fatty acids; (n-3) PUFA, (n-3) polyunsaturated fatty acid; (n-6):(n-3) 
PUFA ratio, (n-6):(n-3) polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; 
SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; TAG, triacylglycerol; T-C, total 
cholesterol; T-C:HDL-C ratio, total cholesterol:HDL-cholesterol ratio; TNFA, tumour necrosis factor-α 







9.2. Polymorphisms of the human IL-6 gene 
 
Table 2S IV. Single nucleotide polymorphisms (SNPs) within the 5’- and 3’-
untranslated region (UTR), exon and introns of the human IL-6 gene tabulating the 
rare allele and the reported minor allele frequencies (MAF) within the black and white 
populations (pop). The presence (restriction fragment length polymorphisms, RFLPs) 
or absence (none) of restriction endonuclease sites that encompass the SNP of 
potentially informative markers is also indicated. SNPs selected for this thesis are 
indicated in bold. 
 




SNP Rare Allele Black Pop MAF White Pop MAF RFLP 
5'-UTR 1 rs2069857 A>C A 0.0 2.2  
5'-UTR 2 rs3087226 C>T G    
Exon 2 1 rs2069830 C>T T 9.2 0.0  
Intron 2 1 rs2069831 C>T T 2.1 0.0  
Intron 2 2 rs2069858 A>G A 0.0 4.8  
Intron 2 3 rs2069832 A>G A 2.1 52.5  
Intron 2 4 rs2069833 C>T C 2.2 50.0  
Intron 2 5 rs2069834 C>T T 3.3 0.0  
Intron 2 6 rs2069835 C>T C 10.8 10.0  
Intron 2 7 rs3087230 A>G G    
Intron 2 8 rs1474348 C>G G 2.1 54.3  
Intron 2 9 rs2069836 G>T T 2.3 0.0  
Intron 2 10 rs2069837 A>G G 13.4 6.7  
Intron 2 11 rs1474347 G>T G 8.7 50.0  
Intron 2 12 rs3087231 C>T T    
Intron 2 13 rs3087232 C>T T    
Intron 2 14 rs1524107 C>T T 8.3 4.2  
Intron 2 15 rs3087233 G>T T    
Intron 2 16 rs2066992 G>T T 8.7 4.2  
Intron 3 1 rs2069838 C>T     
Intron 3 2 rs2069839 A>G     
Intron 3 3 rs2069840 C>G G 17.4 37.5 None 
Intron 3 4 rs1554606 G>T T 41.3 56.5 DdeI 
Intron 3 5 rs2069841 A>G     
Intron 3 6 rs13306433 A>G     
Intron 4 1 rs2069842 A>G     
Intron 4 2 rs1548216 C>G     
Intron 4 3 rs2069843 A>G     
Intron 4 4 rs2069844 A>C     
Intron 4 5 rs2069845 A>G G 38.6 54.8 MspI 
Intron 4 6 rs2069859 C>T     
Intron 4 7 rs2069846 A>G     
Intron 4 8 rs2069847 A>G     
Intron 4 9 rs2069848 A>T     
Exon 5 1 rs2069860 T>A     
Exon 5 2 rs13306435 A>T     
Exon 5 3 rs2069849 C>T T 20.8 6.5  
3'-UTR 1 rs2069850 C>T     
3'-UTR 2 rs13306436 A>G     





9.3. Statistical analysis:  an example 
 
The following provides an example from Chapter 4; assessing the interaction 
between a diet variable and a genetic factor on a quantitative trait, followed by a 
discussion of the steps in general. 
 
In nutrition, as in many other disciplines, it is becoming clear that many factors do 
not affect outcome in a linear way, but rather modify the effect of each other.  Testing 
for interactions between dietary intake and a genetic factor, such as genotypes on an 
outcome such as body composition (e.g. BMI, body fat percentage) or serum lipids 
(e.g. T-C, HDL-C) is often necessary.  
 
In this example, we assess the interaction between a genotype (TNFA -238 G>A) 
and dietary intake (n-3 PUFA) on the T-C:HDL-C ratio in a convenience sample of 
129 black SA women. The group was selected to include both normal-weight and 
obese women. The T-C:HDL-C ratio is significantly associated with both age (years) 
and fat mass (kilograms), and is therefore adjusted for these in our model.   
  
Preparing the data for analysis 
 
The n-3 PUFA values were converted to a percentage of total energy intake (% E), 
to make the effect sizes comparable.  Because there were positive outliers, the n-3 
PUFA intakes were log-transformed towards symmetry, to avoid spurious 




The distribution of the outcome, T-C:HDL-C ratio  is skewed to the right, so it was 
also log-transformed towards symmetry. There was a single minor TNFA -238 
homozygote (AA), which was grouped with the heterozygotes (GA), hence assuming 
a dominant model. The TNFA -238 G>A genotype is therefore a factor with only two 
levels, the wild type homozygote, GG, and women bearing at least one A allele, 




We use a general linear model to write log(T-C:HDL-C ratio) as a linear function of 
age and fat mass and the interaction between the TNFA -238 G>A SNP and log(n-3 
PUFA). The interaction term means that T-C:HDL-C ratio is written as a different 
function of n-3 PUFA for the TNFA -238 wild type (GG) as for other TNFA -238 A 
allele carriers. It also means that the effect of TNFA -238 G>A SNP on T-C:HDL-C 
ratio depends on n-3 PUFAs.   
 
Table 2S V. The analysis of variance for the linear model for TNFA -238 G>A  
Response: log(T-C:HDL-C ratio) 
   
 
Df Sum Sq Mean Sq F value Pr(>F) 
Age 1 0.80 0.80 10.6 0.001 
Fat mass 1 0.89 0.89 11.8 0.001 
TNFA -238 G>A 1 0.00 0.00 0.0 0.859 
log(n-3 PUFA) 1 0.24 0.24 3.2 0.077 
TNFA -238 G>A:log(n-3 PUFA) 1 0.49 0.49 6.4 0.012 
Residuals 123 9.27 0.08 
  
 
The last term in the table, is the interaction term, with the colon indicating statistical 
interaction (TNFA -238 G>A:log(n-3 PUFA)). Main effects are, and should be, 
automatically included in the model. The sums of squares were calculated 
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successively, the sum of squares for fat mass, after removal of age, the sum of 
squares for TNFA -238 G>A, after removal of the sums of squares for both age and 
fat mass. That means that each F-test is covaried for those preceding it (those 
higher up in the table). For the interaction term, the blend of effect size and 
precision, the p-value, is below 5%, a signal to explore further. This means that there 
is a statistical interaction between the TNFA -238 G>A SNP and n-3 PUFA, over and 
above the main effects, and that the regression lines of T-C:HDL-C ratio on n-3 
PUFA, have different slopes for the different genotypes. A different but equivalent 
interpretation is that the genotype effect on T-C:HDL-C ratio depends on n-3 PUFA 
intake. 
 
Table 2S VI. Summary table for interaction between TNFA -238 G>A SNP and n-3 
PUFAs on T-C:HDL-C ratio 
 
Effect size SE t value P-value 
(Intercept) 1.098 0.150 7.3 < 0.001 
Age 0.007 0.004 1.8 0.075 
Fat mass 0.006 0.002 3.1 0.003 
TNFA -238 AG+AA -0.373 0.150 -2.5 0.014 
log(n-3 PUFA) 0.285 0.093 3.1 0.003 
TNFA -238 AG+AA:log(n-3 PUFA) -0.315 0.124 -2.5 0.012 
 
Residual standard error: 0.2746 on 123 degrees of freedom 
Multiple R-squared: 0.2067, Adjusted R-squared: 0.1745  
F-statistic: 6.411 on 5 and 123 DF, p-value: 0.0001 
 
Multiple R-squared means that over 20% of the variation in T-C:HDL-C ratio can be 
explained by the factors in the linear model. All the statistics for factors listed in this 
table are adjusted for all the other factors in the model.  Those that are statistically 
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significant are said to be independently significant, meaning that they remain 
significant after adjusting for confounders. Note that only the p-values in the last line 
of the ANOVA and summary (coefficient) tables are the same. The others are not, 
because of the way they are calculated. 
 
The standard errors of the estimates, in the second column, are the indication of the 
precision of the estimate. The smaller the standard error, the more precise is the 
estimate. The t-value is a statistic that simultaneously tests whether the estimate is 
significantly large and significantly precise. The t-values and their corresponding  
p-values blend those two tests.  
 
The effect estimates in the table    
 
If you want to estimate the outcome (log (T-C:HDL-C ratio))  for a specific woman, 
start with the intercept 1.098 then add 0.007 for every year of age, in other words 
multiply her age with 0.007 and add that to the intercept. The effect of one year of 
age is to add 0.007 to the outcome. Similarly, each kilogram of fat mass adds 0.006 
to the outcome. Next is genotype, with only two possible values: GG (wild type) and 
GA+AA and women with GA and AA subtract 0.373 from their outcome. Each unit of 
log(n-3 PUFA) adds 0.285 to her estimated outcome (in other words multiply  
log(n-PUFA) with 0.285). If there was no interaction between the last two factors, 
that would be the end of the linear model.  But for women with GA+AA genotype, we 




For a specific example: woman aged 30 years, fat mass 40 kg, TNFA -238 genotype 
GG.  Her outcome will be: 
 1.098 + 30 x 0.007 + 40 x 0.006 + 0.285 x log(n-3 PUFA), 
 which is 1.548 + 0.285 x log(n-3 PUFA), because the terms with TNFA -238 GA and 
AA genotype do not apply to her. 
 
As n-3 PUFA is her dietary consumption of n-3 PUFA, we can calculate an outcome 
for each possible value of log(n-3 PUFA). This can be plotted on a graph (figure 2.1). 
In our data, n-3 PUFA ranged from 0.13 to 0.81. This means log(n-3 PUFA) ranged 
from -2.04 to -0.12. And our corresponding values of outcomes from 1.548 – 0.285 * 
2.04 to 1.548 – 0.285 * 0.12. This is represented by the solid line on the plot. 
 
If her TNFA -238 genotype was not GG, but GA or AA, then the model explaining her 
outcome has to change in two ways. Subtract 0.373 (main effect) from the intercept 
and subtract -0.315 multiplied with) log(n-3 PUFA). The GA model then becomes: 
1.548 – 0.373 + (0.285-0.315) x log(n-3 PUFA) which is 1.175 – 0.030 x log (n-3 





Figure 2S 2. Modelled relationship between TNFA -238 G>A and log(n-3 PUFA) on log(T-C:HDL-C 
ratio). Points are observed values (logs in A, original in B). Lines are A: linear model in log(T-C:HDL-C 
ratio) and log(n-3 PUFA), and B: back transformed to original scale. Abbreviations: n-3 PUFA, omega-
3 polyunsaturated fatty acid; TNFA, tumour necrosis factor alpha gene; T-C:HDL-C ratio, total 
cholesterol: high-density lipoprotein cholesterol ratio. 
 
The graph for older women will simply move 0.007 up for every year that she is older 
than 30 or down for younger.  But the modelled relationship between TNFA -238 
G>A and n-3 PUFA and T-C:HDL-C ratio relative to one another remains the same. 
If you have the wild type genotype (GG), your log(T-C:HDL-C ratio) increases 
significantly with increasing log(n-3 PUFA), while if you have the GG+AA genotype, 
your n-3 PUFA intake does not make much difference. The significant interaction is 
the significant difference between the GG genotype slope and the AG+AA genotype 
slope. Generally, the significant interaction does not necessarily mean that either of 
the individual slopes are significantly different from zero. 
 
It is preferable to report effect sizes in terms of the original measurements, where 
possible transforming our model back to the original units, by taking the antilogs 














































(exp). Figure 2S 2B. illustrates that if a woman with the TNFA -238 GG genotype 
consumes a larger percentage of n-3 PUFA, her T-C:HDL-C ratio will increase 
significantly, but the increase is logarithmically, becoming smaller as intake 
increases. For the women with the GA+AA genotype, we see a small, not-significant 
decrease in T-C:HDL-C ratio with increasing n-3 PUFA intake. Figure 2S 2. includes 






9.4. Chapter three supplementary tables 
 
Supplementary Table 3S I. P-values for black and white women combined, testing 
association with BMI group, ethnic group and TNFA -308 G>A genotype on body 
composition and serum lipids, each adjusted for age and the factors listed before it. 





Body composition      
Height (m) < 0.001 < 0.001 0.815 
Weight (kg)  < 0.001 0.002 0.710 
BMI (kg/m2) < 0.001 0.001 0.605 
Body fat (%)  < 0.001 0.016 0.271 
Fat Mass (kg) < 0.001 0.205 0.850 
Waist (cm) < 0.001 0.036 0.889 
WHR < 0.001 0.012 0.853 
VAT < 0.001 < 0.001 0.914 
SAT < 0.001 0.011 0.864 
Serum lipids     
TAG (mmol/L) < 0.001 < 0.001 0.841 
T-C (mmol/L) 0.917 < 0.001 0.749 
HDL-C (mmol/L)  < 0.001 < 0.001 0.848 
LDL-C (mmol/L)  0.003 < 0.001 0.575 
TC:HDL-C ratio < 0.001 0.516 0.616 
Abbreviations: BMI, body mass index, HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; SAT, subcutaneous adipose tissue; TAG, triacylglycerol; TNFA, tumour 
necrosis factor-α gene; T-C, total cholesterol; T-C:HDL-C ratio, total cholesterol:HDL-cholesterol ratio; 
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Supplementary Table 6S VI (A,B).  P-values for interaction between dietary fat 
intake (%E) and IL-6 polymorphisms (genotype) on body composition in 266 white 
and black adequate reporter women, adjusted for age and ethnicity. 
 
Table 6S VI A. 




%  Fat Mass 
Waist, 
cm  WHR  VAT, cm
2  SAT, cm2  
 IL-6 IVS3+281 G>T n=257 
Fat, % E 0.150 0.085 0.383 0.093 0.078 0.169 0.124 0.124 
SFA, % E 0.736 0.578 0.515 0.630 0.622 0.554 0.409 0.699 
MUFA, % E 0.448 0.188 0.889 0.308 0.300 0.146 0.065 0.270 
PUFA, % E 0.416 0.359 0.557 0.354 0.289 0.130 0.780 0.268 
P:S ratio 0.770 0.809 0.604 0.718 0.672 0.383 0.976 0.586 
n-3 PUFA. % E 0.433 0.222 0.692 0.299 0.384 0.595 0.212 0.420 
n-6 PUFA, % E 0.459 0.444 0.559 0.411 0.349 0.120 0.773 0.336 
n-6:n-3 PUFA ratio 0.378 0.376 0.421 0.276 0.434 0.649 0.457 0.154 
ALA, % E 0.645 0.465 0.707 0.392 0.567 0.659 0.244 0.827 
LA, % E 0.475 0.463 0.563 0.430 0.361 0.126 0.781 0.351 
AA, % E  0.385 0.352 0.896 0.366 0.551 0.922 0.735 0.942 
EPA, %E 0.304 0.182 0.377 0.219 0.374 0.614 0.144 0.480 
DHA, %E 0.340 0.211 0.451 0.218 0.375 0.641 0.094 0.476 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid, IL-6, Interleukin-6 gene; LA, linoleic acid; MUFA, 
mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-
6 polyunsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, 
omega-6:omega-3 polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; 
SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; WHR, 












%  Fat Mass 
Waist, 
cm  WHR  VAT, cm
2  SAT, cm2  
 IL-6 IVS4+869 A>G n=251 
Fat, % E 0.009 0.029 0.179 0.011 0.018 0.861 0.069 0.042 
SFA, % E 0.014 0.009 0.378 0.015 0.049 0.759 0.050 0.255 
MUFA, % E 0.057 0.113 0.747 0.096 0.260 0.510 0.121 0.131 
PUFA, % E 0.157 0.272 0.310 0.187 0.275 0.559 0.380 0.135 
P:S ratio 0.461 0.523 0.559 0.514 0.747 0.613 0.899 0.450 
n-3 PUFA. % E 0.645 0.678 0.606 0.393 0.620 0.106 0.010 0.139 
n-6 PUFA, % E 0.201 0.350 0.288 0.203 0.376 0.423 0.420 0.194 
n-6:n-3 PUFA ratio 0.096 0.167 0.053 0.035 0.171 0.444 0.041 0.030 
ALA, % E 0.774 0.776 0.845 0.722 0.894 0.296 0.049 0.420 
LA, % E 0.209 0.364 0.289 0.211 0.385 0.444 0.431 0.201 
AA, % E  0.208 0.184 0.688 0.306 0.472 0.415 0.795 0.708 
EPA, %E 0.807 0.688 0.694 0.483 0.893 0.137 0.073 0.502 
DHA, %E 0.656 0.561 0.707 0.374 0.941 0.198 0.133 0.578 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid, IL-6, Interleukin-6 gene; LA, linoleic acid; MUFA, 
mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA,  
omega-6 polyunsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA 
ratio, omega-6:omega-3 polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat 
ratio; SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; 






Supplementary Table 6S VII (A,B).  P-values for interaction between dietary fat 
intake (%E) and IL-6 polymorphisms (genotype) on serum lipids in 266 white and 
black adequate reporter women, adjusted for age, fat mass, and ethnicity. 
 
Table 6S VII A. 
 





 IL-6 IVS3+281 G>T n=257 
Fat, % E 0.565 0.522 0.276 0.057 0.038 
SFA, % E 0.526 0.190 0.322 0.263 0.583 
MUFA, % E 0.268 0.596 0.328 0.327 0.100 
PUFA, % E 0.271 0.158 0.286 0.021 0.133 
P:S ratio 0.738 0.059 0.435 0.041 0.475 
n-3 PUFA. % E 0.589 0.230 0.332 0.134 0.014 
n-6 PUFA, % E 0.306 0.162 0.250 0.026 0.103 
n-6:n-3 PUFA ratio 0.496 0.056 0.704 0.006 0.055 
ALA, % E 0.518 0.386 0.278 0.111 0.027 
LA, % E 0.296 0.155 0.244 0.026 0.102 
AA, % E  0.906 0.855 0.285 0.988 0.735 
EPA, %E 0.492 0.309 0.718 0.336 0.110 
DHA, %E 0.329 0.251 0.902 0.202 0.129 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid, HDL-C, high-density lipoprotein cholesterol; IL-6, Interleukin-6 gene; LA, 
linoleic acid; LDL-C, low-density lipoprotein cholesterol; MUFA, mono-unsaturated fat; percentage 
energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acids; n-3 
PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, omega-6:omega-3 polyunsaturated 
fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; SFA, saturated fatty acid; TAG, 






Table 6S VII B. 
 





 IL-6 IVS4+869 A>G n=251 
Fat, % E 0.527 0.212 0.242 0.037 0.013 
SFA, % E 0.669 0.644 0.987 0.596 0.596 
MUFA, % E 0.989 0.444 0.407 0.139 0.041 
PUFA, % E 0.097 0.195 0.133 0.029 0.017 
P:S ratio 0.219 0.360 0.278 0.132 0.089 
n-3 PUFA. % E 0.953 0.706 0.733 0.881 0.722 
n-6 PUFA, % E 0.078 0.214 0.119 0.039 0.017 
n-6:n-3 PUFA ratio 0.311 0.278 0.473 0.076 0.148 
ALA, % E 0.963 0.746 0.620 0.936 0.790 
LA, % E 0.077 0.214 0.114 0.039 0.017 
AA, % E  0.477 0.998 0.284 0.733 0.238 
EPA, %E 0.837 0.883 0.763 0.726 0.474 
DHA, %E 0.865 0.865 0.742 0.883 0.814 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid, HDL-C, high-density lipoprotein cholesterol; IL-6, Interleukin-6 gene; LA, 
linoleic acid; LDL-C, low-density lipoprotein cholesterol; MUFA, mono-unsaturated fat; percentage 
energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acids; n-3 
PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, omega-6:omega-3 polyunsaturated 
fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; SFA, saturated fatty acid; TAG, 






Supplementary Table 6S VIII (A,B).  P-values for interaction between dietary fat 
intake (%E) and IL-6 polymorphisms (allelic) on body composition in 266 white and 
black adequate reporter women, adjusted for age and ethnicity. 
 







%  Fat Mass 
Waist, 
cm  WHR  VAT, cm
2  SAT, cm2  
 IL-6 IVS3+281 G>T n=257 
Fat, % E 0.487 0.266 0.670 0.454 0.466 0.209 0.315 0.523 
SFA, % E 0.763 0.692 0.279 0.746 0.854 0.933 0.520 0.640 
MUFA, % E 0.477 0.222 0.851 0.350 0.313 0.064 0.198 0.265 
PUFA, % E 0.579 0.428 0.958 0.576 0.368 0.070 0.620 0.825 
P:S ratio 0.958 0.864 0.762 0.939 0.635 0.208 0.923 0.763 
n-3 PUFA. % E 0.229 0.098 0.549 0.147 0.211 0.382 0.217 0.350 
n-6 PUFA, % E 0.678 0.530 0.886 0.731 0.403 0.061 0.598 0.893 
n-6:n-3 PUFA ratio 0.480 0.355 0.312 0.265 0.616 0.548 0.633 0.507 
ALA, % E 0.637 0.463 0.974 0.578 0.430 0.396 0.103 0.516 
LA, % E 0.678 0.535 0.890 0.746 0.410 0.067 0.595 0.880 
AA, % E  0.263 0.234 0.781 0.247 0.502 0.996 0.940 0.798 
EPA, %E 0.191 0.084 0.248 0.108 0.278 0.481 0.473 0.531 
DHA, %E 0.210 0.098 0.315 0.111 0.284 0.497 0.923 0.724 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid, IL-6, Interleukin-6 gene; LA, linoleic acid; MUFA, 
mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA,  
omega-6 polyunsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA 
ratio, omega-6:omega-3 polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat 
ratio; SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; 













%  Fat Mass 
Waist, 
cm  WHR  VAT, cm
2  SAT, cm2  
 IL-6 IVS4+869 A>G n=251 
Fat, % E 0.443 0.896 0.204 0.571 0.503 0.634 0.734 0.459 
SFA, % E 0.715 0.935 0.123 0.632 0.362 0.380 0.185 0.537 
MUFA, % E 0.685 0.860 0.394 0.766 0.729 0.419 0.890 0.969 
PUFA, % E 0.428 0.660 0.378 0.534 0.773 0.173 0.899 0.491 
P:S ratio 0.373 0.417 0.607 0.422 0.760 0.217 0.629 0.557 
n-3 PUFA. % E 0.548 0.560 0.735 0.312 0.907 0.551 0.287 0.437 
n-6 PUFA, % E 0.432 0.663 0.331 0.467 0.846 0.114 0.700 0.535 
n-6:n-3 PUFA ratio 0.241 0.336 0.133 0.123 0.659 0.172 0.804 0.322 
ALA, % E 0.863 0.992 0.829 0.792 0.922 0.566 0.164 0.568 
LA, % E 0.432 0.659 0.338 0.461 0.837 0.120 0.697 0.544 
AA, % E  0.917 0.916 0.507 0.805 0.629 0.305 0.602 0.657 
EPA, %E 0.540 0.403 0.504 0.242 0.958 0.663 0.488 0.850 
DHA, %E 0.440 0.329 0.485 0.178 0.831 0.574 0.728 0.833 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid, IL-6, Interleukin-6 gene; LA, linoleic acid; MUFA, 
mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA,  
omega-6 polyunsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA 
ratio, omega-6:omega-3 polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat 
ratio; SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; 





Supplementary Table 6S IX (A,B).  P-values for interaction between dietary fat 
intake (%E) and IL-6 polymorphisms (allelic) on serum lipids in 266 white and black 
adequate reporter women, adjusted for age, fat mass and ethnicity. 
 
Table 6S IX A. 
 





 IL-6 IVS3+281 G>T n=257 
Fat, % E 0.998 0.939 0.444 0.698 0.245 
SFA, % E 0.973 0.086 0.490 0.108 0.584 
MUFA, % E 0.229 0.326 0.370 0.208 0.087 
PUFA, % E 0.474 0.203 0.291 0.391 0.622 
P:S ratio 0.763 0.095 0.175 0.215 0.700 
n-3 PUFA. % E 0.290 0.491 0.106 0.157 0.004 
n-6 PUFA, % E 0.456 0.208 0.228 0.451 0.505 
n-6:n-3 PUFA ratio 0.357 0.169 0.901 0.129 0.155 
ALA, % E 0.572 0.225 0.130 0.037 0.008 
LA, % E 0.454 0.195 0.212 0.439 0.489 
AA, % E  0.965 0.915 0.544 0.912 0.856 
EPA, %E 0.175 0.582 0.406 0.437 0.037 
DHA, %E 0.154 0.438 0.607 0.385 0.068 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid, HDL-C, high-density lipoprotein cholesterol; IL-6, Interleukin-6 gene; LA, 
linoleic acid; LDL-C, low-density lipoprotein cholesterol; MUFA, mono-unsaturated fat; percentage 
energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acids; n-3 
PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, omega-6:omega-3 polyunsaturated 
fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; SFA, saturated fatty acid; TAG, 





Table 6S IX B. 
 





 IL-6 IVS4+869 A>G n=251 
Fat, % E 0.290 0.464 0.624 0.736 0.647 
SFA, % E 0.593 0.548 0.840 0.457 0.280 
MUFA, % E 0.825 0.962 0.377 0.615 0.222 
PUFA, % E 0.023 0.211 0.614 0.500 0.799 
P:S ratio 0.053 0.230 0.738 0.415 0.497 
n-3 PUFA. % E 0.812 0.775 0.569 0.982 0.341 
n-6 PUFA, % E 0.018 0.203 0.500 0.550 0.966 
n-6:n-3 PUFA ratio 0.082 0.364 0.848 0.536 0.459 
ALA, % E 0.608 0.736 0.300 0.903 0.293 
LA, % E 0.018 0.204 0.477 0.565 0.998 
AA, % E  0.239 0.981 0.423 0.906 0.497 
EPA, %E 0.652 0.598 0.855 0.491 0.444 
DHA, %E 0.683 0.552 0.517 0.578 0.759 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid, HDL-C, high-density lipoprotein cholesterol; IL-6, Interleukin-6 gene; LA, 
linoleic acid; LDL-C, low-density lipoprotein cholesterol; MUFA, mono-unsaturated fat; percentage 
energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acids; n-3 
PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, omega-6:omega-3 polyunsaturated 
fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; SFA, saturated fatty acid; TAG, 




Supplementary Table 6S X (A,B).  P-values for 3-way interaction between ethnic 
group, dietary fat intake (%E) and IL-6 polymorphisms (genotype) on body 
composition in 266 white and black adequate reporter women, adjusted for age.  
 







%  Fat Mass 
Waist, 
cm  WHR  VAT, cm
2  SAT, cm2  
 IL-6 IVS3+281 G>T n=257 
Fat, % E 0.171 0.114 0.512 0.118 0.259 0.957 0.962 0.429 
SFA, % E 0.112 0.045 0.424 0.054 0.241 0.856 0.605 0.872 
MUFA, % E 0.144 0.162 0.815 0.154 0.418 0.980 0.536 0.504 
PUFA, % E 0.057 0.024 0.725 0.075 0.077 0.975 0.566 0.228 
P:S ratio 0.267 0.231 0.758 0.400 0.249 0.990 0.570 0.348 
n-3 PUFA. % E 0.692 0.622 0.348 0.588 0.455 0.156 0.063 0.134 
n-6 PUFA, % E 0.065 0.027 0.680 0.082 0.085 0.961 0.512 0.376 
n-6:n-3 PUFA ratio 0.055 0.023 0.500 0.081 0.015 0.224 0.077 0.151 
ALA, % E 0.384 0.313 0.604 0.410 0.306 0.141 0.022 0.052 
LA, % E 0.069 0.029 0.679 0.086 0.089 0.963 0.518 0.387 
AA, % E  0.010 0.005 0.045 0.016 0.054 0.692 0.668 0.576 
EPA, %E 0.643 0.645 0.087 0.339 0.639 0.515 0.445 0.484 
DHA, %E 0.554 0.507 0.282 0.400 0.570 0.510 0.619 0.617 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid, IL-6, Interleukin-6 gene; LA, linoleic acid; MUFA, 
mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-
6 polyunsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, 
omega-6:omega-3 polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; 
SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; WHR, 











%  Fat Mass 
Waist, 
cm  WHR  VAT, cm
2  SAT, cm2  
 IL-6 IVS4+869 A>G n=251 
Fat, % E 0.761 0.518 0.476 0.718 0.591 0.358 0.683 0.137 
SFA, % E 0.834 0.479 0.352 0.588 0.725 0.583 0.946 0.374 
MUFA, % E 0.706 0.359 0.488 0.665 0.404 0.157 0.534 0.105 
PUFA, % E 0.915 0.865 0.889 0.923 0.887 0.605 0.523 0.389 
P:S ratio 0.477 0.884 0.886 0.671 0.409 0.497 0.639 0.614 
n-3 PUFA. % E 0.231 0.204 0.099 0.062 0.275 0.368 0.179 0.231 
n-6 PUFA, % E 0.833 0.867 0.869 0.880 0.872 0.582 0.529 0.590 
n-6:n-3 PUFA ratio 0.974 0.827 0.635 0.588 0.972 0.807 0.280 0.992 
ALA, % E 0.027 0.027 0.046 0.010 0.093 0.223 0.007 0.011 
LA, % E 0.850 0.847 0.856 0.863 0.885 0.571 0.520 0.609 
AA, % E  0.134 0.101 0.167 0.183 0.080 0.494 0.963 0.601 
EPA, %E 0.626 0.452 0.127 0.175 0.522 0.916 0.905 0.865 
DHA, %E 0.635 0.472 0.414 0.356 0.568 0.909 0.862 0.819 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid, IL-6, Interleukin-6 gene; LA, linoleic acid; MUFA, 
mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA,  
omega-6 polyunsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA 
ratio, omega-6:omega-3 polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat 
ratio; SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; 




Supplementary Table 6S XI (A,B).  P-values for 3-way interaction between ethnic 
group, dietary fat intake (%E) and IL-6 polymorphisms (genotype) on serum lipids in 
266 white and black adequate reporter women, adjusted for age and fat mass.  
 
Table 6S XI A. 
 





 IL-6 IVS3+281 G>T n=257 
Fat, % E 0.512 0.259 0.957 0.962 0.429 
SFA, % E 0.424 0.241 0.856 0.605 0.872 
MUFA, % E 0.815 0.418 0.980 0.536 0.504 
PUFA, % E 0.725 0.077 0.975 0.566 0.228 
P:S ratio 0.758 0.249 0.990 0.570 0.348 
n-3 PUFA. % E 0.348 0.455 0.156 0.063 0.134 
n-6 PUFA, % E 0.680 0.085 0.961 0.512 0.376 
n-6:n-3 PUFA ratio 0.500 0.015 0.224 0.077 0.151 
ALA, % E 0.604 0.306 0.141 0.022 0.052 
LA, % E 0.679 0.089 0.963 0.518 0.387 
AA, % E  0.045 0.054 0.692 0.668 0.576 
EPA, %E 0.087 0.639 0.515 0.445 0.484 
DHA, %E 0.282 0.570 0.510 0.619 0.617 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid, HDL-C, high-density lipoprotein cholesterol; IL-6, Interleukin-6 gene; LA, 
linoleic acid; LDL-C, low-density lipoprotein cholesterol; MUFA, mono-unsaturated fat; percentage 
energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acids; n-3 
PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, omega-6:omega-3 polyunsaturated 
fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; SFA, saturated fatty acid; TAG, 





Table 6S XI B. 
 





 IL-6 IVS4+869 A>G n=251 
Fat, % E 0.476 0.591 0.358 0.683 0.137 
SFA, % E 0.352 0.725 0.583 0.946 0.374 
MUFA, % E 0.488 0.404 0.157 0.534 0.105 
PUFA, % E 0.889 0.887 0.605 0.523 0.389 
P:S ratio 0.886 0.409 0.497 0.639 0.614 
n-3 PUFA. % E 0.099 0.275 0.368 0.179 0.231 
n-6 PUFA, % E 0.869 0.872 0.582 0.529 0.590 
n-6:n-3 PUFA ratio 0.635 0.972 0.807 0.280 0.992 
ALA, % E 0.046 0.093 0.223 0.007 0.011 
LA, % E 0.856 0.885 0.571 0.520 0.609 
AA, % E  0.167 0.080 0.494 0.963 0.601 
EPA, %E 0.127 0.522 0.916 0.905 0.865 
DHA, %E 0.414 0.568 0.909 0.862 0.819 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid, HDL-C, high-density lipoprotein cholesterol; IL-6, Interleukin-6 gene; LA, 
linoleic acid; LDL-C, low-density lipoprotein cholesterol; MUFA, mono-unsaturated fat; percentage 
energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acids; n-3 
PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, omega-6:omega-3 polyunsaturated 
fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; SFA, saturated fatty acid; TAG, 





Supplementary Table 6S XII (A,B).  P-values for 3-way interaction between ethnic 
group, dietary fat intake (%E) and IL-6 polymorphisms (allelic) on body composition 
in 266 white and black adequate reporter women, adjusted for age.  
 
Table 6S XII A. 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid, IL-6, Interleukin-6 gene; LA, linoleic acid; MUFA, 
mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA,  
omega-6 polyunsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA 
ratio, omega-6:omega-3 polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat 
ratio; SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; 









%  Fat Mass 
Waist, 
cm  WHR  VAT, cm
2  SAT, cm2  
 IL-6 IVS3+281 G>T n=257 
Fat, % E 0.749 0.609 0.710 0.833 0.735 0.909 0.769 0.434 
SFA, % E 0.717 0.716 0.283 0.835 0.862 0.777 0.912 0.639 
MUFA, % E 0.667 0.688 0.718 0.810 0.923 0.910 0.744 0.696 
PUFA, % E 0.336 0.157 0.402 0.293 0.264 0.718 0.577 0.958 
P:S ratio 0.430 0.259 0.326 0.351 0.393 0.818 0.292 0.608 
n-3 PUFA. % E 0.384 0.327 0.086 0.347 0.196 0.091 0.196 0.179 
n-6 PUFA, % E 0.301 0.128 0.344 0.256 0.223 0.671 0.473 0.794 
n-6:n-3 PUFA  0.151 0.078 0.097 0.124 0.049 0.135 0.056 0.205 
ALA, % E 0.076 0.055 0.080 0.066 0.062 0.086 0.024 0.051 
LA, % E 0.295 0.126 0.340 0.251 0.221 0.677 0.469 0.780 
AA, % E  0.999 0.851 0.146 0.920 0.642 0.346 0.379 0.472 
EPA, %E 0.924 0.916 0.111 0.800 0.604 0.470 0.946 0.509 
DHA, %E 0.950 0.966 0.280 0.945 0.665 0.346 0.933 0.579 
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%  Fat Mass 
Waist, 
cm  WHR  VAT, cm
2  SAT, cm2  
 IL-6 IVS4+869 A>G n=251 
Fat, % E 0.168 0.206 0.636 0.147 0.201 0.922 0.164 0.924 
SFA, % E 0.227 0.338 0.757 0.289 0.344 0.999 0.319 0.935 
MUFA, % E 0.276 0.463 0.895 0.287 0.594 0.383 0.856 0.498 
PUFA, % E 0.251 0.115 0.271 0.163 0.206 0.778 0.207 0.654 
P:S ratio 0.752 0.362 0.448 0.566 0.692 0.890 0.528 0.627 
n-3 PUFA. % E 0.391 0.446 0.188 0.176 0.361 0.210 0.027 0.071 
n-6 PUFA, % E 0.339 0.145 0.297 0.176 0.256 0.827 0.274 0.670 
n-6:n-3 PUFA ratio 0.268 0.199 0.188 0.091 0.216 0.518 0.032 0.183 
ALA, % E 0.069 0.088 0.081 0.036 0.123 0.123 0.002 0.004 
LA, % E 0.332 0.142 0.290 0.173 0.254 0.840 0.273 0.655 
AA, % E  0.874 0.777 0.431 0.742 0.847 0.810 0.911 0.703 
EPA, %E 0.982 0.896 0.245 0.464 0.770 0.772 0.489 0.553 
DHA, %E 0.925 0.821 0.485 0.598 0.718 0.720 0.570 0.551 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DHA, 
docosahexaenoic acid; EPA, eicosapentaenoic acid, IL-6, Interleukin-6 gene; LA, linoleic acid; MUFA, 
mono-unsaturated fat; percentage energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA,  
omega-6 polyunsaturated fatty acids; n-3 PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA 
ratio, omega-6:omega-3 polyunsaturated fatty acids ratio; P:S ratio, polyunsaturated:saturated fat 
ratio; SFA, saturated fatty acid; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; 





Supplementary Table 6S XIII (A,B) P-values for 3-way interaction between ethnic 
group, dietary fat intake (%E) and IL-6 polymorphisms (allelic) on serum lipids in 266 
white and black adequate reporter women, adjusted for age and fat mass.  
 
Table 6S XIII A. 
 





 IL-6 IVS3+281 G>T n=257 
Fat, % E 0.298 0.496 0.816 0.767 0.967 
SFA, % E 0.213 0.641 0.550 0.873 0.472 
MUFA, % E 0.264 0.957 0.628 0.831 0.901 
PUFA, % E 0.891 0.934 0.846 0.918 0.894 
P:S ratio 0.961 0.533 0.395 0.782 0.555 
n-3 PUFA. % E 0.598 0.502 0.961 0.586 0.690 
n-6 PUFA, % E 0.969 0.835 0.767 0.883 0.965 
n-6:n-3 PUFA ratio 0.938 0.773 0.845 0.805 0.982 
ALA, % E 0.795 0.892 0.583 0.812 0.986 
LA, % E 0.979 0.833 0.770 0.877 0.954 
AA, % E  0.969 0.531 0.952 0.449 0.536 
EPA, %E 0.419 0.283 0.360 0.534 0.771 
DHA, %E 0.432 0.131 0.371 0.261 0.583 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid, HDL-C, high-density lipoprotein cholesterol; IL-6, Interleukin-6 gene; LA, 
linoleic acid; LDL-C, low-density lipoprotein cholesterol; MUFA, mono-unsaturated fat; percentage 
energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acids; n-3 
PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, omega-6:omega-3 polyunsaturated 
fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; SFA, saturated fatty acid; TAG, 




Table 6S XIII B. 
 





 IL-6 IVS4+869 A>G n=251 
Fat, % E 0.211 0.800 0.831 0.653 0.974 
SFA, % E 0.072 0.848 0.773 0.430 0.499 
MUFA, % E 0.171 0.762 0.728 0.612 0.976 
PUFA, % E 0.675 0.486 0.452 0.774 0.915 
P:S ratio 0.316 0.444 0.358 0.877 0.780 
n-3 PUFA. % E 0.802 0.763 0.110 0.299 0.080 
n-6 PUFA, % E 0.526 0.417 0.336 0.788 0.940 
n-6:n-3 PUFA ratio 0.980 0.857 0.053 0.441 0.080 
ALA, % E 0.674 0.623 0.509 0.301 0.106 
LA, % E 0.535 0.414 0.330 0.784 0.942 
AA, % E  0.760 0.957 0.691 0.999 0.947 
EPA, %E 0.641 0.334 0.026 0.817 0.252 
DHA, %E 0.408 0.196 0.013 0.556 0.283 
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid, HDL-C, high-density lipoprotein cholesterol; IL-6, Interleukin-6 gene; LA, 
linoleic acid; LDL-C, low-density lipoprotein cholesterol; MUFA, mono-unsaturated fat; percentage 
energy; %E; PUFA, polyunsaturated fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acids; n-3 
PUFA, omega-3 polyunsaturated fatty acid; n-6:n-3 PUFA ratio, omega-6:omega-3 polyunsaturated 
fatty acids ratio; P:S ratio, polyunsaturated:saturated fat ratio; SFA, saturated fatty acid; TAG, 

























Reagents for the isolation of DNA from Whole Blood 
 
TKM1 Buffer (pH 7.6) 
 Final Conc. MW For  500ml For 1000ml 
Tris-HCl 10mM 121.00 0.6056 1.2112 
KCl 10mM 74.56 0.3728 0.7456 
MgCl2.6H2O 10mM 203.20 1.016 2.032 
EDTA 2mM 372.24 0.372 0.744 
dH2O   to 500ml  
• Set the pH with HCl 
• Autoclave 
• Make up 1 volume which includes 2.5% NP40 and 1 volume without 
NP40 
 
TKM2 Buffer (pH 7.6) 
 Final Conc. MW For 200ml 
Tris-HCl 10mM 121.00 0.242 
KCl 10mM 74.56 0.149 
MgCl2.6H2O 10mM 203.20 0.406 
EDTA 2mM 372.24 0.1488 
NaCl   4.675 
dH2O   to 200 ml 




 Final Conc. MW For 200ml 
SDS 10%  20 
dH2O   to 200 ml 
• Autoclave 
 
1X TE buffer (pH 8.0) 
 Final Conc. MW For 100ml 
Tris-HCl 10mM 121.00 0.121 
EDTA 1mM 372.24 0.037 
dH2O   to 100 ml 




 Final Conc. MW For 100ml 
NaClO4 5M 122.4 61.2 
dH2O   to 100 ml 
• Autoclave 
 
Other Chemicals and Reagents 
• Chloroform 
• NP40 
• Absolute ethanol 
 
 
DNA Extraction from Whole Blood 
 
• Draw 5mls of blood into an EDTA vacutainer tube (Purple top). 
• Blood can be stored at 4ºC up to 1 week before the DNA is extracted. 
• Transfer the blood to a sterile 15ml polyporpolene tube. 
• Add 2 volumes (10ml) of TKM1 buffer containing 2.5% NP40. 
• Mix by inverting several times and incubate at room temperature for 10 
minutes in order to enhance the haemolysis of red blood cells. 
• Centrifuge at 3000rpm (1200Xg) at room temperature for 10 minutes. 
• Decant off the supernatant containing leaving the white pellet at the 
bottom of the tube. 
• Add 1 volume (5ml) of TKM1 buffer (without NP40) 
• Invert and vortex the solution. 
• Centrifuge at 3000rpm (1200Xg) at room temperature for 10 minutes. 
• Decant the supernatant leaving the white pellet in the bottom of the 
tube. 
• Repeat steps 7-10 until the pellet in the bottom of the tube is clean and 
white. 
• Add 800ul of TKM2 buffer and 50ul of the 10% SDS solution. 
• Vortex and then mix using a blue pipette tip in order to assist in the 
lyses of the white blood cells. 
• Incubate for 10 minutes at 55ºC in a water bath (make sure the 
element of the water bath is totally covered with dH20). 
• Add 150ul of 5M NaClO4. 
• Add 500ul of molecular biology grade chloroform. 
 
• Vortex the solution. 
• Transfer the solution to sterile 1.5ml microfuge tubes. 
• Centrifuge at 1300rpm at room temperature for 5 minutes. 
• Carefully transfer 500ul of the top aqueous phase to a new sterile 
microfuge tube. 
• Add 1ml of absolute ethanol. 
• Invert until DNA precipitates. 
• Centrifuge at 1300rpm at room temperature for 5 minutes. 
• Carefully tip off supernatant leaving the pellet in the bottom of the tube. 
• Allow pellet to air dry completely. 
• Add 100ul of 1XTE buffer. 
• Incubate the tubes at 65ºC for 15 minutes in a heating block. 
• Store DNA at 4ºC. 
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